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Neurodegenerative diseases such as Alzheimer’s disease are notoriously heterogeneous;
pathologically as well as in their clinical presentation in patients. There are differences
between different patients in terms of the pathways of progression, the speed of progression,
and the effect the progression has on a patient’s cognition. These myriad of differences
not only makes clinical diagnosis of these diseases very challenging, but also has major
implications for the efficacy of drug trials. As heterogeneous as these diseases are, there
is an underlying order in their progression. An underlying method to their disruption of
homeostasis. An underlying symphony leading to the cacophony.
This thesis is about developing data-driven methods for understanding the orderly
progression of neurodegenerative diseases and validating their utility in providing insights
into the progression patterns of four such diseases: Alzheimer’s disease (AD), frontotemporal
dementia (FTD), Creutzfeldt-Jakob disease (CJD) and multiple sclerosis (MS).
1.1 Neurodegenerative diseases
Neurodegenerative diseases are characterized by a cascade of changes in the structure and
function of the central nervous system. This section provides an overview of the above
mentioned four diseases and their underlying processes resulting in neurodegeneration.
AD is a fatal progressive brain disease that gradually deteriorates memory, thinking, and
other cognitive skills. AD is associated with accumulation of amyloid-β plaques
and hyperphosphorylated tau tangles in the brain [1, 2, 3]. These neuropathological
alterations starts to occur up to 10 − 20 years before symptom onset [4]. These
abnormalities eventually cascade to disrupt the structural integrity of the brain [5].
The structural disruptions in the brain eventually impair the cognition of the patient,
eventually leading to their death.
FTD is the second most common form of presenile dementia (symptom onset age < 65)
accounting for ∼10% of all presenile dementia cases [6]. This is also a fatal
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progressive brain disease that gradually causes deterioration in personality and
behavior. Pathologically, FTD is associated with abnormal forms of Tau, TAR DNA-
binding protein 43 (TDP-43) or FET proteins [7]. These abnormalities eventually
cascade to disrupt the white matter microstructural integrity of the brain [8] as well as
the integrity of the gray matter [9], causing cognitive problems. The earliest structural
changes in the brain were identified ∼10 years before symptoms onset, while the
earliest signs of cognitive decline were identified ∼5 years before symptoms onset [10].
The pattern of structural degeneration in the brain as well as in cognition is distinct
from that in AD [11, 12].
CJD is a rare neurodegenerative disease caused by abnormal prion proteins in the brain. CJD
has a very prolonged incubation period [13, 14], but after the initial onset of symptoms
the lesions in the brain and the clinical symptoms, such as memory impairment and
poor coordination, cascade rapidly. The survival time after the symptom onset varies
from a few weeks to a few months [15], although a few slow progressing variants
could take decades [13]. The lesions in the brain are characterized by spongiform
abnormalities.
MS is a non-fatal chronic inflammatory disease of the central nervous system [16]. MS is
associated with a cascading accumulation of demyelinating lesions that occur in the
brain’s gray matter and white matter regions, as well as in the spinal cord [17, 18].
These abnormalities frequently result in cognitive [19] and physical disabilities in
patients [20].
1.2 Biomarkers of neurodegeneration
Biomarkers are measures of different biological states or processes used for objectively
quantifying different aspects of a disease or susceptibility to it. They are standardized
so as to be comparable among different subjects. The biomarkers of neurodegeneration
can be broadly categorized as follows: i) fluid-based biomarkers extracted from blood or
cerebrospinal fluids (CSF), ii) imaging biomarkers such as those extracted from a magnetic
resonance image (MRI) or positron emission tomography (PET), iii) cognitive biomarkers
obtained from neuropsychological examinations, and iv) genetic biomarkers. The commonly
used biomarkers for the aforementioned four neurodegenerative diseases are as follows:
AD: Biomarkers for Amyloid-β and hyperphosphorylated tau protein abnormalities can be
measured in blood [21, 22], CSF [23], or can be observed using brain PET imaging [24,
25]. MRI based biomarkers such as the volumes of different brain regions (volumetric
biomarkers) quantify the structural integrity of the brain. Cognitive biomarkers
such as measures quantifying attention, episodic memory etc., can be quantified by
neuropsychological tests [26]. Genetic biomarkers such as mutations in the amyloid
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precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes are used
as genetic biomarkers to identify familial AD [3]. Alleles of the Apolipoprotein E (APoE)
gene are used to identify genetic risk factors of sporadic AD [27].
FTD: Specific biomarkers to identify TDP-43 or FET pathology in-vivo are still lacking [28, 29].
In the absence of such biomarkers, neurofilament lightchain (NfL) obtained from blood
or CSF is used as a non-specific biomarker of neuroaxonal degeneration [30]. Diffusion
tensor imaging (DTI) based biomarkers are used to quantify microstructural white
matter integrity in the brain [8] and volumetric biomarkers obtained from MRI are used
to quantify structural integrity. Cognitive biomarkers such as measures quantifying
behavior, language etc., can be quantified by neuropsychological tests [31]. Genetic
biomarkers such as mutations in the progranulin (GRN), microtubule-associated
protein tau (MAPT), and chromosome 9 open reading frame 72 (C9orf72) genes are used
as genetic biomarkers to identify familial FTD [7].
CJD: The characteristic spongiform abnormalities in the brain can be observed using
diffusion weighted MRI [15]. CSF biomarkers of Tau and 14-3-3 proteins are also used
for diagnostic purposes [32]. Homozygosity at the PRNP gene is used to identify a
genetic risk factor for sporadic CJD [33].
MS: MRI scans of brain and spine are often used for observing the demyelinating
abnormalities that are characteristic of MS [34]. The volumetric biomarkers derived
from MRIs quantify the structural integrity of the brain [35]. CSF biomarkers
of oligoclonal bands (OCB) are also used to confirm the diagnosis of MS [36].
Neuropsychological tests and expanded disability status scale [37] are used to assess
the cognitive and physical disabilities in patients.
1.3 Need for understanding neurodegenerative diseases
In spite of the similarity in the pathological processes that helps us categorize each of these
neurodegenerative diseases, there are multiple pathological pathways through which these
diseases progress, resulting in distinct subtypes [38, 39, 40, 41]. Clinical trials in AD, FTD,
CJD have failed so far to be effective in altering the natural course of these diseases. Although
there have been a few drugs for MS that alter its natural course [42], they are only effective for
the earliest stages of the disease [43].
Understanding the progression in the different subtypes of these neurodegenerative diseases
is pivotal for a multitude of reasons. Understanding the earliest biomarkers in the
neuropathologic cascade in different subtypes of these diseases can help identify individuals
at-risk of developing symptoms, and monitor their progression effectively in the pre-clinical
stages of the diseases. This would help in selecting patients in the earliest stages of the disease
for clinical trials, which could be crucial for their success [39, 43, 44, 45].
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Grasping the various pathologic pathways can help in identifying novel therapeutic targets
for clinical trials [46, 47, 48, 49] and formulating evidence-based personalized treatment
strategies. Until effective treatments are discovered, understanding the earliest symptoms
in different clinical subtypes of the diseases can also help in formulating supportive therapies
for efficient patient care.
One of the earliest attempts to understand the progression of neurodegenerative diseases was
done for AD by Braak and Braak [50], where they used neuropathological data from deceased
AD patients to understand the spatial spread of Amyloid-β plaques and Tau tangles. Almost
two decades later, Jack Jr. et al. [5] proposed a hypothetical model of AD’s pathological cascade
of key biomarkers, using meta-analysis from literature. While such approaches give a bird’s
eye view of the diseases, there is a need for computational approaches to understand the
heterogeneous progression of such diseases from in-vivo data.
1.4 Data-driven disease progression models
Disease progression models are data-driven approaches to understand the temporal evolution
of multi-modal biomarkers and can be used to understand the temporal sequence of disease
events in neurodegeneration. Several data-driven approaches have emerged in the last
decade [51, 52, 53]. Such data-driven disease progression models can be largely classified
into two categories: i) models that estimate the trajectories of biomarkers, and the pathways
of progression using longitudinal datasets ii) models that estimate the cascade of biomarker
changes after the onset of the disease using cross-sectional datasets.
Longitudinal datasets of neurodegenerative diseases are usually created by including subjects
with or at-risk of developing the disease and repeatedly measuring a combination of imaging,
fluid, cognitive biomarkers over a period of time. Such datasets are available for AD [54],
familial AD [55], and familial FTD [10].
One of the requirements for modeling the biomarker trajectories through regression is to have
an independent variable (or an x-axis) that causes the changes in biomarker values. In this
case, since the onset of the disease causes the observed changes, time since onset of the disease
is the required variable for this purpose. However, this variable is unobservable in practice,
as clinical symptoms typically arise years or decades after the onset of such diseases. One
of the main challenges of such modeling approaches is therefore to construct the biomarker
trajectories using robust proxy measures of this latent independent variable. Some of the
different approaches developed for constructing biomarker trajectories in such situations are




While longitudinal datasets are rich in temporal information of neurodegeneration, they
are also time-consuming and expensive to collect. In fast-progressing diseases like CJD,
collecting longitudinal datasets is often not feasible. To circumvent this problem, several
disease progression models have emerged that only require cross-sectional data [53, 59, 60].
Event-based models (EBM) [53, 59, 61] are one such class of models that were developed
to estimate a temporal sequence of biomarker abnormality events from case-control cross-
sectional data. A biomarker abnormality event is defined as the moment when a biomarker
goes from a normal state to an abnormal state, after disease onset. Consequently, such an
estimation of temporal progression patterns from cross-sectional data is feasible only when
the biomarkers are (or can be approximated to be) monotonically increasing or decreasing in
neurodegeneration. Under such conditions, selecting a large cohort of patients in different
stages of the disease would result in sampling more abnormal biomarker values for early
biomarkers than for late biomarkers. EBMs use data-driven probabilistic methods to exploit
this for estimating the temporal sequence of biomarker abnormality events.
Some of the open challenges in data-driven disease progression modeling are: i) robustly
dealing with disease heterogeneity, ii) accurately estimating the effect of genetics on disease
progression, iii) exploiting disease progression models for diagnosis and prognosis of a
patient.
1.5 Research aim
The research described in this thesis aims at the development and validation of novel data-
driven disease progression models that provide comprehensive insight into the orderly
progression of neurodegenerative diseases using multi-modal in-vivo biomarker data from
cross-sectional studies. I focused particularly on EBMs in this thesis since the concept
of estimating a temporal sequence of biomarker abnormality events from cross-sectional
data intrigued me, and because of the high practical impact of models that do not rely on
longitudinal data.
1.6 Outline
This thesis is divided into two parts: The first part focuses on developing a novel and robust
disease progression model called discriminative EBM (DEBM) and validating it in AD, FTD,
and MS. The second part focuses on further methodological extensions of DEBM and their
validations in AD and CJD.
Part I: In Chapter 2, we developed a novel and robust disease progression model called
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discriminative EBM (DEBM), which estimates a mean disease progression timeline in a
cohort with heterogeneous disease progression patterns. Furthermore, we developed
a novel patient-staging approach that estimates the severity of the disease in an
individual using the estimated disease progression timeline. We validated the utility
of each of these innovations in a synthetic dataset simulating the progression of AD,
as well in a large AD cohort. In Chapter 3, we validated the generalizability of the
temporal cascades provided by DEBM as well as the original EBM methods in multiple
clinical cohorts for AD.
In Chapter 4, we obtained novel insights into the progression of progranulin related
FTD, a fast-progressing form of familial FTD, using DEBM. In Chapter 5, we obtained
novel insights into the progression of relapse-onset MS using structural, functional and
cognitive biomarkers, using DEBM.
We participated in a global challenge to predict the future clinical diagnosis of subjects,
volume of ventricles in the brain of these subjects, as well as their cognitive summary
scores, in a large AD cohort. We developed novel approaches for these challenges using
DEBM, which ended up as the winning entry for the ventricular volume prediction and
came second in the overall challenge. The details of the challenge, comparative analysis
of all the submitted approaches, as well their brief algorithmic details are provided in
Chapter 6.
Part II: In Chapter 7, we developed a novel extension of DEBM to effectively estimate
the spatio-temporal disease progression timeline using high-dimensional imaging
biomarkers, which was validated using a new deep-learning based simulation
framework as well as in a large AD cohort. In Chapter 8, we further developed a
novel extension of DEBM to estimate orderings in stratified populations and used it
to estimate the effect of APOE genotypes on the disease progression timeline of AD.
In Chapter 9, we investigated if the APOE-specific disease progression timelines of AD
constructed in a case-controlled setting are generalizable to a population-based cohort,
and can be used there to identify preclinical and prodromal AD cases.
In Chapter 10, we obtained novel insights into the progression of seven molecular
subtypes of sporadic CJD and developed a novel approach for ante-mortem
identification of these subtypes using their disease progression timelines.
Lastly, Chapter 11 discusses the novel contributions in this thesis, and provides a roadmap for
further research in this field.
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Disease progression timeline estimation for Alzheimer’s
disease using discriminative event based modeling
This chapter contains the content of the manuscript ‘Disease progression timeline
estimation for Alzheimer’s disease using discriminative event based modeling. Vikram
Venkatraghavan, Esther E. Bron, Wiro J. Niessen, Stefan Klein, for the Alzheimer’s Disease
Neuroimaging Initiative. NeuroImage, 186: 518-532, 2019.’ An earlier version of this chapter
was presented (oral) at the International Conference on Information Processing in Medical
Imaging (IPMI) 2017 and at the Dutch Biomedical Engineering Conference (BME) 2017.
Vikram Venkatraghavan’s contributions in this chapter are: Conceptualization, methodology,




Alzheimer’s Disease (AD) is characterized by a cascade of biomarkers becoming abnormal, the
pathophysiology of which is very complex and largely unknown. Event-based modeling (EBM) is a data-
driven technique to estimate the sequence in which biomarkers for a disease become abnormal based on
cross-sectional data. It can help in understanding the dynamics of disease progression and facilitate early
diagnosis and prognosis by staging patients. In this work we propose a novel discriminative approach
to EBM, which is shown to be more accurate than existing state-of-the-art EBM methods. The method
first estimates for each subject an approximate ordering of events. Subsequently, the central ordering
over all subjects is estimated by fitting a generalized Mallows model to these approximate subject-specific
orderings based on a novel probabilistic Kendall’s Tau distance. We also introduce the concept of relative
distance between events which helps in creating a disease progression timeline. Subsequently, we propose
a method to stage subjects by placing them on the estimated disease progression timeline. We evaluated
the proposed method on Alzheimer’s Disease Neuroimaging Initiative (ADNI) data and compared the
results with existing state-of-the-art EBM methods. We also performed extensive experiments on synthetic
data simulating the progression of Alzheimer’s disease. The event orderings obtained on ADNI data
seem plausible and are in agreement with the current understanding of progression of AD. The proposed
patient staging algorithm performed consistently better than that of state-of-the-art EBM methods. Event
orderings obtained in simulation experiments were more accurate than those of other EBM methods and
the estimated disease progression timeline was observed to correlate with the timeline of actual disease
progression. The results of these experiments are encouraging and suggest that discriminative EBM is a
promising approach to disease progression modeling.
2.1 Introduction
Dementia is considered a major global health problem as the number of people living with
dementia was estimated to be about 46.8 million in 2015. It is expected to increase to 131.5
million in 2050 [62]. Alzheimer’s Disease (AD) is the most common form of dementia. There
is a gradual shift in the definition of AD from it being a clinical-pathologic entity (based on
clinical symptoms), to a biological one based on neuropathologic change (change of imaging
and non-imaging biomarkers from normal to abnormal) [63]. The latter definition is more
useful for understanding the mechanisms of disease progression.
Preventive and supportive therapy for patients at risk of developing dementia due to AD
could improve their quality of life and reduce costs related to care and lifestyle changes. To
identify the at-risk individuals as well as monitor the effectiveness of these preventive and
supportive therapies, methods for accurate patient staging (estimating the disease severity
in each individual) are needed. To enable accurate patient staging in an objective and
quantitative way, it is important to understand how the different imaging and non-imaging
biomarkers progress after disease onset.
Longitudinal models of disease progression, such as [51], reconstruct long-term biomarker
trajectories using short term data. [52] estimate these trajectories based on self-modeling
16
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Figure 2.1: Illustration of the output expected in an EBM. The biomarker trajectories shown here are
hypothetical trajectories representing a change of biomarker value from normal state. The dots on these
trajectories are biomarker events as defined in an EBM. Output of an EBM is the ordering of such events.
regression, whereas Cox regression was used in [64]. Rather than focussing only on
a mean trajectory for the entire population, [65] estimate percentile curves based on
quantile regression. [66, 67] estimate subject-specific trajectories using a mixed model. [68]
provide a probabilistic estimate of biomarker trajectories. While such models are useful for
understanding disease progression, their utility in identifying at-risk individuals is restricted.
This is due to the fact that selecting a cohort of at-risk individuals for clinical trials based on a
longitudinal dataset is not feasible [69]. The utility of these models in studying other forms of
dementia is also restricted because longitudinal data in large groups of patients is often scarce.
To circumvent this problem, methods to infer the order in which biomarkers become abnormal
during disease progression using cross-sectional data have been proposed [53, 59, 60]. The
model used in [60] relies on stratification of patients into several subgroups based on
symptomatic staging, for inferring the aforementioned ordering. However, the problem with
using symptomatic staging is that it is very coarse and qualitative. The models used in [53, 59]
are variants of Event-Based Models (EBM). EBM algorithms neither rely on symptomatic
staging nor on the presence of longitudinal data for inferring the temporal ordering of events,
where an event is defined by a biomarker becoming abnormal. Figure 2.1 shows these
biomarker events on hypothetical trajectories as expected in a typical neuropathologic change.
An important assumption made in [53] is that the ordering of events is common for all
the subjects in a dataset. AD is known to be a heterogeneous disease with multiple
disease subtypes. The assumptions in Fonteijn’s EBM may therefore be too restrictive. The
assumptions in Huang’s EBM on the other hand are more realistic, as they do assume that




To make EBM more scalable to large number of biomarkers and subjects, as well as make it
robust to variations in ordering, we propose a novel approach to EBM, discriminative event-
based model (DEBM), for estimating the ordering of events. We also introduce the concept
of relative distance between events which helps in creating a disease progression timeline.
Subsequently, we propose a method to stage subjects by placing them on the estimated disease
progression timeline. The other contributions of this paper include an optimization technique
for Gaussian mixture modeling that helps in accurate estimation of event ordering in DEBM
as well as improving the accuracies of other EBMs, and a novel probabilistic distance metric
between event orderings (probabilistic Kendall’s Tau).
The remainder of the paper is organized as follows: An introduction to the existing EBM
models is given in Section 2.2. In Section 2.3, we propose our novel method for estimating
central ordering of events. We perform extensive sets of experiments on ADNI data as well
as on simulation data, the details of which are in Section 8.3. Section 9.3 summarizes the
results of the experiments. Section 9.4 discusses the implications of these findings followed
by concluding remarks in Section 8.6.
2.2 Event-Based Models
EBM assumes monotonic increase or decrease of biomarker values with increase in disease
severity (with the exception of measurement noise). It considers disease progression as a series
of events, where each event corresponds to a new biomarker becoming abnormal. Fonteijn’s
EBM [53] finds the ordering of events (S) such that the likelihood that a dataset was generated
from subjects following this event ordering is maximized. S is a set of integer indices of
biomarkers, which represents the order in which they become abnormal. Thus, disease
progression is defined by {ES(1), ES(2), ..., ES(N)}, where N is the number of biomarkers
per subject in the dataset and ES(i) is the i-th event that is associated with biomarker S(i)
becoming abnormal.
In a cross-sectional dataset (X) of M subjects, Xj denotes a measurement of biomarkers for
subject j ∈ [1,M ], consisting of N scalar biomarker values xj,i. Probabilistic formulation of
an EBM, as proposed in [53], can be given by argmaxS(p(S|X)), where p(S|X) can be written




An important assumption in [53] is that p(S) is uniformly distributed. This makes inferring S,
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equivalent to the maximum likelihood problem of maximizing p (X|S)* . This can be further




p (Xj |S) (2.2)
where p (Xj |S) can be written as:
p (Xj |S) =
N∑
k=0
p(k|S)p (Xj |k, S) (2.3)
where p(k|S) is the prior probability of a subject being at position k of the event ordering,
which is assumed to be equal for each position. The k which maximizes p (Xj |S) denotes
subject j’s disease stage. This method of identifying disease severity for a subject results in
discrete set of stages, where the number of stages is one more than the number of biomarkers
used for creating the model. p (Xj |k, S) can be expressed as:



















is the likelihood of observing xj,S(i) in subject j, conditioned on event i




, on the other hand, computes a similar likelihood,
given that event i has not occurred.
With the assumption that all the biomarkers in the control population are normal and that the





biomarker values in the patient population are assumed to follow a uniform distribution
but not all biomarkers of a patient could be assumed to be abnormal. For this reason, the
likelihoods were obtained using a mixture model of a Gaussian and a uniform distribution,
where only the parameters of the uniform distribution were allowed to be optimized.
This method was modified in [61] to estimate the optimal ordering in a sporadic AD dataset
with significant proportions of controls expected to have presymptomatic AD [71]. A
Gaussian distribution was used to describe both the control and patient population, and
*Fonteijn’s EBM uses Markov Chain Monte Carlo (MCMC) sampling to estimate the posterior
distribution P (S|X). Average position of events in all the MCMC samples was used as a way for selecting




the mixture model allowed for optimization of parameters for the Gaussians describing both
control and patient population. The Gaussian mixture model was also used to incorporate
more subjects from the dataset with clinical diagnosis of mild cognitive impairment (MCI).
After obtaining the central ordering S which maximizes the likelihood p (X|S), staging of
patients is done by finding a disease stage k for subject j, such that p (Xj |k, S) is maximized.
The assumption that subjects follow a unique event ordering was relaxed by [59], who
estimate a distribution of event orderings with a central event ordering (S) and a spread (φ)
as per a generalized Mallows model [72] using an expectation maximization algorithm. The
E-step estimates the likelihood of patients’ biomarker value measurements following subject-
specific event order sj , given S and φ. In the M-step, S and φ are estimated based on sj
estimated in the E-step. This is done iteratively to maximize the likelihood of generation of
patients’ data based on S and φ. Patient staging in Huang’s EBM is also a maximum likelihood
estimate, but unlike Fonteijn’s EBM, the staging is done on the subject-specific event ordering
sj .
In both Fonteijn’s and Huang’s EBM, relative distances between events, that can be observed
in Figure 2.1, are not captured†. Some events can be closer to each other than others and
using these relative distance between events could help create a more informative disease
progression model.
2.3 Discriminative Event-Based Model
Fonteijn’s and Huang’s EBM are generative models where the likelihood p (X|S) is
maximized. Huang’s EBM also estimates subject-specific ordering based on a generative
approach. Here, we propose our novel method for estimating central ordering of events (S),
a discriminative event-based model (DEBM).
The proposed framework is discriminative in nature, since we estimate sj directly based on
the posterior probabilities of individual biomarkers becoming abnormal. We also introduce
a new concept of relative distance between events. This subsequently leads to a novel
continuous patient staging algorithm. Figure 2.2 shows the different steps involved in our
approach.
In Section 2.3.1, we present the method to robustly estimate biomarker distributions in pre-
event and post-event classes, given a single cross-sectional measurement of biomarkers. In
Section 2.3.2, we present a way for estimating sj , and we address the problem of estimating a
† [53] briefly mention the idea of capturing relative distance between events, but it was not validated
or used in any of the experiments.
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Figure 2.2: Overview of the steps in DEBM. A) Biomarkers measured from different subjects are converted
to probabilities of abnormality for individual biomarkers. This is done by estimating normal and
abnormal distributions using Gaussian mixture modeling before classifying individual biomarkers using
a Bayesian classifier. B) Subject-specific orderings of biomarker abnormalities are inferred from these
probabilities which are then used to estimate the central ordering and for creating the disease progression
timeline. C) This is then used to stage subjects based on disease severity.
disease timeline from noisy estimates of sj . In Section 2.3.3, we present the continuous patient
staging method.
2.3.1 Biomarker Progression
In this section, we propose a method to robustly convert xj,i to p (Ei|xj,i), which denotes the
posterior probability of a biomarker measurement being abnormal. Assuming a paradigm
similar to that in previous EBM variants [59, 61], the probability density functions (PDF) of
pre-event (p (xj,i|¬Ei)) and post-event (p (xj,i|Ei)) classes in the biomarkers are assumed to
be represented by Gaussians, independently for each biomarker. There are two reasons why
constructing these PDFs is non-trivial. Firstly, the labels (clinical diagnoses) for the subjects do
not necessarily represent the true labels of all the biomarkers extracted from the subject. Not
all biomarkers are abnormal for subjects with AD diagnosis, while some of the cognitively
normal (CN) subjects could have undiagnosed pre-symptomatic conditions. Secondly, the
clinical diagnosis can be non-binary and include classes such as MCI, with significant number
of biomarkers in normal and abnormal classes.
In our approach we address these two issues independently. We make an initial estimate of
21
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the PDFs using biomarkers from easily classifiable CN and easily classifiable AD subjects and
later refine the estimated PDF using the entire dataset.
A Bayesian classifier is trained for each biomarker using CN and AD subjects, based on the
assumption that there are no biomarkers in the pre-symptomatic stage for CN subjects and
all the biomarkers are abnormal for AD subjects. This classifier is subsequently applied to the
training data, and the predicted labels are compared with the clinical labels. The misclassified
data in the dataset could either be outliers in each class resulting from our aforementioned
assumption or could genuinely belong to their respective classes and represent the tails
of the true PDFs. Irrespective of the reason of misclassification, we remove them for
initial estimation of the PDFs. This procedure thus results, for each biomarker, in a set of
easily classifiable CN subjects (whose biomarker values represent normal values) and easily
classifiable AD subjects (whose biomarker values represent abnormal values). This is shown
in the top part of Figure 2.3.
As we use Gaussians to represent the PDFs, we calculate initial estimates for mean and
standard deviation for both normal (µ¬Ei , σ¬Ei ) and abnormal classes (µEi , σEi ) based on ‘easy’
CN and ‘easy’ AD subjects for each biomarker i. As these means and standard deviations are
estimated based on truncated Gaussians, these are biased estimates. The initial estimates of
standard deviations are always smaller than the expected unbiased estimates whereas the
initial estimates of means are underestimated for Gaussians with smaller means (as compared
to the other class for corresponding biomarkers) and overestimated for Gaussians with larger
means.
We refine the initial estimates using a Gaussian mixture model (GMM) and include all the
available data, including MCI subjects and previously misclassified cases. To obtain a robust
GMM fit, a constrained optimization method is used, with bounds on the means, standard
deviations and mixing parameters, based on the aforementioned relationship between the
initial estimates and their corresponding expected unbiased estimates. The objective function





where the likelihood function f(xj,i) is computed as a function of mixing parameters
(θEi , θ
¬E
i ) for the groups corresponding to post-event and pre-event respectively and their
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Figure 2.3: Overview of the steps involved in the proposed Gaussian Mixture Model optimization
strategy. A) Illustration of the initialization step for Gaussian Mixture Model. Rejecting the tails of the
Gaussian distribution in CN and AD class is done to account for the fact that some of the CN subjects could
be in pre-symptomatic stage of disease progression and some of the biomarkers could still be normal in
AD subjects. B and C) This is followed by iterative estimation of Gaussian parameter optimization and
Mixing parameter optimization.
corresponding Gaussian distributions (µEi , σEi ) and (µ¬Ei , σ¬Ei ):
f(xj,i) = θ
E
i p(xj,i|µEi , σEi ) + θ¬Ei p(xj,i|µ¬Ei , σ¬Ei ) = θEi p(xj,i|Ei) + θ¬Ei p(xj,i|¬Ei) (2.6)
θEi and θ¬Ei are selected such that θEi + θ¬Ei = 1. The mixing parameters and the Gaussian
parameters are optimized alternately, until convergence of the mixing parameters. The
initialization and optimization strategy in GMM is illustrated in Figure 2.3.
The strategy of alternating between optimizing for mixing parameter and optimizing for
Gaussian parameters in combination with the initialization strategy and the subsequent
constraints is different from all previous versions of EBM and it will be shown in Section 9.3
that this results in more accurate central ordering of events in most cases.
2.3.2 Estimating a disease progression timeline
Estimating Subject-Specific Orderings
The PDF thus obtained is used for classification of the biomarkers using a Bayesian classifier,
where the mixing parameters (θEi and θ¬Ei ) are used as the prior probabilities (p(Ei) and
p(¬Ei) respectively) when estimating posterior probabilities for each biomarker. We assume
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these posterior probabilities to be a measure of progression of a biomarker. Thus, sj is
established such that:
sj 3 p(Esj(1)|xj,sj(1)) > p(Esj(2)|xj,sj(2)) > ... > p(Esj(N)|xj,sj(N)) (2.7)
Missing biomarker values are implicitly handled in this definition of sj , as sj only consists
of events for which biomarkers are present for subject j. The posterior probabilities
in Equation 8.3 are influenced not only by progression of the biomarker values to their
abnormal states, but also by inherent variability in normal and abnormal biomarker values
across subjects, and by measurement noise. Disentangling measurement noise and inherent
variability in normal biomarker values from progression of the biomarker to its abnormal state
can only be done based on longitudinal data. This makes sj a noisy estimate.
Estimating a central ordering
Since the event ordering for each subject is estimated independently, any heterogeneity in
disease progression is captured in the estimates of sj . The central event ordering (S) is the
mean of the subject-specific estimates of sj . To describe the distribution of sj , we make use of
a generalized Mallows model. The generalized Mallows model is parameterized by a central
(‘mean’) ordering as well as spread parameters (analogous to the standard deviation in a
normal distribution). The central ordering is defined as the ordering that minimizes the sum
of distances to all subject-wise orderings sj . To measure distance between orderings, an often
used measure is Kendall’s Tau distance [59]. Kendall’s Tau distance between a subject specific





where Vi(S, sj) is the number of adjacent swaps needed so that event at position i is the same
in sj and S. In case of missing biomarkers, K(S, sj) is computed for a subset of S consisting
only of the events corresponding to the available biomarkers for subject j.
Since the estimates of sj are based on rankings of posterior probabilities, it would be desirable
to penalize certain swaps more than others, based on how close the posterior probabilities are
to each other. To this end, we introduce a probabilistic Kendall’s Tau distance, which penalizes
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V̂i∀i ∈ [1, N − 1] is computed sequentially using the following algorithm‡:
Algorithm 1 Probabilistic Kendall Tau distance between Subject-specific event
orderings and central event ordering
1: for i ∈ [1, N − 1] do
2: k ← s−1j (S(i))
3: if k > i then
4: V̂i(S, sj)←
∑k
l=i+1 pi − pl
5: Move sj(k) to position i and update sj
6: else
7: V̂i(S, sj)← 0





This variant of Kendall’s Tau distance is quite close to the weighted Kendall’s Tau distance
defined in the permutation space introduced in [73]. The difference stems from the fact that
since the probabilistic Kendall’s Tau distance is between individual estimates and a central-
ordering, the penalization of each swap is weighted asymmetrically as V̂i(S, sj) 6= V̂i(sj , S).
The optimum S is the one that minimizes
∑
∀j K̂(S, sj). However, computing a global
optimum S based on subject-wise orderings is NP-hard. Thus getting a good initial estimate
of S is important to ensure the estimated S is not a suboptimal local optimum. In our
implementation the initial estimate of S is based on ordering θ¬Ei . The motivation for this
is discussed in Section 2.3.3. S was further optimized based on the algorithm introduced by
[72] to estimate the central ordering.
Estimating Event Centers
The S that has been derived in this manner, is an estimate of the sequence in which the
biomarkers become abnormal during the progression of a disease. However, it falls short
of being a disease timeline, because it does not provide information about the proximity of
‡The summation symbol in step 4 was missed accidentally in [70].
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consecutive events. To address this issue, we estimate distances between events by computing
the cost of adjacent swaps in the event ordering, as measured by summation of probabilistic




K̂(Si+1,i, sj)− K̂(S, sj) (2.10)
where Si+1,i is identical to S except for the swap between events at locations i and i+ 1, and
Γi+1,i is the cost of the swap. This represents the cost for the central ordering to be Si+1,i
instead of S. We hypothesize that the closer the events i+ 1 and i are to each other, the lower
the swapping cost would be. Hence we consider these costs to be proportional to distance
between events in terms of biomarker progression.
To estimate the distance of the first biomarker being abnormal (event) in S to a hypothetical
disease-free individual, we introduce a pseudo-event which becomes abnormal at the
beginning of the disease timeline and hence is abnormal for all the subjects in the database i.e.
p (E0|xj,0) = 1 ∀j. Similarly, we introduce another pseudo-event which becomes abnormal
at the end of the disease timeline and hence is normal for all the subjects in the database i.e.
p (EN+1|xj,N+1) = 0 ∀j. We scale Γi+1,i∀i ∈ [0, N ] such that
∑
Γi+1,i = 1. Event center (λk)





In fact, the concept of event centers can also be extended to Fonteijn’s EBM by computing the
cost of adjacent swaps in the event ordering as the difference in log-likelihoods as follows:
Γi+1,i = log (p(X|S))− log (p(X|Si+1,i)) (2.12)
Extension of this concept to Huang’s EBM is not straightforward and is beyond this paper’s
scope.
The set of event centers λ1,2,...,N , will henceforth be referred to as Λ. This results in a disease
timeline, with S giving information about the order of progression of biomarkers and Λ giving




Once the central ordering of events (S) and event centers (Λ) have been determined, we
propose a patient staging algorithm where a patient stage (Υj) is interpreted as an expectation














Using chain rule of probability, we can write p(k, S,Xj) as:
p(k, S,Xj) = p(Xj |k, S)p(k, S) (2.15)
If we assume a uniform distribution of p(k|S) and p(S) as in [53], p(k, S,Xj) becomes equal to
p(Xj |k, S), which was used for patient staging in Fonteijn’s EBM as discussed in Section 2.2.












where Z is a normalizing factor, chosen so as to make this a probability. This choice of p(k, S)
can be justified because biomarkers which become abnormal earlier in the disease process are
more likely to have a higher value of θEi than the biomarkers which become abnormal later.
Hence it is far more likely to have a central-ordering based on ascending values of θ¬Ei than
an ordering with ascending values of θEi . It should be noted that, the choice of p(k, S) is not
unique. For example, it could also be any n-th power of the above equation ∀n > 0. Thus,
from Equations 8.5, 2.16 and 2.4, we get:

















Using the above value of p (k, S,Xj) in Equation 7.2, results in continuous patient stages.
2.4 Experiments
This section describes the experiments performed to benchmark the accuracy of the proposed
DEBM algorithm and compare it with state-of-the-art EBM methods. The EBM methods used
for comparison in these experiments are Huang’s EBM [59] and the variant of Fonteijn’s EBM
that is suited for AD disease progression modeling [61]. The source code for DEBM and
Fonteijn’s EBM, with different mixture modeling techniques and patient staging techniques
discussed in this paper have been made publicly available online under the GPL 3.0 license:
https://github.com/88vikram/pyebm/. The source code for Huang’s EBM used in our
experiments was provided by the authors of the method.
For brevity, Fonteijn’s EBM and Huang’s EBM will henceforth be referred to as FEBM and
HEBM, respectively. The mixture model used with an EBM model (as the one described
in Section 2.3.1) will be denoted by a subscript. For example, FEBM with the Gaussian
mixture model proposed in [61] will be referred to as FEBMay. The Gaussian mixture model
optimization techniques in [59], [70] and the one introduced in this paper will be denoted
with subscripts ‘jh’, ‘vv1’ and ‘vv2’ respectively.§
Data used in the experiments were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu) ¶ . We begin with the details of the experiments
performed on ADNI data to estimate the event ordering in Section 8.3.2. Since the ground-
truth event ordering is unknown for clinical datasets, we resort to using the ability of patient
staging to classify AD and CN subjects, as an indirect way of measuring the reliability of the
event ordering. We also measure the accuracy of event ordering and relative distance between
events more directly by performing extensive experiments on synthetic data simulating the
progression of AD. The details of these experiments are given in Section 7.4.2.
§Mixture model ‘ay’ optimizes for Gaussian and mixing parameters together. Initialization of
Gaussian parameters for optimization is done without rejecting the overlapping part of Gaussians in
CN and AD classes. ‘vv1’ also optimizes for Gaussian and mixing parameters together (although with
much stricter bounds) but the initialization of Gaussian parameters is similar to the one in this paper. ‘jh’
couples mixture modeling with estimation of subject-specific ordering to estimate a combined optimum
solution.
¶The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild cognitive





Diagnosis n Sex M/F Age [yrs.] Edu. [yrs.]
CN 417 209/208 74.76± 5.72 16.28± 2.73
SMC 106 44/62 72.20± 5.53 16.76± 2.51
MCI 872 515/357 73.00± 7.61 15.90± 2.83
AD 342 189/153 75.02± 7.78 15.17± 2.98
Table 2.1: Demographics for the whole population.
2.4.1 ADNI Data
We considered 1737 subjects from ADNI 1, Go and 2 (417 CN, 106 with Significant Memory
Concern (SMC), 872 MCI and 342 AD subjects) who had a structural MRI (T1w) scan at
baseline. Study subject demographics are summarized in Table 8.1. The T1w scans were
non-uniformity corrected using the N3 algorithm [74]. This was followed by multi-atlas brain
extraction using the method described in [9]. Multi-atlas segmentation was performed [75, 76]
using the structural MRI scans to obtain a region-labeling for 83 brain regions in each
subject using a set of 30 atlases. Probabilistic tissue segmentations were obtained for white
matter, gray matter (GM), and cerebrospinal fluid on the T1w image using the unified
tissue segmentation method [77] of SPM8 (Statistical Parametric Mapping, London, UK).
The probabilistic GM segmentation was then combined with region labeling to obtain GM
volumes in the extracted regions. We also downloaded CSF (Aβ1−42 (ABETA), TAU and p-
TAU) and cognitive score (MMSE, ADAS-Cog) values from the ADNI database, making the
total number of features equal to 88.
The features TAU and p-TAU were transformed to logarithmic scales to make the distributions
less skewed. GM volumes of segmented regions were regressed with age, sex and intra-
cranial volume (ICV) and the effects of these factors were subsequently corrected for, before
being used as biomarkers. The effect of age and sex was regressed out of CSF based features,
whereas effects of age, sex and education was regressed out of cognitive scores.
We retained 52 biomarkers (GM volume based biomarkers of 47 regions, 3 CSF and 2 cognitive
scores) having significant differences between CN and AD subjects using Student’s t-test
with p < 0.005, after Bonferroni correction. These biomarker values were used to perform
Experiments 1 and 2.
Experiment 1(a): A subset of 7 biomarkers including the 3 CSF features, MMSE score, ADAS-
Cog score, gray matter volume of the hippocampus (combined volume of left and right
hippocampi) and gray matter volume in whole brain was created. Event ordering of these 7




Diagnosis n Sex M/F Age [yrs.] Edu. [yrs.]
CN 160 83/77 73.56± 5.81 16.38± 2.66
MCI 414 249/165 73.20± 7.11 16.01± 2.79
AD 216 125/91 74.36± 8.06 15.45± 2.94
Table 2.2: Demographics for the homogeneous subset of subjects.
and variance of event centers inferred by DEBM by creating 100 bootstrapped samples of the
data.
Experiment 1(b): The Biomarkers were ranked based on their aforementioned p-value and the
above experiment was repeated with top 25 and top 50 biomarkers to investigate if the event-
centers estimated for the subset of Biomarkers used in Experiment 1(a), remain comparable to
the ones estimated in Experiment 1(a).
Experiment 2: As an indirect way of measuring the accuracy of the estimated event ordering,
we use patient staging based on the estimated event orderings as a way to classify CN and AD
subjects in the database. 10-fold cross validation was used for this purpose. AUC measures
were used to measure the performance of these classifications and thus indirectly hint at
the reliability of the event ordering based on which the corresponding patient staging were
performed.
We used varying number of biomarkers (ranked based on their p-value) ranging from 5 to
50 in steps of 5 for this experiment. We used the methods FEBMay, HEBMjh, DEBMvv1 and
DEBMvv2 for inferring the ordering. Patient staging was done based on the methods described
in their respective papers. Since the earlier version of DEBM [70] had not introduced a patient
staging method, we use the patient staging method described in this paper for evaluating the
method.
Experiment 3(a): To study disease progression in a homogeneous population showing signs
of typical AD progression, Experiment 1(a) was repeated with a subset of subjects, selected
based on their CSF ABETA values. For this experiment, we selected ABETA positive MCI
and AD subjects (ABETA < 192 pg/ml) and ABETA negative CN subjects (ABETA >= 192
pg/ml). This cut-off was chosen according to the results of [78]. Moreover, we excluded all
SMC subjects and subjects with missing ABETA biomarker values. This subset of subjects will
henceforth be referred to as the ‘homogeneous subset’. Demographics for the homogeneous
subset are summarized in Table 2.ST1. We excluded ABETA biomarker when inferring the
event ordering using DEBM.
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Experiment 3(b): We retained 49 biomarkers (GM volume based biomarkers of 45 regions,
2 CSF biomarkers excluding ABETA and 2 cognitive scores) having significant differences
between CN and AD subjects in the homogeneous subset using Student’s t-test with p < 0.05,
after Bonferroni correction. The biomarkers were ranked based on their aforementioned
p-value and the above experiment was repeated with top 24 and top 49 biomarkers, to
investigate if the event-centers estimated for the subset of biomarkers used in Experiment
3(a), remain comparable to the ones estimated in Experiment 3(a).
2.4.2 Simulation Data
We used the framework developed by [79] for simulating cross-sectional data consisting of
scalar biomarker values for CN, MCI and AD subjects. In this framework, disease progression
in a subject is modeled by a cascade of biomarkers becoming abnormal and individual
biomarker trajectories are represented by a sigmoid. The equation for generating biomarker
values for different subjects is given below:
xj,i(Ψ) =
Ri
1 + exp(−ρi(Ψ− ξj,i))
+ βj,i (2.18)
Ψ denotes disease stage of a subject which we take to be a random variable distributed
uniformly throughout the disease timeline. ρi signifies the rate of progression of a biomarker,
which we take to be equal for all subjects. ξj,i denotes the disease stage at which the biomarker
becomes abnormal. βj,i denotes the value of the biomarker when the subject is normal andRi
denotes the range of the sigmoidal trajectory of the biomarker, which we take to be equal for
all subjects.
In our experiments, βj,i and ξj,i ∀j are assumed to be random variables with Normal
distribution N(µβi ,Σβi) and N(µξi ,Σξi) respectively. µβi is equal to the mean value of the
corresponding biomarker in the CN group of the selected ADNI data. Ri is equal to the
difference between the mean values of the biomarker in the CN and AD groups of the selected
ADNI data. Σβi represents the variability of biomarker values in the CN group. We consider
a relative scale for Σβi , where 1 refers to the observed variation among the CN subjects in
ADNI data. Variation in ξj,i is controlled by Σξi and results in variation in ordering among
subjects in population and could be seen as a parameter controlling the disease heterogeneity
within a simulated population. Σξi ∀i is varied in multiples of ∆ξ, where ∆ξ is the average
difference between adjacent µξi . µξi refers to the event centers of various biomarkers. The set
of µξi∀i will collectively be referred to as Λgt and they will be used to assess the accuracy of
estimated event centers (λi).
The parameters in the simulation framework that could have an effect on the performance of
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EBMs are Σβi , µξi , Σξi , and ρi. Apart from this, the number of subjects (M) and the number
of biomarkers (N) in the dataset could also have an effect on the performance of EBMs.
Using this simulation framework, we study the effect of the aforementioned parameters on
the ability of different variants of EBM algorithms to accurately infer the ground-truth central
ordering in the population. Change in µβi results only in a translational effect on biomarker
values and change in Ri results only in a scaling effect on biomarker values. These factors do
not affect the performance of the EBMs and hence were not evaluated in our experiments.
Performance of an EBM method can be measured using error in estimation of either S or Λ.
Error in estimating S (εS) will henceforth be referred to as ‘ordering error’ whereas the error
in estimating Λ (εΛ) will henceforth be referred to as ‘event-center error’. εS is computed






where Sgt is the ground truth ordering. εS is effectively a normalized Kendall’s Tau distance





, was chosen to make the accuracy
measure interpretable for different number of biomarkers.
For comparing Λ and Λgt, Λ were scaled and translated such that the mean and standard
deviation of Λ were equal to that of Λgt. This is done because we are only interested in
evaluating the errors in estimating relative distance between events and not the absolute
position of event-centers. The choice of scale in event-centers are arbitrary and the chosen
scale for the estimated event-centers was based on pseudo-events, which need not necessarily




|λsti − µξi | (2.20)
where λsti is the scaled and translated version of λi.
As mentioned before, the factors that can have an effect on the performance of EBMs are Σβi ,
µξi , Σξi , ρi, M and N . In each of the following 5 experiments, a few of these factors were
varied while the others were set to their default values. The default value for Σβi was taken
to be 1 as this corresponds to the observed variation among CN subjects in ADNI. µξi were
spaced equidistantly, i.e., µξi+1 − µξi = 1/(N + 1). As the actual variation in event centers
among different subjects is not known in a clinical dataset, the default value of Σξi was taken
to be 2∆ξ. For the sake of simplicity of notation ∆ξ will be omitted henceforth, and the values
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of Σξi are implicitly in multiples of ∆ξ. ρi was considered to be equal for all biomarkers by
default. The default values for M and N were 1737 and 7 respectively, mimicking the dataset
used in Experiment 1(a). For each simulation setting, 50 repetitions of simulation data were
created and used for benchmarking the performance of EBMs on synthetic data.
Experiment 4: The first simulation experiment was performed to study the effect of Σβ ∈
[0.2, 1.8] and Σξ ∈ [0, 4], varying one at a time while keeping the other at its mean value. The
εS of FEBMay, FEBMvv2, HEBMjh, HEBMvv2, DEBMvv1 and DEBMvv2 were determined.
Experiment 5: The above experiment was repeated for DEBMvv2 and FEBMvv2 and the εΛ were
measured for the two methods.
Experiment 6: This experiment was performed to study the effect of a non-uniform
distribution of µξi . Σβ and Σξ combinations of (0.6, 1), (1.0, 2), (1.4, 3) and (1.8, 4) were
tested to study their effect in non-uniformly spaced biomarkers. εS of DEBMvv2, FEBMvv2
and HEBMvv2 were measured. Additionally, εΛ of DEBMvv2 and FEBMvv2 were measured. To
also study the effect of unequal rates of progression of biomarkers (ρi), the above experiment
was performed once with equal ρi for all biomarkers and once when they were unequal. The
experiment with unequal biomarker rates had the same mean biomarker progression rate as
the the experiment with equal biomarker rates. The progression rates of different biomarkers
has been included as supplementary material (Figure 2.SF1).
Experiment 7: This experiment was performed to study the influence of the number of
subjects (M). M was varied from 100 to 2100 in steps of 200. εS of DEBMvv2, FEBMvv2 and
HEBMvv2 were measured. DEBMvv2 and FEBMvv2 were also assessed based on εΛ.
Experiment 8: This experiment was performed to study the influence of the number of
biomarkers (N). N was varied from 7 to 52 in steps of 5. In each random generation of a
dataset, we randomly selected (with replacement) the biomarkers to be used in the iteration.
This was done to study the effect of N on the EBM models and separate it from the effect of
adding weaker biomarkers. εS of DEBMvv2, FEBMvv2 and HEBMvv2 were measured. DEBMvv2
and FEBMvv2 were also assessed based on εΛ.
2.5 Results
2.5.1 ADNI Data
Experiment 1: Figure 2.4 shows the positional variance and event-center variance obtained
using DEBMvv2 with 7 events. The Gaussian mixture model parameters for every biomarker
have been tabulated in the supplementary material, Table 2.ST1
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Figure 2.4: Experiment 1(a): DEBMvv2 with 7 Events. The positional variance diagram (left) shows the
uncertainty in estimating the central event ordering. The event-center variance diagram (right) shows the
standard error of estimated event centers. These were measured by 100 repetitions of bootstrapping.
Figure 2.5: Experiment 1(b): DEBMvv2 with 25 Events. The positional variance diagram (left) shows the
uncertainty in estimating the central event ordering and the event-center variance diagram (right) shows
the standard error of estimated event centers. These were measured by 100 repetitions of bootstrapping.
The event centers of the biomarkers used in Figure 2.4 are marked in red. Table 2.3 shows the full forms
of the abbreviations used in the y-axis labels. Figure 2.7 maps the colors used for y-axis labels to different
lobes in the brain.
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Figure 2.6: Experiment 1(b): DEBMvv2 with 50 Events. Positional variance diagram (left) shows the
uncertainty in estimating the central event ordering and event center variance diagram (right) shows the
standard error of estimated event-centers. These were measured by 100 repetitions of bootstrapping. The
event-centers of the biomarkers used in Figure 2.4 are marked in red, whereas the ones used in Figure 2.5
are marked in blue. Table 2.3 shows the full forms of the abbreviations used in the y-axis labels. Figure 2.7
maps the colors used for y-axis labels to different lobes in the brain.
It can be seen from Figure 2.4 (left) that CSF-based biomarkers ABETA becomes abnormal
before MMSE and CSF-based p-TAU. This is followed by ADAS13, Hippocampal volume,




















Table 2.3: Abbreviations used in Figures 2.5 and 2.6 along with their full names [75].
Figure 2.7: Legend for the colors used in Figures 2.5 and 2.6. The colors map different biomarker labels
to lobes in the brain.
for MMSE, ADAS13, p-TAU are close to each other and so are the event-centers of TAU and
hippocampus volume. The event associated with the TAU biomarker seems closer to the
whole brain volume event as they are in positions 6 and 7 of Figure 2.4 (left). However,
the centers of these two events are quite far apart in Figure 2.4 (right) and the p-TAU event
(position 2) is closer to the TAU event than whole brain volume event.
As the number of biomarkers increases, the variation in the positions also increases
considerably, as seen in Figures 2.5 (left) and 2.6 (left). The event centers of the biomarkers
used in Experiment 1(a) remain fairly consistent (±0.05) in Experiment 1(b). It can also
be seen that biomarkers with lower p-values (biomarkers included in the model with 50
biomarkers and not in the model with 25 biomarkers), have larger variance in their event-
center estimation.
Experiment 2: Figure 2.8 (a) shows the mean AUC when using patient stages for classifying
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CN versus AD subjects using DEBM and other variants of EBM methods. It can be observed
that the AUC of all the methods decreases as the number of events increases. The proposed
method DEBMvv2 followed by the proposed patient staging algorithm outperforms all the
existing EBM variants consistently.
Figure 2.8 (b) shows the distribution of patient stages for the whole population when the most
significant 25 features were given as input to DEBMvv2. This graph shows a peak at disease
stage 0 dominated by CN and MCI non-converters, which shows that these subjects are not
progressing towards AD. The non-zero lower disease stages are dominated by CN subjects
and MCI non-converters, whereas MCI converters|| and the subjects with AD have higher
disease stages.
Experiment 3: Figure 2.9 shows the positional variance and event-center variance obtained
using DEBMvv2 with 6 events, in the homogeneous subset of subjects. It can be seen from
Figure 2.9 that in the homogeneous subset of subjects, p-TAU event occurs before ADAS13 and
MMSE events as opposed to p-TAU event occurring after ADAS13 and MMSE in Figure 2.4.
It can also be seen from Figure 2.9 that the TAU event precedes Hippocampus volume event
as opposed to Hippocampus event preceding the TAU event in Figure 2.4.
The results of Experiment 3(b) with 24 and 49 have been included as supplementary material
(Figures 2.SF2 and 2.SF3).
2.5.2 Simulation Data
Experiment 4: Figures 2.10 shows the ordering errors of DEBM, FEBM and HEBM models
with different mixture models as Σβ and Σξ increase. The error-bars depict mean and
standard deviation of the errors obtained in 50 repetitions of simulations. It can be seen that
the proposed optimization technique improves the performance of all three EBM models. The
change is particularly evident when comparing the performance of FEBMvv2 and FEBMay.
It can also be seen that FEBMvv2 performs slightly better than DEBMvv2 when Σξ is low, but as
Σξ increases, the performance of FEBMvv2 degrades significantly. The performance of HEBM
is almost always worse than its FEBM or DEBM counterpart.
Experiment 5: Figure 2.11 (a) and (b) shows the event-center errors in DEBMvv2 and FEBMvv2
as the variability in population (Σβ) and disease heterogeneity (Σξ) increases respectively. It
should be noted from Figure 2.10(b) and Figure 2.11 (b) that, even when the FEBMvv2 gets
the ordering more accurately than DEBMvv2 in cases of low Σξ, the event-center estimation of
DEBMvv2 is on par with or better than its FEBM counterpart.































Figure 2.8: Experiment 2: In (a) we see the variation of AUC with respect the number of biomarkers used
for building the model using DEBM, when the obtained patient stages were used for classification of CN
versus AD subjects. The AUC measure was obtained using 10-fold cross-validation. In (b) we see the
frequency of occurrence of subjects in different disease stages, when the most significant 25 features were
given as input to DEBMvv2 for inferring the ordering as well as for patient staging.
Figure 2.11 (c) shows the estimated event-center locations for Σβ = 1.0 and Σξ = 2 and the
ground truth event-centers.
Experiment 6: Figure 2.12 (a) shows the ordering errors of DEBMvv2, FEBMvv2 and HEBMvv2
as Σβ and Σξ increase, when the ground-truth event centers (µξi ) are non-uniformly spaced.
The spacing of µξi can be observed in Figure 2.12 (b), where the ground truth event-centers
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Figure 2.9: Experiment 3(a): DEBMvv2 with 6 Events, in the homogeneous subset of subjects. The
positional variance diagram (left) shows the uncertainty in estimating the central event ordering. The
event-center variance diagram (right) shows the standard error of estimated event centers. These were
measured by 100 repetitions of bootstrapping.
as well as the estimated event-centers of DEBMvv2 and FEBMvv2 are shown for Σβ = 1.0 and
Σξ = 2. It can be observed that the estimated event-centers for DEBMvv2 are much closer to
the ground-truth event centers than those of FEBMvv2 and also have a much lower variance
over different iterations of simulations.
Figure 2.12 (c) shows the ordering errors as Σβ and Σξ increases, when µξi is non-uniformly
spaced and ρi is not identical for all biomarkers. It should also be noted that the mean of ρi
over all i has not changed between (a) and (c). The variation of errors in (c) is quite similar
to the one in (a). This shows that performance of EBM methods that are reported in other
experiments (where ρi is equal for all biomarkers) can be expected to not deteriorate in the
more realistic scenario of ρi not being equal for all biomarkers. The event-center variance for
Σβ = 1.0 and Σξ = 2 for the case of unequal ρi is very similar to (b) and has been included as
supplementary material (Figure 2.SF4).
Experiment 7: Figure 2.13 shows the mean ordering errors of DEBMvv2, FEBMvv2 and
HEBMvv2 as a function of number of subjects in the dataset on one vertical axis and shows the
mean event-center errors of DEBMvv2 and FEBMvv2 on the other vertical axis. As expected,
the models perform better as the number of subjects increases. DEBMvv2 is slightly better
at inferring the central ordering than FEBMvv2 when the number of subjects is very low, but
FEBMvv2 outperforms DEBMvv2 when the number of subjects is higher. However, when the
accuracy of event centers are considered, DEBMvv2 consistently outperforms FEBMvv2.
Experiment 8: Figure 2.14 shows the mean ordering errors of DEBMvv2, FEBMvv2 and
























Figure 2.10: Experiment 4: Ordering errors of DEBMvv1, DEBMvv2, FEBMay, FEBMvv2, HEBMjh and
HEBMvv2 for 50 repetitions of simulations. Figure (a) shows the ordering error as a function of variability
in population (Σβ ). Figure (a) shows the ordering error as a function of variation in ordering (Σξ). Error
bars in (a) and (b) represent standard deviations over the 50 repetitions. Figure (c) shows the legend for
the plots in (a) and (b).
and shows the mean event-center errors of DEBMvv2 and FEBMvv2 on the other vertical axis.
The biomarkers were selected randomly after replacement so that the chances of selecting a
bad biomarker remain equal as the number of events increases. It can be noted that the errors





























Figure 2.11: Experiment 5: Figures (a) and (b) show the event-center errors of DEBMvv2 and FEBMvv2 as
a function of Σβ and Σξ respectively. Figure (c) shows the estimated event-center locations for both
methods as well as the ground-truth event centers. Error bars in (a), (b) and (c) represent standard
deviation over 50 repetitions of simulation.
quality of biomarkers remains the same. However the errors stabilize beyond a certain point

























Figure 2.12: Experiment 6: Figures (a) and (c) show the ordering errors of DEBMvv2, FEBMvv2 and
HEBMvv2 when µξi are not uniformly distributed. Σβ and Σξ increase as we move from left to right.
Figure (a) shows the errors in the case when ρi are identical for all the biomarkers whereas (c) shows the
errors when ρi are different. Figure (b) shows the non-uniform µξi as well as the estimated event-centers
by DEBMvv2 and FEBMvv2 for the case of ρi being equal. Error bars in (a), (b) and (c) represent standard
deviation over 50 repetitions of simulation.
2.6 Discussion
We proposed a novel discriminative EBM framework to estimate the ordering in which
biomarkers become abnormal during disease progression, based on a cross-sectional dataset.
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Number of Subjects (M)
Figure 2.13: Experiment 7: Ordering errors of DEBMvv2, FEBMvv2 and HEBMvv2 as a function of number
of subjects (M) in the dataset. It also shows the event-center errors of DEBMvv2 and FEBMvv2 as a function
of M .
Number of Events (N)
Figure 2.14: Experiment 8: Ordering errors of DEBMvv2, FEBMvv2 and HEBMvv2 as a function of number
of events (N) in the dataset. It also shows the event-center errors of DEBMvv2 and FEBMvv2 as a function
of N .
The proposed framework outperforms state-of-the-art EBM techniques in estimating the event
ordering. We also introduced the concept of relative distance between event-centers, which
enables creating a disease progression timeline. This in turn led to the development of a
new continuous patient staging mechanism. In addition to the framework, we also proposed
a novel probabilistic Kendall’s Tau distance metric and a robust biomarker distribution




Event-centers capture relative distance between events. This helps in creating the disease
progression timeline from an ordering of events. If an event (Event A) leads to another event
(Event B), this would be observed as event-center for A occurring before event-center for B.
However EBMs cannot assess causality, and cannot distinguish the aforementioned case from
the case when Event B is caused by some external factor which happened to occur after Event
A.
Event centers are an intrinsic property of the biomarker used, for the selected population. This
was observed in Experiment 1(b) where the event-centers estimated using DEBMvv2 remained
fairly consistent (±0.05) across models using different number of biomarkers.
The estimated disease progression timeline can be used for inferring progression of the
disease, with the event centers being synonymous to milestones of progression. A strict
quantization of position in ordering of events (as reported in [80], [70], [81], [61], [53])
in the positional variance diagram can sometimes be non-intuitive in terms of inferring actual
progression of the disease. This was seen in Experiment 1, where the event center variance
diagram showed that the TAU event (at position 6) was closer to the p-TAU event (at position
2) than the whole brain event (position 7).
The approach of scaling the event-centers between [0, 1] has its advantages and disadvantages.
The advantage of such a scaling is that models built on different biomarkers, but within the
same population, remain comparable. For example, a model built with CSF and MRI based
biomarkers can be compared with a model built on MRI based biomarkers alone, as the event-
centers of MRI based biomarkers would approximately be the same. On the other hand, the
position of the first event relies heavily on the number of ‘true’ controls in the dataset (CN
subjects who are not in an early asymptomatic stage of the disease). This is the result of
introducing pseudo-events for scaling the events-centers.
Comparison of the event centers across different datasets with different number of controls
(albeit with the same biomarkers) can be done in three ways. Event-centers can be scaled
and translated such that the mean and standard deviation of event centers computed across
different datasets are the same (similar to the comparisons between estimated and ground-
truth event centers in this paper). Alternately, the event center of the first biomarker can be
set as 0 and the event center of the last biomarker can be set to 1, before comparison. Lastly,
in a dataset where controls (i.e., subjects whose biomarker values are all normal) can be easily
identified, it would be better to exclude them for event-center computation.
The estimated event centers have a good correlation with the groundtruth disease timeline.
This can be seen in the simulation experiments with and without uniform spacing of events
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(Experiments 5 and 6). It must however be noted that, the disease stages Ψ of the simulated
subjects were distributed uniformly throughout the disease timeline. If the distribution is
not uniform, we expect it to have an effect on the estimation of event centers. Analyzing the
exact effect of such non-uniform distributions on the estimation of event centers and ways to
estimate event centers invariant to the distribution of subjects on the disease timeline could
be an interesting extension of the current work.
Experiment 6 also showed that different biomarkers having different rates of progression does
not degrade the performance of EBM models, as long as the mean rate of progression is the
same. We did not perform an experiment to benchmark the accuracies by changing the mean
rates of progression of biomarkers. This experiment was already performed in [79] and it was
observed that FEBM ordering error decreases as the mean rates of progression increase.
FEBM assumes that the disease is homogeneous, as it expects all the subjects in the dataset
to follow the same ordering. When the variability of ordering in different subjects is low,
FEBM with the proposed mixture model ‘vv2’ outperforms DEBM with the proposed mixture
model. This can be seen in the results of Experiments 4, 6 and 7. When the assumption
becomes too restrictive, DEBM with the proposed mixture model outperforms FEBM. Even
when the assumption holds true, estimation of event-centers with DEBM is more accurate
than with FEBM.
2.6.2 Patient Staging
Existing patient staging algorithms discretize the patient stages based on event position,
whereas the patient staging algorithm introduced in this paper takes relative distance between
events into consideration while staging new subjects. This makes patient stages more useful
for diagnosis and prognosis as they correlate more with the actual disease progression
timeline. Discrete patient stages without considering the event centers could diminish the
prognosis value of the obtained stages.
The cross-validation experiment on ADNI data (Experiment 2) showed that the CN and AD
subjects are well separated after patient staging and that the AUC of the proposed method is
better than that of the state-of-the-art EBM techniques. It also showed that MCI converters
and non-converters are well separated after patient staging, without explicitly training the
model to achieve this.
It must however be noted that even though heterogeneity of the disease was considered while
inferring the central ordering, it was not considered for patient staging. Inferring multiple
central orderings corresponding to different disease subtypes [81] and staging patients on one
of these central orderings may help us overcome this drawback. Patient staging with respect to
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subject-specific orderings (as done in HEBM) can also be considered when extending DEBM
for longitudinal data, where the subject-specific orderings might be estimated with higher
confidence.
2.6.3 Scalability of Event-Based Models
Understanding the progression of several imaging and non-imaging biomarkers after disease
onset is important for assessing the severity of the disease. Hence it is desirable to have
a model scalable to a large number of biomarkers. FEBM and DEBM are scalable to large
number of events, whereas HEBM is not. This was seen in the simulation experiment on
varying number of events (Experiment 8), where the errors of FEBM and DEBM increased
asymptotically with increasing number of events. The ordering errors of HEBM reached 0.5
for large number of events, which is equivalent to random prediction.
In Experiment 7, we observed that the errors of the EBMs decrease with increasing number of
subjects in the dataset. We hence expect FEBM, DEBM and HEBMvv2 to be scalable to a large
number of subjects.
The performance of HEBMjh is seen to be consistently worse than FEBMay in Experiment 4.
This is in contrast with the findings of [70], where HEBMjh performed better than FEBMay
when the number of biomarkers used were 7, while it performed worse when the number of
biomarkers used were 42. One of the key differences between the experiment performed
in [70] and Experiment 4 is the number of subjects in the simulation dataset. While the
previous study considered 509 subjects, Experiment 4 considered 1737 subjects. HEBMjh
jointly estimates the subject-specific orderings of all the subjects and the mixture model
to represent the biomarkers in different diagnostic groups. We think that while the joint
estimation was good for low number of subjects, increasing the number of subjects had an
adverse effect on the convergence of the algorithm. Hence HEBMjh is not scalable to a large
number of subjects.
We decoupled the mixture model and estimation of subject-specific orderings in HEBMvv2
(Experiments 4, 6, 7 and 8). This made HEBM more scalable as it improved the results in
Experiment 4 with 1737 subjects, but the decoupling had an adverse effect on the algorithm
when the number of subjects was low, as seen in Experiment 7, where HEBMvv2 performs
worse than FEBMvv2 even when the number of subjects was low.
FEBM and HEBM are generative approaches for estimating the central ordering. Our results
suggest that HEBM is not very scalable. Although FEBM is scalable, the assumptions made
in FEBM are too restrictive for heterogeneous disease such as AD. DEBM is a discriminative
approach to event-based modeling, which is both scalable and can robustly estimate central
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ordering even when the disease is heterogeneous.
2.6.4 The Mixture Model
The optimization technique for the Gaussian mixture model that is presented in this paper
decouples the optimization of Gaussian parameters and mixing parameters. When the
Gaussians of the pre-event and post-event classes are highly overlapping, the optimum
mixing parameter changes a lot even for small changes in the Gaussian parameters. By
decoupling the optimizations for Gaussian parameters and mixing parameters, we get more
stable mixing parameters. This helps in improving the accuracy of all EBMs. This was
observed in Experiment 4.
2.6.5 The Importance of Good Biomarkers
Quality of biomarkers plays a huge role in the accuracy of the EBMs. This was seen in
Experiment 8, where the mean error value for 7 biomarkers was considerably higher than
the mean error value with the same number of biomarkers in Experiment 5 (for the same Σβ
and Σξ parameters). The observed difference can be explained by the choice of the biomarkers
used in those experiments. While the biomarkers chosen in Experiment 8 was at random, the
ones chosen in Experiment 5 were the 7 best biomarkers.
2.6.6 Interpretation of model results on ADNI
Experiment 1(a) showed that CSF biomarker ABETA is the first biomarker to become
abnormal, followed by MMSE, p-TAU and ADAS13. However, Experiment 3(a) showed that
in the homogeneous subset of subjects showing signs of typical AD progression (with ABETA
positive subjects in MCI and AD, and with ABETA negative CN subjects) p-TAU becomes
abnormal before cognitive biomarkers of ADAS13 and MMSE, which is in agreement with
Jack’s hypothetical model [82]. The earlier position of MMSE in Experiment 1 as compared
to Experiment 3 can be attributed to the inclusion of SMC subjects as well, who need not
necessarily be progressing towards AD. The ordering of p-TAU becoming abnormal before
ADAS13 which is then followed by Hippoccampus was also observed by [52] in ABETA
positive subjects.
ADAS13 and MMSE are seen to become abnormal quite early in the disease progression
timeline in Experiments 1 and 3. This is in agreement with other studies on prodromal
Alzheimer’s Disease[83, 84]. Cognitive biomarkers becoming abnormal before abnormality in
Hippocampus and other structural biomarkers, as seen in Experiments 1 and 3, could be due
to the fact that the region-based volumes from structural MRI may not be sensitive enough to
detect mild structural changes.
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The event centers of Hippocampus volume and TAU are quite close to each other in both
Experiment 1(a) and 3(a), which is also in agreement with the current understanding of the
disease [85].
Figure 2.5 shows that abnormality in the anterior temporal lobe precedes that of the posterior
temporal lobe. This was also observed by [67], where the anterior temporal lobe had a higher
averaged acceleration factor than the posterior temporal lobe, in a study on AD patients and
stable controls.
Nucleus accumbens right and left are the first biomarkers to become abnormal as seen in
Figure 2.6. This was also observed by [86] in one of the subtypes of AD identified in their
work. However, the large standard error of the event centers for the events before ABETA
suggests that the exact position of those events are unreliable. Experiment 1(b) showed that
weak biomarkers (biomarkers excluded in Figure 2.5, but included in Figure 2.6) could lead to
greater uncertainty in event centers. This can be explained by the fact that weak biomarkers
are the ones where there is a lot of overlap between the Gaussians of pre-event and post-
event classes. Small variation in the sampling population during bootstrapping leads to large
changes in the parameters estimated in the mixture modeling step of the algorithm. It also
showed that majority of the early structural biomarkers are from Temporal lobe, followed by
Central structures, Frontal lobe, Parietal lobe and Occipital lobe.
2.7 Conclusion
We proposed a new framework for event-based modeling, called discriminative event-
based modeling (DEBM), which includes a new optimization strategy for Gaussian mixture
modeling, a new paradigm for inferring the mean ordering, a way for estimating the proximity
of events in the order to create a disease progression timeline, and a new way of staging
patients that uses these relative proximities of events while placing new subjects on the
estimated timeline. The source code for DEBM and FEBM was made publicly available online
under the GPL 3.0 license: https://github.com/88vikram/pyebm/.
We applied the DEBM framework to a set of 1737 subjects from the baseline ADNI
measurement, and also performed an extensive set of simulation experiments verifying the
technical validity of DEBM. The experiment on ADNI data illustrated a number of advantages
of the new approach. Firstly, we showed that strict quantization of position in ordering
of events in the positional variance diagram can sometimes be non-intuitive in terms of
inferring actual progression of a disease. Secondly, we showed that the patient staging
based on the proposed approach separates CN and AD group of subjects much better than
the previous EBM models. Thirdly, we showed that the patient staging can be used to
identify individuals at-risk of developing AD as the MCI converters and non-converters were
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well-separated. Staging patients based on the estimated disease progression timeline can
thus make computer-aided diagnosis and prognosis more explainable. The results of these




















Figure 2.SF1: Biomarker progression rates for different biomarkers used in the second part of Experiment
6.
Biomarker (unit) Normal Parameters
(Mean ± Std. Dev.)
Abnormal Parameters
(Mean ± Std. Dev.)
Mixing Parameter (θ¬E )
ABETA (pg/ml) 228.47± 32.99 136.55± 26.63 0.40
P-TAU (log(pg/ml)) 3.22± 0.43 3.85± 0.49 0.51
TAU (log(pg/ml)) 4.07± 0.40 4.78± 0.45 0.59
ADAS13 10.77± 4.21 23.28± 8.99 0.51
MMSE 29.10± 0.80 25.36± 2.41 0.49
Hippocampus (ml) 3.64± 0.40 3.22± 0.52 0.58
WholeBrain (ml) 466.89± 29.32 434.07± 49.48 0.73
Table 2.ST1: Gaussian mixture model parameters for the biomarkers in Experiment 1(a).
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Figure 2.SF2: Experiment 3(b): DEBMvv2 with 24 Events, in the homogeneous subset of subjects. The
positional variance diagram (left) shows the uncertainty in estimating the central event ordering and the
event-center variance diagram (right) shows the standard error of estimated event centers. These were
measured by 100 repetitions of bootstrapping. The event centers of the biomarkers used in Figure 9 are
marked in red. Table 3 shows the full forms of the abbreviations used in the y-axis labels. Figure 7 maps
the colors used for y-axis labels to different lobes in the brain.
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Figure 2.SF3: Experiment 3(b): DEBMvv2 with 49 Events, in the homogeneous subset of subjects.
Positional variance diagram (left) shows the uncertainty in estimating the central event ordering and
event center variance diagram (right) shows the standard error of estimated event-centers. These were
measured by 100 repetitions of bootstrapping. The event-centers of the biomarkers used in Figure 9 are
marked in red, whereas the ones used in Figure 2.SF2 are marked in blue. Table 3 shows the full forms
of the abbreviations used in the y-axis labels. Figure 7 maps the colors used for y-axis labels to different




Figure 2.SF4: Experiment 6: The non-uniform µξi as well as the estimated event-centers by DEBMvv2 and




Multi-study validation of data-driven disease
progression models to characterize evolution of
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Understanding the sequence of biological and clinical events along the course of Alzheimer’s disease
provides insights into dementia pathophysiology and can help participant selection in clinical trials.
Our objective is to train two data-driven computational models for sequencing these events, the Event
Based Model (EBM) and discriminative-EBM (DEBM), on the basis of well-characterized research data,
then validate the trained models on subjects from clinical cohorts characterized by less-structured data-
acquisition protocols.
Seven independent data cohorts were considered totalling 2389 cognitively normal (CN), 1424 mild
cognitive impairment (MCI) and 743 Alzheimer’s disease (AD) patients. The Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data set was used as training set for the constriction of disease models
while a collection of multi-centric data cohorts was used as test set for validation. Cross-sectional
information related to clinical, cognitive, imaging and cerebrospinal fluid (CSF) biomarkers was used.
Event sequences obtained with EBM and DEBM showed differences in the ordering of single biomarkers
but according to both the first biomarkers to become abnormal were those related to CSF, followed by
cognitive scores, while structural imaging showed significant volumetric decreases at later stages of the
disease progression. Staging of test set subjects based on sequences obtained with both models showed
good linear correlation with the Mini Mental State Examination score (R2EBM = 0.866; R
2
DEBM = 0.906).
In discriminant analyses, significant differences (p-value≤0.05) between the staging of subjects from
training and test sets were observed in both models. No significant difference between the staging of
subjects from the training and test was observed (p-value > 0.05) when considering a subset composed
by 562 subjects for which all biomarker families (cognitive, imaging and CSF) are available.
Event sequence obtained with DEBM recapitulates the heuristic models in a data-driven fashion and is
clinically plausible. We demonstrated inter-cohort transferability of two disease progression models and
their robustness in detecting AD phases. This is an important step towards the adoption of data-driven
statistical models into clinical domain.
3.1 Introduction
Alzheimer’s disease (AD) is a complex multifactorial neurodegenerative condition characterized by
deposition of abnormal protein-aggregate, synaptic dysfunction, and eventually neuronal loss in the
brain [50]. While progression of the disease invariably results in dementia, it has been estimated that
clinically-overt manifestations are preceded by a latent phase with no measurable cognitive dysfunction
lasting approximately 15-20 years [87]. As AD onset remains insidious in terms of clinical manifestations,
biomarkers are the most accurate approach to track disease onset and progression [87].
A variety of biomarkers have been proposed to describe the different phases of the disease, each mirroring
different biochemical, functional, or structural changes as the disease develops and progresses. The
correct sequence of biomarker transitions to abnormality would allow an appropriate characterization
of the different clinical and preclinical disease stages. In addition, this approach could inform the
development of individualized treatments in the context of precision medicine or the identification of
individuals at-risk of dementia for secondary prevention strategies [88, 89].
56
Multi-cohort validation of EBMs
While the recently published research criteria [90, 91] for the definition of AD stages outlined robust
principles [5, 82, 92], their operationalization in mathematical models and out-of-the-box algorithms has
recently begun.
The event-based model (EBM) [53, 61] and the discriminative event-based model (DEBM) [93] are
two among an increasing number [80] of probabilistic data-driven methods developed to understand
evolution of biomarkers as disease develops and progresses [51, 52, 57, 68]. Their assumption is that the
disease is characterized by an irreversible and monotonic change of biomarkers towards abnormality,
which might track disease progression. Both algorithms are cross-sectional statistical models that use
no strong a priori assumptions regarding the relationship among the different biomarkers or pre-defined
cut-offs separating their normal and abnormal values. Both models estimate disease progression as a
single average sequence, albeit in slightly different ways: the EBM estimates the maximum-likelihood
sequence over all individuals, whereas the DEBM calculates the optimal event sequence as an average of
estimations of patient-specific orderings.
Previous works demonstrated the EBM’s capability to order biomarkers and stage subjects with a
fine-grained ability in classification of Cognitively normal (CN) and AD subjects as well as to predict
conversion from Mild Cognitive Impairment (MCI) to AD or from CN to MCI [53, 61].
So far, statistical models have been tested and validated exclusively on a few well-characterized research
data sets, such as: Alzheimer’s Disease Neuroimaging Initiative (ADNI) [53, 61, 93], Magnetic Resonance
in Multiple Sclerosis (MAGNIMS) [94], GENetic Frontotemporal dementia Initiative (GENFI) [86] and
TRACK-HD study of Huntington’s disease [95], or on synthetic data. This work focusses on transferability
of the models to clinical data in AD and provides new evidence that supports widespread clinical
adoption of the EBM and DEBM.
Key steps in the validation for the adoption of this kind of models are: (i) ability to build robust disease
models on the basis of well-phenotyped research data sets, such as ADNI; (ii) consistency of the disease
models on less well-phenotyped clinical data sets in terms of model stability and subjects’ staging; (iii)
clear end-user interfaces to make model results accessible by clinicians.
In the next sections, we addressed the aforementioned points towards the definition of two valid models
for disease progression. Our goal was to assess the transferability of EBM and DEBM’s optimal sequence
of biomarkers on independent clinical data coming from six different multi-centric initiatives spanning
the entire AD spectrum.
3.2 Material and Methods
3.2.1 Participants
A total of 4556 subjects (CN=2389; MCI=1424; AD=743) from different cohorts were selected for this
study. The initiatives and projects included in this study are described in Tab. 3.1 and Tab. 3.2. Each cohort
had different proportions of subjects in different AD stages depending on the scope of the study. Each
study was approved by the local medical ethics committee. Participants for our study were selected using
of the following criteria: 1) availability of information on syndromic diagnosis at baseline; 2) availability of
T1-weighted Magnetic Resonance Imaging (MRI) scans obtained by either 1.5T or 3T scanners at baseline;
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The Alzheimer’s Disease Neuroimaging Initiative [96] is a
longitudinal multicentre study designed to develop
clinical, imaging, genetic, and biochemical biomarkers for
the early detection and tracking of Alzheimer’s disease
(AD). ADNI was originally launched in 2003 as a
public-private partnership; its primary goal has been to
test whether magnetic resonance imaging (MRI),
biological markers, clinical and neuropsychological
assessments can be combined to measure the progression
of MCI and Alzheimer’s disease. The initial five-year
study (ADNI-1) was extended by two years in 2009 by a
Grand Opportunities grant (ADNI-GO), and in 2011 by
further competitive renewal of the ADNI-1 grant
(ADNI-2). Through its 3 phases, it has targeted


















Table 3.1: Characteristics of the training dataset
3) absence of any other major neurological, psychiatric or somatic disorders that could cause cognitive
impairment at baseline. Subjects were divided in two subsets: training set, used to define the event
sequences that serve as disease model, and test set, used for the validation of the disease models.
. The training set was composed of 1488 subjects from the ADNI data set of which 468 were CN, 753 were
MCI and 267 were AD. The test set was formed by 3068 subjects from six independent data sets of which
1921 were CN, 671 were MCI and 476 were AD 3.3.
Subjects from ADNI and Amsterdam Dementia Cohort (ADC) with a diagnosis of subjective memory
complaints (SMC) were assimilated to CN group, since Mini Mental State Examination (MMSE) score of
these individuals was 28.1 ± 1.6. Significant differences in demographical (age, sex and education) and
genetic (carriers of Apolipoprotein E ε4 (APOE4)) information between diagnostic groups were observed
for both training and test sets. Differences were observed in the estimated Total Intracranial Volume
(eTIV) only in the training set. All demographic and genetic data of training set subjects were significantly
different (p-value≤0.05) from demographic and genetic data of test subjects in the similar diagnostic
group and for the totality of the populations (see Tab. 3.4 for full demographical information).
3.2.2 Biomarkers
When available, multimodal biomarkers collected at baseline tracking different aspects of disease biology
were retrieved, i.e. (i) results of neuropsychological tests, (ii) cerebrospinal fluid (CSF) markers and (iii)
imaging markers. All the selected subjects had imaging biomarkers, but some missed the results of
neuropsychological tests and/or did not undergo lumbar puncture depending on the study cohort; in
the latter case staging was performed on the basis of the available markers.
Cognitive biomarkers included MMSE, Alzheimer’s Disease Assessment Scale - Cognitive (ADAS-Cog)
and Rey’s Auditory Verbal Learning Test - Immediate Recall (RAVLT).
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The ADC includes all patients who come to the Alzheimer
Center in Amsterdam (since 2004) for diagnostic work-up
and consent to give all their data collected for
research [97]. The aim is to facilitate research into new and
existing biomarkers in the broadest sense, to establish
diagnostic, prognostic values and further insight into the
pathogenesis of neurodegenerative dementias. The data
consist of baseline and annual follow-up assessments.
Clinical, neuropsychological, imaging, and biological
markers are collected. Since it is conception it has grown









ARWiBo is a cross-sectional data set including data from
> 2500 patients enrolled in Brescia (Italy) and nearby
areas. The data set contains socio-demographic, clinical,







EDSD [99] is a framework of nine European centres:
Amsterdam (Netherlands), Brescia (Italy), Dublin
(Ireland), Frankfurt (Germany), Freiburg (Germany),
Milano (Italy), Mainz (Germany), Munich (Germany), and
Rostock (Germany). It is a cross-sectional multi-centre
study characterized by 474 volumetric MRI T1-weighted








OASIS [100] consists of (I) a cross-sectional collection of
416 subjects. 100 of the included subjects, over the age of
60, have been clinically diagnosed with very mild to
moderate Alzheimer’s disease (AD). (II) A longitudinal
collection of 150 subjects aged from 60 to 96 years. Each
subject was scanned on two or more visits, separated by at
least one year for a total of 373 imaging sessions. In














PharmaCog is an industry-academic European project
(IMI) aimed at identifying biomarkers sensitive to
symptomatic and disease modifying effects of drugs for
Alzheimer’s disease [101]. Several clinical sites
participated in this study across Italy (Brescia, Verona,
Milan, Perugia, and Genoa), Spain (Barcelona), France
(Marseille, Lille, and Toulouse), Germany (Leipzig and
Essen), Greece (Thessaloniki) and Netherland
(Amsterdam). 151 MCI patients have been studied






ViTA is a population-based cohort-study of all 75-years
old inhabitants of a geographically defined area of
Vienna [102]. ViTA is composed of 606 subjects followed
longitudinally for 4 years. Recruitment took place between
May 2000 and October 2002. The primary focus of the
VITA work-group was to establish a prospective age




Table 3.2: Characteristics of the test datasets
59
Chapter 3
Diagnoses and biomarker availability
Data Set CN MCI AD Sub-Total MRI CSF Cognitive scores
Training set ADNI 1/GO/2 468 753 267 1488 100% 72% 100%
Test set
ADC 125 80 129 334 100% 83% 99%
ARWiBo 1399 169 152 1720 100% 3% 59%
EDSD 179 138 151 468 100% 19% 97%
OASIS 177 122 42 341 100% NA 100%
PharmaCog 0 147 0 147 100% 99% 100%
ViTA 41 15 2 58 100% NA 100%
Total 2389 1424 743 4556 100% 36% 77%
Table 3.3: The number of cognitively normal (CN), mild cognitive impairment (MCI), Alzheimer’s disease
(AD) and total subjects is reported for each data set. Biomarker availability is expressed as percentage
related to the total subjects in each data set. No CSF biomarker is available for OASIS and ViTA data sets.
Demographics and clinical characteristics
CN MCI AD P-value Total
Training set Age 73.9 ± 6.7 72.5 ± 7.3 73.9 ± 7.9 3.22× 10−4 73.2 ± 7.0
Years of
education
16.4 ± 2.7 15.9 ± 2.8 15.2 ± 2.9 1.09× 10−6 15.9 ± 2.8
eTIV (cm3 ) 1510 ± 180 1540 ± 160 1530 ± 160 4.20× 10−3 1530 ± 160
MMSE 29.1 ± 1.2 27.6 ± 1.8 23.2 ± 2.0 2.2× 10−16 27.3 ± 2.6
Sex (% of
females)
52% 42% 48% 1.43× 10−3 46%
APOE4-
carrier
34% 49%∗ 66% 2.2× 10−16 49%
Test set Age 56 ± 17 70.6 ± 7.7 73.7 ± 8.1 2.2× 10−16 62 ± 16
Years of
education
10.8 ± 4.8 9.0 ± 4.5 8.7 ± 4.5 2.2× 10−16 10.2 ± 4.8
eTIV (cm3 ) 1450 ± 160 1460 ± 170 1470 ± 170 0.157 1460 ± 160
MMSE 28.7 ± 1.4 26.5 ± 2.4 21.0 ± 4.7 2.2× 10−16 26.6 ± 3.9
Sex (% of
females)
61% 49% 63% 1.50× 10−5 58%
APOE4-
carrier
21% 43% 49% 2.2× 10−16 43%
Table 3.4: Data are expressed as mean values ± standard deviations. Acronyms: eTIV: estimated
total intracranial volume; MMSE: Mini Mental State Examination; APOE4: apolipoprotein E ε4; CN:
cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer’s disease. P-values were calculated
via chi square test for dichotomic variables and via ANOVA for non-dichotomic variables. Values of
training set denoted with * are not significantly different from their corresponding values derived from
the test subjects (p-value > 0.05).
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The CSF concentrations of Amyloid-β1,42 (Aβ1,42) [23, 103, 104], total Tau (t-Tau) and phosphorylated
Tau (p-Tau) proteins [23, 103, 104] were collected, and the ratio between the concentrations of Aβ1,42 and
p-Tau was calculated [104].
The selected imaging biomarkers were: volumetric measures of the hippocampus, entorhinal cortex,
fusiform gyrus, middle-temporal gyrus and precuneus, together with whole brain volume and
ventricles [105, 106]. Imaging biomarkers were estimated from MRI 3D-T1 sequences analysed
with FreeSurfer software v5.3 cross-sectional stream (http://surfer.nmr.mgh.harvard.edu) and
outputs were visually checked. We assumed a symmetric pattern of atrophy in AD and selected imaging
biomarkers were averaged between the left and right hemisphere.
Imaging biomarkers and cognitive scores were available for the totality of subjects from the training set,
while CSF biomarkers were available for 72% of these individuals. Imaging biomarkers were available
for the totality of test subjects while cognitive scores were available for 84% of test subjects. Within the
test set, ADAS-Cog and RAVLT scores were available only for subjects from the PharmaCog data set.
CSF biomarkers were available for 18% of test subjects. See Tab. 3.3 for full information on biomarker
availability.
CSF biomarkers were obtained with different assays across different cohorts, i.e. Multiplex xMAP
Luminex platform with Innogenetic immunoassay kit–based reagents [107] for ADNI subjects and
Enzyme Linked Immunosorbent Assay (ELISA) [108] for subjects from all other cohorts, which led
to different CSF biomarkers distributions. In order to tackle this issue and to correct for possible
acquisition-related differences across datasets, all biomarkers (cognitive scores, CSF, imaging) from
subjects from ADC, ARWiBo (Alzheimer disease Repository Without Borders), EDSD (European DTI
Study on Dementia), OASIS (Open Access Series of Imaging Studies), PharmaCog and ViTA (Vienna
Transdanube Aging) cohorts were rescaled to match the mean and standard deviation of biomarkers
distribution of ADNI subjects. In order to ensure Gaussianity, we performed a log-transformation of
p-tau and t-tau as their values were non-normally distributed.
All biomarkers from the training and test sets were regressed against age, education and sex and the
effects of these factors were corrected to compensate inter cohort demographic variability [109]; imaging
biomarkers were additionally regressed and corrected against eTIV [110, 111] to compensate for head size.
Correction of biomarkers was performed separately for training set and test set.
The comparison of the selected biomarkers in this study among the three clinical groups and the seven
data cohorts considered in this study are shown in Supplementary Figure 3.SF1.
3.2.3 Mathematical modelling
Development of EBM and DEBM was based on the fundamental work of Fonteijn et al. [53]. According
to these approaches, each biomarker is considered as either normal or abnormal and its probabilistic
transition from the normal to the abnormal state is defined as event. The aim is to define in a data-driven
manner the sequence of events that describe the most probable ordered cascade that characterizes the
transition of a subject from the healthy state to the full-blown disease spectrum [61]. For this work, we




In the EBM [53, 61] possible event sequences are sampled via a Markov Chain Monte Carlo (MCMC)
process aimed at finding the sequence that best fits the biomarker observations from all subjects. At
each Monte Carlo step a new sequence is sampled as a random swap between two biomarkers of the
current benchmark sequence. If the new sequence is a better fit than the benchmark sequence, which
is determined mathematically by the likelihood, then the new sequence is considered as the benchmark
sequence for the following MCMC step.
The probability of an event for each biomarker is determined by a Gaussian mixture model (GMM) where
the normal and abnormal components are modelled by Gaussian distributions. In EBM [61], distributions
of normal and abnormal biomarkers are initialized as the distributions of biomarkers from the CN and
AD subjects, respectively. The mixture model distribution for each biomarker is then found as the sum,
weighted on the mixing parameters, of the two aforementioned distributions that best fits to biomarker
values from all subjects. Optimization of the GMM function is performed along the Gaussian parameters
and the mixing parameters and in order to avoid the possibility that biomarkers will not show a clear
bimodal distribution, the standard deviations for normal and abnormal components in the GMM are
constrained to be no greater than the standard deviations of CN and AD subjects, respectively.
The approach of DEBM model [70, 93] for the calculation of the central ordering, on the other hand, is a
two-step process where first (i) a specific ordering is calculated for each subject by sorting the posterior
probability that each biomarker has become abnormal and then (ii) the central ordering is calculated as
the event sequence that minimizes the sum of probabilistic Kendall’s tau distances between itself and all
the subject-wise orderings. As the posterior probability is influenced by the physiological variability of
biomarkers, DEBM assumes that single subject orderings are noisy estimates of the central ordering [93].
The original formulation of DEBM [93] also contains a specific mixture model, for which an initial estimate
of the distributions of non-diseased and diseased subjects for each biomarker is performed using values
from subjects at the opposite ends of the disease spectrum, as defined by a Bayesian classifier which
is trained to remove outliers and wrongly labelled data. This allows efficient separation of the two
Gaussian distributions of normal and abnormal values for each biomarker. The biased distributions are
then refined including data from all subjects via a GMM that has constraints based on the aforementioned
relationships between the expected and the biased distributions. The same objective GMM function as for
EBM is optimized alternatively along the Gaussian parameters and the mixing parametersuntil the latter
converge.
Optimal sequences were calculated as averages of orderings obtained from 50 bootstrapped iterations
for both EBM and DEBM. Furthermore, in EBM the number of MCMC steps was set to 50.000 to ensure
convergence of the likelihood. In practice convergence was typically observed before the 15000-th MCMC
step. See Supplementary Material SS1 for detailed mathematical modelling.
3.2.4 Model validation & Statistical Analysis
Validation of the models is performed by staging subjects from the training and test sets on the basis of
the event sequences built on the basis of biomarkers from subjects from the training set. Specific methods
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for staging subjects are available in the original works for both the EBM [61] and DEBM [93]. For the
sake of simplicity, and in order to have a common staging system for both models, the method from [61]
was employed in this work. This method assigns each subject a position of the central event sequence,
resulting in a number of stages that is equal to the number of biomarkers considered for the sequence
plus one, as it is necessary to add stage 0 where no biomarker is abnormal. The stage of each subject
is calculated as the -th step of the event sequence that maximizes the probability that all events up to
have already occurred and events from to the end of the sequence are yet to occur. In case of missing
biomarkers, the probability of the biomarkers to be abnormal was set to 0.5 [61]. Assuming that clinical
diagnoses of all subjects are made through a biomarker-based assessment, it is expected that each subject,
either from the training or test set, is staged at the earlier positions of the event sequences if CN and at
the later positions if AD.
Measures of area under curve (AUC), sensitivity, specificity and balanced accuracy at optimal threshold
were calculated for all pairwise comparisons among clinical groups, i.e. (i) AD vs. CN, (ii) AD vs. MCI,
and (iii) MCI vs. CN. In order to assess significant differences between receiver operating characteristic
(ROC) curves, the DeLong test [112] was performed.
To assess the validity of the EBM and DEBM central orderings we explored the linear correlation between
subjects’ model stages and MMSE scores. The MMSE is the most widely used screening tool to assess
cognitive functions in both routine clinical practice and research settings and its score correlates with the
different phases of AD progression [113]. In order to avoid circularity MMSE scores were excluded from
the initial calculation of the event sequences. Moreover, in order to mitigate the ceiling effect typical of
MMSE [114], the lower limit for the linear regression analysis was set as the model stage that provides the
optimal threshold for separating CN and MCI subjects. To explore how much the missing biomarkers of
test subjects (Tab. 3.3) affected the classification performances in both models, staging was also performed
for a special subset of test subjects having at least one CSF measurement, MMSE score and imaging
biomarkers. These restriction criteria reduced the original test subjects from 3068 to 562 (104 CN,331
MCI, 127 AD) and the number of events considered in our original simulation from 13 to 12 as ADAS-
Cog and RAVLT were excluded since they were available only for the PharmaCog data set, while MMSE
was included.
Statistical analysis was performed with R version 3.5.1.
3.3 Results
3.3.1 Events ordering
Central event sequences and their variances were generated from biomarkers of training subjects for both
EBM and DEBM and were plotted as positional variance diagrams (Fig. 3.1).
The event sequence obtained with the DEBM algorithm showed that amyloid related biomarkers became
abnormal first. The abnormalities of Aβ1,42 protein and Aβ1,42/p-Tau ratio are at the very first positions
followed by cognitive scores, Tau protein-related biomarkers, and finally imaging markers of AD-relevant
brain regions. Averaged volumes between left and right hemisphere of hippocampus and precuneus are
respectively the first and the last brain areas to become abnormal while the medial temporal lobe is in
between. The enlargement of the ventricles and the atrophy of the whole brain were in the last two
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Figure 3.1: Positional variance diagrams of event orderings obtained with EBM and DEBM. Both
diagrams show the number of times each biomarker occurred in a specific position from a batch of 50
independent bootstrapped sequences generated using biomarkers of training subjects with EBM (left)
and DEBM (right) methods
positions.
In EBM, CSF biomarkers are the first to show abnormality, although with a different pattern with respect
to DEBM. Tau related biomarkers became abnormal earlier and often before amyloid-related biomarkers.
The sequence obtained with EBM followed a similar ordering for the cognitive scores although the specific
order of RAVLT and ADAS scores is swapped. The enlargement of the ventricles is placed at the fourth
position of the ordering although the positional variance showed that this event has nonzero probability
of occurring in the first or last position of the sequence. Volumetric measures of the grey matter of the
fusiform gyrus and precuneus are placed at the very last positions of the EBM benchmark sequence. Both
EBM and DEBM showed good positional stability (see Fig. 3.1), and in the case of DEBM no event occurs
far from the diagonal.
3.3.2 Staging of individuals across the AD spectrum
Subjects from both training and test set were staged on the basis of the event sequences derived from the
training set. For the training set, in both EBM and DEBM cases, more than 60% of CN subjects were staged
at position 0 where no abnormalities have occurred yet (Fig. 3.2 (a) & Fig. 3.2 (b)). Similarly, the majority
of AD were staged at positions 12-13 (of 13 total) of both sequences. Most of the remaining CN subjects
were spread across stages 1-6 in EBM and 1-4 in DEBM. The majority of the remaining AD individuals
were staged across stages 7-11 for EBM and stages 5-12 for DEBM.
For the test set, staging of subjects obtained with EBM and DEBM is shown in panels (c) and (d) of Fig. 3.2
respectively. In this case more than 70% of AD subjects was staged at positions 12-13 and more than 60%
of CN subjects were staged at position 0, but the strong separation between CN and AD observed in the
training set was not reproducible in the test set for 30% of CN subjects were staged at positions 6-13.
These test CN subjects belonged to two different phenotypic classes:
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Figure 3.2: Subject staging based on the sequences obtained with EBM and DEBM methods. Staging
of subjects from all diagnostic categories (Cognitively normal (CN) in blue, mild cognitive impairment
(MCI) in orange, Alzheimer’s disease (AD) in red) are shown for (a) training subjects on EBM sequence,
(b) training subjects on DEBM sequence, (c) test subjects on EBM sequence and (d) test subjects on DEBM
sequence. Histograms are normalized for each diagnostic category. (For interpretation of the references
to color in this figure legend, the reader is referred to the web version of this article.)
(1) subjects whose eTIV was very large or very small compared to the eTIV of the CN population. Indeed,
the eTIV of these subjects showed a bimodal distribution with peaks at ±1.1 standard deviations apart
from the average of the test CN population;
(2) subjects aged 76.2±8.7 on average, whose MMSE score was on average 29.11, but whose hippocampal
normalized volume was significantly smaller compared to the hippocampal normalized volume for the
test CN subjects ((2.1± 0.4)× 10−3 vs. (2.7± 0.4)× 10−3).
In each case, the distribution of MCI stages overlapped with the distribution of stages for CN and AD, but
a considerable amount, always between 30% and 40%, was staged at position 0 in both EBM and DEBM
models (Fig.2). MCI subjects staged at position 0 had an average MMSE score of 28.2 ± 2.1 for training
set and 27.0 ± 2.1 for test set. Staging of the subjects from each data set on the basis of EBM and DEBM
sequences shows a good separation between CN and AD subjects in each case, and generally few subjects
are staged at positions 1-7 for EBM and 1-5 for DEBM as these stages correspond to CSF and cognitive
biomarkers (see Supplementary Figure 3.SF2). Linear regression of DEBM stage vs EBM stage resulted in
slopes < 1 for both the training and test set, meaning that on average EBM stage is always greater than
DEBM stage (see Supplementary Figure 3.SF3).
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Figure 3.3: Correlation between MMSE score and subjects staging for (a) training set subjects on EBM
sequence, (b) training set subjects on DEBM sequence, (c) test set subjects on EBM sequence, (d) test set
subjects on DEBM sequence. Average and standard deviation of MMSE score of training and test subjects
staged on the basis of EBM and DEBM sequences are shown. Coefficients of determination (R2) of the
linear regression of MMSE score vs disease stage are reported.
3.3.3 Staging vs MMSE correlation
Average and standard deviation of the MMSE scores of the training and test sets at each stage is shown
in Fig. 3.3. The plot showed decreasing MMSE scores in the latter stages in both EBM and DEBM.
Linear regression of the MMSE scores of all subjects excluding the initial ceiling effect showed correlation
between the decrease in MMSE score and patient staging of training subjects for both EBM (0.896) and
DEBM (0.860). The limit of the initial ceiling was set as the model stage threshold that optimally separates
CN and MCI subjects, that is stage 6 for EBM and stage 5 for DEBM in the case of the training set. Good
linear correlation between MMSE scores and subject staging was observed for individuals from the test
set (0.866 for EBM and 0.906 for DEBM), although the ceiling effect thresholds were different from the
thresholds of the training set (stage 1 for both EBM and DEBM).
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Prediction of clinical diagnosis
EBM DEBM
kT Sens Spec BalAcc AUC kT Sens Spec BalAcc AUC p
Training
AD vs CN 7 0.97 0.96 0.96 0.97* 5 0.92 0.94 0.93 0.95* 1.88× 10−3
AD vs MCI 9 0.59 0.96 0.77 0.81 5 0.48 0.94 0.71 0.76 5.30× 10−5
MCI vs CN 6 0.88 0.52 0.70 0.73* 5 0.92 0.52 0.72 0.73* 0.537
Test
AD vs CN 5 0.71 0.91 0.81 0.87 7 0.78 0.85 0.81 0.86 3.99× 10−2
AD vs MCI 12 0.77 0.71 0.74 0.78 11 0.70 0.75 0.73 0.77 0.393
MCI vs CN 1 0.63 0.62 0.62 0.63 1 0.68 0.60 0.64 0.64 0.676
Table 3.5: Measurements of area under curve (AUC), sensitivity (Sens), specificity (Spec) and balanced
accuracy (BalAcc) at a specific threshold (kT ) for the staging obtained with EBM and DEBM methods on
training and test data sets not containing missing values. Thresholds are chosen to maximize the balanced
accuracy in each classification task. P-values of Delong test performed to compare AUCs of EBM and
DEBM methods are reported in the last column. AUCs of training set denoted with * are significantly
different from their corresponding values derived from the test subjects (p-value of DeLong test ≤ 0.05)
3.3.4 Prediction of clinical diagnosis
Clinical diagnosis classification of each individual from both training and test data sets was computed.
All the possible combinations were assessed, i.e. AD vs. CN, AD vs. MCI and MCI vs. CN. The balanced
accuracy and AUC values of the classification obtained on both training and test sets were comparable
to other state-of-the-art classification approaches [61]. In the case of AD vs. CN, balanced accuracy and
AUC of the ROC curve, alongside measures of sensitivity and specificity, are greater than 0.93 in the
training set and greater than 0.81 for test set for both models (see Tab. 3.5). The comparison of the AUC
showed significant differences (p-value≤ 0.05) between EBM and DEBM in both training and test sets.
For AD vs. MCI subjects, balanced accuracy and AUC in both training and test sets were always greater
than 0.71. No significant differences were registered between the AUC of EBM and DEBM. In the case of
MCI vs. CN subjects, balanced accuracy and AUC values were between 0.62 and 0.73 without significant
differences between EBM and DEBM. In both models, a significant difference (p-value ≤ 0.05) between
training and test sets was observed in two of the three classification tasks: (i) AD vs. CN; (ii) MCI vs CN.
The maximum balanced accuracy threshold (kT) used in the classification increases across the disease
spectrum in both models with the exception of DEBM on ADNI subjects where the threshold is constant
for all classifications. This is compatible with the idea that EBM and DEBM produce event sequences that
track disease progression.
To fully explore the capabilities of the two models and to perform a fair head to head comparison we
run similar analyses in the training and test sets considering all the 14 biomarkers (see Supplementary
Figures 3.SF4, 3.SF5). On average, the general performance in discriminating subjects from the test set
improved by 2 and 4 percentage points respectively for DEBM and EBM (see Supplementary Table 3.ST1).
This improvement is achieved by the inclusion of the MMSE score, which is available for a large portion
of test subjects.
Results of the case where all test subjects do not have missing biomarkers showed improvement in the
performances for all the computed metrics. In the test set, on average, DEBM showed an increase of
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Prediction of clinical diagnosis with no missing biomarkers
EBM DEBM
kT Sens Spec BalAcc AUC kT Sens Spec BalAcc AUC p
Training
AD vs CN 8 0.98 0.95 0.97 0.97 3 0.86 0.99 0.92 0.95 3.10× 10−2
AD vs MCI 8 0.70 0.95 0.83 0.83 7 0.66 0.76 0.71 0.76 0.104
MCI vs CN 5 0.89 0.51 0.70 0.72 3 0.86 0.58 0.72 0.73 1.99× 10−8
Test
AD vs CN 4 0.88 0.94 0.91 0.95 3 0.91 0.91 0.91 0.94 0.332
AD vs MCI 4 0.57 0.94 0.76 0.80 5 0.63 0.87 0.75 0.79 1.65× 10−2
MCI vs CN 4 0.88 0.43 0.66 0.66 3 0.91 0.52 0.71 0.70 0.296
Table 3.6: Measurements of area under curve (AUC), sensitivity (Sens), specificity (Spec) and balanced
accuracy (BalAcc) at a specific threshold (kT ) for the staging obtained with EBM and DEBM methods on
training and test data sets not containing missing values. P-values of Delong test performed to compare
AUCs of EBM and DEBM methods are reported in the last column. In DEBM and EBM AUCs of the
training set were not significantly different to their corresponding AUCs in the test set (p-values of
DeLong test always > 0.05).
4.3% in balanced accuracy and an increase of 3.0% in AUC compared with the metrics obtained from
the complete 13 biomarker sequences. Similarly, EBM showed an increase of 7.2% in balanced accuracy
and an increase of 5.5% in AUC. Generally, no statistically significant differences between staging of
training and test subjects were observed (p-value> 0.05) for all groups in both models. Detailed results
are reported in Tab. 3.6.
3.3.5 Sequence consistency
In order to ensure consistency of the benchmark sequence generated from the training set, a disease model
was also built on the basis of the test set (i.e.: ADC, ARWiBo, EDSD, OASIS, PharmaCog, ViTA) using both
EBM and DEBM. ADAS-Cog and RAVLT cognitive scores were not included since these specific tests were
available only for MCI subjects from the PharmaCog data set. MMSE was included so that all biomarker
families (cognitive, CSF and imaging) were represented.
In both sequences obtained with the EBM, CSF biomarkers occupy the first positions of the sequences
(Fig. 3.4(a)) but the second halves of the sequences differ considerably, especially in the position of
ventricles and hippocampus. In total, 23 swaps between adjacent biomarkers are needed in order to
turn the sequence obtained from the test set into the sequence obtained from the training set.
In DEBM, the event sequences obtained from training and test sets are similar. Only 11 swaps between
adjacent events are needed to turn the test set sequence into the benchmarked training set sequence
(Fig. 3.4(b)). With the exception of t-Tau and p-Tau both sequences obtained with DEBM can be divided
in four partial rankings that contain the same biomarkers: Aβ1,42/p-Tau ratio, Aβ1,42 and MMSE in the
first partial ranking, hippocampus and entorhinal cortex in the second, middle temporal gyrus, fusiform
gyrus and precuneus in the third and whole brain and ventricles in the last partial ranking.
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Figure 3.4: Positional variance diagrams of event sequences computed from training set (left) and test set
(right) using EBM (a) and DEBM (b) algorithms. In the case of DEBM green lines divide the sequences into
homogeneous blocks between the training and test sets. Orange boxes represent biomarker exceptions not
conserved in the same block comparing the training vs. test positional variance diagrams. Clear event
blocks cannot be identified for EBM sequences.
3.4 Discussion
To our knowledge, this is the first translational study showing viability of the EBM and DEBM, trained on
research data, in a clinical setting. This is also the first cross-cohort assessment of the models’ validity on
cross-sectional multimodal biomarkers. Previous literature focused only on well characterized research
datasets and synthetic data [58, 60, 61, 67, 70, 93, 115] but this kind of approach does not take into
consideration the aspects of real clinical data. We investigated and compared the performance of EBM
and DEBM when applied to the same training and test data sets which included subjects across the entire
disease spectrum, accounting for missing data.
EBM and DEBM rely on different estimates of the Gaussian mixture models and in the definition of the
optimal sequence of biomarkers. As highlighted in literature [93], the optimization technique adopted in
DEBM, for which Gaussian parameters and mixing parameters are optimized alternatively, prevents the




We observed differences between EBM and DEBM optimal event sequences. The DEBM sequence is closer
to Jack’s model [105] and also mirrors stages V and VI of cortical degeneration due to neurofibrillary
tangles deposition as described in Braak’s Model [116]. The DEBM sequence starts with Aβ1,42 and
Aβ1,42/p-Tau ratio, while the EBM sequences suggests p-Tau as the first biomarker to become abnormal.
Although in literature it is not completely understood which is triggering the other (if at all), much
evidence suggests Aβ1,42 deposition to be upstream of Tau deposition. The deposition of amyloid
plaques presumably triggers the conversion of Tau protein to toxic state, while less evidence suggests
that toxic Tau can enhance Aβ1,42 toxicity via a feedback loop. Soluble toxic aggregates of Aβ1,42 and
p-Tau can self-propagate and spread throughout the entire brain, perhaps enhancing other destructive
biochemical pathways [117] and triggering the abnormality cascade of the other biomarkers. It is
important to consider, however, that the transition to abnormality of a biomarker may not correspond
to its pathological change, since no a priori thresholds are set.
Coherently with Iturria-Medina’s model [60], where spatiotemporal abnormalities of multiple biomarkers
are explored via a multi-factorial data-driven analysis, both EBM and DEBM orderings showed a drop
in the performance of cognitive test scores after events related to CSF biomarkers. In particular, EBM
ordering of cognitive results seems slightly more plausible, ordering the RAVLT before ADAS13, as
RAVLT has been reported to be more sensitive to detect abnormal changes in pre-dementia condition [118]
while ADAS is more specific to detect moderate AD conditions [119]. According to both methods,
cognitive tests were positioned before group-level neurodegeneration events in the benchmark sequences.
This fact might be in contrast with literature [5, 120] for which memory impairment occurs after
volumetric decrease of brain regions. This difference can be explained by the fact that population-level
volume changes may affect the event sequence [61]. The earlier position of cognitive scores with respect
to imaging biomarkers could be explained partially by the different GMMs used in the two algorithms
and partially because of specific inclusion criteria for the ADNI training subjects. In ADNI, no subjects
with severe cognitive impairments were included since one of the inclusion criteria was to have MMSE
score at least equal to 18. This may affect the position in which cognitive test scores were considered
abnormal because the threshold that separates normal from abnormal values might be overestimated by
the models, considering that no a priori assumptions are made in EBM and DEBM.
As far as the MRI biomarkers are concerned, DEBM showed an expected pattern of grey matter
atrophy with AD progression. Abnormalities were ordered throughout the temporal lobes as
follows: hippocampus, entorhinal cortex, fusiform and mid temporal regions. Precuneus was affected
subsequently, in agreement with model of cortical atrophy progression proposed by ten Kate et al. [121],
where atrophy of parietal regions is associated with progression from MCI to dementia. The DEBM
sequence presented the whole brain and subcortical abnormalities as end-sequence events. EBM did
not capture the expected atrophic evolution of the grey matter and the main anomaly was represented
by ventricles. Their abnormality was reported in the fourth position of the optimal sequence and their
variability is spanning from the first to the last position. Two different local likelihood maxima due to
different subtypes of AD [86] in the EBM sequence space could be one possible reason. Also, this issue is
not observable in DEBM, where normally the variance of an event is distributed continuously around its
specific position, that means around the positional variance diagram bisector. The difference between the
two models can be attributed to the smoothing effect intrinsic to the DEBM algorithm and, as highlighted
in [93], to the specific mixture model used in EBM. The sequences generated by EBM and DEBM models,
however, represent a general event ordering for the progression of the disease and individual trajectories
may show variability with respect to the optimal sequences.
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We demonstrated, using data from ADNI and 6 other independent clinical cohorts, the performances of
EBM and DEBM across the entire Alzheimer’s time course. Staging of subjects in both the training and
test sets showed separation between AD and CN in the two methods. This meant that the algorithms
were effective at distinguishing subjects having only a few abnormal biomarkers from those having only
a few normal biomarkers. As expected, the majority of CN subjects from the training set were staged at
position 0, where no abnormality manifested yet, and a large number of AD subjects was at end-sequence
stages 11-13. Staging of the test subjects followed the same general trend as ADNI, although subjects
with a lack of CSF values or cognitive assessments and with normal imaging biomarker values were
staged in proximity of non-symptomatic stage 0. The large number of CN subjects in the test sets that
were staged in the last positions for both models, can be partly explained considering that a significant
portion of these individuals are CN elderlies with volumetric anomalies and no other biomarker available,
thus contributing to subjects’ misclassification although MMSE score showed no abnormalities. Another
portion of misclassified CN subjects is formed by individuals with abnormal imaging biomarkers but
here the misclassification is due to the linear regression correction since the average eTIV of test subjects
is significantly lower than the average eTIV of training subjects, thus, the imaging biomarkers of test
subjects are artificially considered as atrophic with respect to the imaging biomarkers from the training
set subjects.
Some concerns may arise from the large number of MCI subjects staged at stage 0. The CSF and cognitive
scores for the majority of these individuals were close but not yet over the probabilistic threshold values,
therefore they were still in the normal ranges, and the models considered those subjects as normal.
Despite this, staging evidences give comparable results to state-of-the-art classification techniques for
prediction of conversion from MCI to dementia [81, 122].
EBM and DEBM showed good linear correlation with MMSE scores, fairly consistent with the clinical
and regional biomarkers, thus producing an indirect validation of models with respect to the disease
evolution. Both methods, after an initial plateau due to the ceiling effect typical for MMSE test [114],
showed an expected linear decline [123]. Although it was a rather trivial approach, we tried to validate
the EBM and DEBM event sequences even in absence of a validated pathological gold-standard across the
data cohorts.
When all test subjects are considered, we detected a significant drop of performance in classifying AD
vs CN as well as in MCI vs CN subjects from ADNI to the test cohorts. This is probably due to
missing data (CSF biomarkers and cognitive scores), which is known to increase uncertainty in subject
staging [61]. Indeed, when considering a reduced set of test subjects for which all biomarkers were
available, the performances became much closer to those obtained from the training set and no more
significant differences between training and test data sets were observable for both EBM and DEBM (p-
values¿0.05). This reinforces the importance to collect an adequate set of biomarkers for an accurate
staging of single subjects into the correct diagnostic class.
As far as the test set is concerned, the classification of AD vs CN subjects was significantly better in
EBM than in DEBM (p-values≤0.05). In classifying AD vs MCI, EBM was slightly better with higher
sensitivity, balanced accuracy and AUC. In MCI vs CN, DEBM reached higher sensitivity and balanced
accuracy while EBM reached higher specificity. This evidence might represent specific hints to guide the




An interesting consideration for future works is the possibility to use such methods to follow MCI in
specific sub-classes, namely: amnestic MCI, non-amnestic MCI and MCI due to AD. Additional studies
with extended age range of subject, larger and additional groups and additional biomarkers such as
other brain regions will be helpful to achieve a more accurate description of AD via event-based models.
Clinically relevant information related to patients’ staging, together with the models’ robustness as well
as progressive tracking capabilities along the CN-to-AD course, might be implemented into a clinical
decision support tool, to aid diagnosis and prognostic assessment of AD at early stages.
Additional efforts will be needed to understand the capabilities of staging subjects during clinical routine
by means of EBM and DEBM in: (I) reducing the number of patients needed for future clinical trials, (II)
monitoring the efficacy of disease modifying drugs, (III) personalized medicine.
So far, EBM and DEBM have been validated against well-characterized research datasets, synthetic data
and, in the present study, multicentric clinical cohorts, but none of them has been yet compared against
different stages of the AD pathology. In the next future, we would have to focus on further validation of
both models against databases of population of normal and abnormal post-mortem studies on subjects
assessed with as many biomarkers as possible, such as those collected in the Religious Orders Study [124],
Rush Memory and Aging Project [125], the Adult Changes in Thought study [126], and the National
Alzheimer’s Coordinating Center data set [127].
Some limitations of the current results should be considered in future validations of event-based models.
First, the tools here described need to be further compared with other complementary techniques based
on longitudinal data sets, such as: temporal continuous models and spatiotemporal models – see [80] for
a recent review of the field. Second, as clinicians are the potential beneficiaries of the tools based on such
models, independent evaluators should rate the diagnostic added value and accuracy of EBM and DEBM.
Third, the greatest limitations in the methods applied is the assumption of a common or average disease
trajectory across individuals, while AD is highly heterogeneous and clearly violates this assumption. In
this perspective single subject orderings already available in DEBM, and data-driven subtype progression
patterns estimated using SuStaIn (Subtype and Stage Inference) [86] could play a central role in the
description of AD progression at the level of the single subject. Finally, computational time is worth
considering: the extensive use of EBM or DEBM to analyse large volumes of data that must be pre-
processed and that require large computational resources, such as: HPC, Grid, or Cloud [128, 129, 130],
indeed the models can be trained a priori and then they should be used in the clinical practice only to
evaluate new subjects on the basis of the preferred model within an acceptable time frame.
The state of the art of these data driven models is represented by research tools (https://github.com/
EuroPOND), that should be implemented in more user-friendly interfaces compatible with the clinical
routine. Efforts towards the opportunities for clinical adoption and perceived importance of such a tool
in clinical setting has started to appear (https://icometrix.com) (see Supplementary Figure 3.SF6).
3.5 Conclusions
We have performed an inter-cohort model transferability study and model performance comparison
via external validation approach for event-based models. In the field of healthcare, the importance of
data driven models will grow in the coming years, and the results presented here represent the first
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viability and generalizability proof of principle to train such models on research data and apply them
clinically: on cross-sectional, less-well-characterized cohorts. We trained data-driven disease progression
models with the ADNI data set and compared patients’ ordering, staging and performance through ADC,
ARWiBo, EDSD, OASIS, PharmaCog and ViTA data sets. Overall, we tested both models on 4556 subjects
and 14 multimodal biomarkers. Both EBM and DEBM demonstrated similar and good classification
performances especially when all biomarkers were available for test subjects. Orderings obtained from
both models agreed with previous heuristic models. The event sequence generated through DEBM
returned a more reasonable description of the course of AD, while EBM showed better classification




Figure 3.SF1: Box plots of biomarkers for each diagnostic category (CN, MCI and AD) for subjects from
ADNI and Test datasets. Lower and upper hinges of each boxplot correspond to 25th and 75th percentiles
of data. φ: no significant difference (p-value≤0.05) between biomarkers of MCI subjects from training
and test datasets; ζ: no significant difference (p-value≤ 0.05) between biomarkers of AD subjects from
training and test datasets
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Mathematical modelling details
According to EBM and DEBM approaches, each biomarker is considered as either normal or abnormal and
its probabilistic transition from the normal to the abnormal state is defined as event. The aim is to define
in a data-driven manner the sequence of events that describe the most probable cascade of symptoms that
characterize the transition from the healthy state to the full-blown disease spectrum.
Event Based Model (EBM)
In EBM various event sequences are sampled via a Markov Chain Monte Carlo (MCMC) process that aims














where X denotes the entire data set, NB is the number of biomarkers, P (k) is the probability of being
at stage k, xij is the j-th biomarker of subject i and P (xij |Ej) and P (xij |¬Ej) are the likelihoods of
measurement xij given that biomarker j has or has not become abnormal respectively, implying that
events E1, . . . , Ek already occurred and events Ek+1, . . . , ENB still have to occur. The central ordering
is therefore the ordering for which P (X|S) is maximum, or equivalently the ordering that best fits X .
Sequences are sampled via an MCMC process where at each Monte Carlo step a new sequence S′ is
sampled as a random swap between two biomarkers of the benchmark sequence S. If the likelihood of
S′ is greater than the likelihood of S, then S′ is considered as the benchmark sequence for the following
MCMC step. The transition to a new state can also happen if the likelihood of S′ is less than the likelihood
of the benchmark sequence, and in this case the transition occurs with probability:
p = eP (X|S
′)−P (X|S)
so that event sequences can be chosen hierarchically as benchmark sequences based on their likelihood.
The normal and abnormal states for each biomarker are defined by a gaussian mixture model (GMM),
where the populations of CN and AD subjects are described respectively by the normal distributions
Nj(µCN , σCN ) and Nj(µAD, σAD). To avoid the possibility that biomarkers will not show a clear
bimodal distribution, the standard deviations of P (x|Ej) and P (x|¬Ej) must be less or equal to the
distributions of biomarkers from AD and CN subjects respectively. The mixture model distribution for




log (θjP (xij |Ej , Nj(µAD, σAD)) + (1− θj)P (xij |¬Ej , Nj(µCN , σCN )))
where N is the number of subjects in the dataset. The parameter θj is a mixing parameter between 0 and
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1 weighs the CN and AD distributions for the j-th biomarker.
Discriminative Event Based Model (DEBM)
The approach of DEBM model for the calculation of the central ordering, on the other hand, is a two-
step process where first (i) a specific ordering Si is calculated for each subject by sorting the posterior
probability that biomarker xij has become abnormal and then (ii) computing the central ordering S as the
event sequence that minimizes the sum of modified Kendall’s tau distances (see the following subsection)
between itself and all the subject-wise orderings Si.
As the posterior probability is influenced by the physiological variability of biomarkers, DEBM assumes
that single subject orderings Si are noisy estimates of the central ordering S. An initial estimate of the
distributions of non-diseased and diseased subjects for each biomarker is performed using values from
subjects at the very opposite sides of the disease spectrum, as defined by a Bayesian classifier which is
trained to remove outliers and wrongly labelled data. It generates truncated Gaussian functions that
neglect the tails of the distributions of the two populations, thus reducing the value of the standard
deviations of the two distributions with respect to those of the whole population distribution. This
allows to separate efficiently the two normal distributions for the j-th biomarker Nj(µCN , σCN ) and
Nj(µAD, σAD). With this method the resulting distributions are biased estimates of the expected
distribution, characterized by smaller variance and a mean that is greater than the expected one for the
distribution with the larger mean and minor for the distribution that has the smaller mean.
The biased distributions are then refined including data from all subjects via a GMM that has constraints
based on the aforementioned relationships between the expected and the biased distributions, where the
objective function for optimization of biomarker j is the same as that for EBM. The optimization of Cj
is performed by alternatively optimizing the gaussian parameters µCN , σAD, µAD, σAD and the mixing
parameter θj until the latter converges. The mixing parameters of the Bayesian classifier are used as prior
probabilities for the class they represent, i.e. pathological or non-pathological.
Modified Kendall’s Tau
Traditional Kendall’s Tau distance is often used in order to measure quantitative differences between






Where S and S′ are the two sequences, N is the total number of events and Vn(S, S′) is the number
of adjacent swaps needed so that event n of sequence S is at the same position in both sequences. In a
nutshell, Kendall’s tau distance computes the total number of adjacent swaps that are needed to transform
the sequence S′ into sequence S. In DEBM model the estimates of the individual sequences are based on
rankings of posterior probabilities of biomarkers being abnormal, therefore it is convenient to define a
model version of Kendall’s Tau distance that takes into account of posterior probabilities where swaps
between events for which the difference of probability is large is penalized. In this case the number of
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Where n and k denote the positions of the same biomarker in S and S′ respectively and pi denotes the
probability that biomarker at position i has become abnormal. After V̂n(S, S′) has been calculated for a
single biomarker S′ is updated by swapping event at position k with event at position n.
Subject Staging
Specific methods for staging subjects on the basis of the event sequences are available in both EBM and
DEBM original formulations. For the sake of simplicity, and in order to have a common staging system
for both models, the method from EBM was employed in this work. This method stages each subject on
the central event sequence, with the inclusion of stage 0 where no biomarker is abnormal, and assigns
each individual the stage σi defined as:








The stage σi is the k-th step of the optimal sequence S that maximizes the probability that all events up to
k already occurred for subject i and events from (k+ 1) toNB have not occurred yet given the biomarker




Performance metrics of EBM and DEBM including all biomarkers
EBM DEBM
kT Sens Spec BalAcc AUC kT Sens Spec BalAcc AUC p
Training
AD vs CN 11 0.99 0.97 0.98 0.99* 6 0.95 0.96 0.96 0.97* 5.66× 10−2
AD vs MCI 11 0.72 0.97 0.84 0.85* 6 0.50 0.96 0.73 0.78 7.64× 10−2
MCI vs CN 7 0.97 0.48 0.73 0.75* 3 0.90 0.58 0.74 0.76* 0.671
Test
AD vs CN 11 0.90 0.84 0.87 0.91 3 0.70 0.97 0.84 0.89 1.24× 10−3
AD vs MCI 11 0.70 0.84 0.77 0.80 9 0.64 0.82 0.73 0.78 0.222
MCI vs CN 1 0.64 0.69 0.66 0.68 1 0.69 0.66 0.67 0.67 0.251
Table 3.ST1: Measurements of area under curve (AUC), sensitivity (Sens), specificity (Spec) and balanced
accuracy (BalAcc) at a specific threshold (kT ) for the subject staged with EBM and DEBM methods on train
and test datasets when MMSE is included in the set of biomarkers. Thresholds are chosen to maximize
the balanced accuracy in each classification task. P-values of Delong test performed to compare AUCs
obtained with EBM and DEBM methods are reported in the last column. AUCs of ADNI subjects denoted
with * are significantly different from their analogous of test subjects (p-value ≤ 0.05).
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Figure 3.SF2: Staging based on the sequences obtained with EBM and DEBM for subjects of each test
cohort. Staging of subjects from all diagnostic categories (Cognitively normal (CN) in blue, mild cognitive
impairment (MCI) in orange, and Alzheimer’s disease (AD) in red) are shown for the cases of (a) ADC
subjects on EBM sequence; (b) ADC subjects on DEBM sequence; (c) ARWiBo subjects on EBM sequence;
(d) ARWiBo subjects on DEBM sequence; (e) EDSD subjects on EBM sequence; (f) EDSD subjects on DEBM
sequence; (g) OASIS subjects on EBM sequence; (h) OASIS subjects on DEBM sequence; (i) ViTA subjects
on EBM sequence; (j) ViTA subjects on DEBM sequence.
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Figure 3.SF3: Scatter plot of DEBM stage vs. EBM stage for training (left) and test (right) subjects. Areas of
annuli are proportional to the number of subjects. Linear regression resulted in slopes of 0.891 (R2=0.802)
for training subjects and 0.829 (R2=0.680) for test subjects.
Figure 3.SF4: Positional variance diagrams of Event ordering obtained with EBM and DEBM when MMSE
is included in the original set of biomarkers. Both diagrams show the number of times each biomarker
occurred in a certain position from a batch of 50 independent bootstrapped sequences generated form
biomarkers of subjects from the training set with EBM (left) and DEBM (right) methods.
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Figure 3.SF5: Subject staging based on the sequences obtained with EBM and DEBM methods when
MMSE is included in the set of biomarkers. Staging of subjects from all diagnostic categories (Cognitively
normal (CN) in blue, mild cognitive impairment (MCI) in orange, and Alzheimer’s disease (AD) in red)
are shown for the cases of (a) training subjects on EBM sequence; (b) training subjects on DEBM sequence;
(c) test subjects on EBM sequence and (d) test subjects on DEBM sequence. Histograms are normalized
for each diagnostic category.
Figure 3.SF6: Single case interface (alpha release developed by Icometrix NV in the context of the
EuroPOND H2020 initiative) to stage patient according to the biomarkers data availability. X-axis reports
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Objective: Progranulin related frontotemporal dementia (FTD-GRN) is a fast progressive disease.
Modelling the cascade of multimodal biomarker changes aids in understanding the etiology of this
disease and enables monitoring of individual mutation carriers. In this cross-sectional study, we estimated
the temporal cascade of biomarker changes for FTD-GRN, in a data-driven way.
Methods: We included 56 presymptomatic and 35 symptomatic GRN mutation carriers, and 35 healthy
non-carriers. Selected biomarkers were neurofilament light chain (NfL), grey matter volume, white
matter microstructure, and cognitive domains. We used discriminative event-based modelling to infer
the cascade of biomarker changes in FTD-GRN and estimated individual disease severity through cross-
validation. We derived the biomarker cascades in non-fluent variant primary progressive aphasia
(nfvPPA) and behavioural variant FTD (bvFTD) to understand the differences between these phenotypes.
Results: Language functioning and NfL were the earliest abnormal biomarkers in FTD-GRN. White
matter tracts were affected before grey matter volume, and the left hemisphere degenerated before
the right. Based on individual disease severities, presymptomatic carriers could be delineated from
symptomatic carriers with a sensitivity of 100% and specificity of 96.1%. The estimated disease severity
strongly correlated with functional severity in nfvPPA, but not in bvFTD. In addition, the biomarker
cascade in bvFTD showed more uncertainty than nfvPPA.
Conclusion: Degeneration of axons and language deficits are indicated to be the earliest biomarkers in
FTD-GRN, with bvFTD being more heterogeneous in disease progression than nfvPPA. Our data-driven
model could help identify presymptomatic GRN mutation carriers at risk of conversion to the clinical
stage.
4.1 Background
Mutations in the progranulin (GRN) gene on chromosome 17q21 are a major cause of
autosomal dominant inherited frontotemporal dementia (FTD) [131, 132]. The majority of
mutation carriers develops a behavioural variant FTD (bvFTD) phenotype [133], and another
significant proportion of patients present with non-fluent variant primary progressive aphasia
(nfvPPA) [133, 134]. The age of symptom onset varies between 35 and 90 in GRN mutation
carriers [131, 132], without clear associations with familial age of onset [134]. Brain changes in
FTD-GRN patients can evolve symmetrically, or predominantly asymmetrically, in either the
left or right hemisphere [86, 135].
Recent longitudinal studies have suggested that the time-window between emerging
pathophysiological changes and the first clinical symptoms is short in GRN mutation carriers,
and covers only two to four years [10, 136]. During this period, the serum neurofilament light
chain (NfL) level – a marker of axonal degeneration – increases two to three-fold [30, 137],
loss of grey and white matter emerges [10, 138], and cognitive functioning declines [136].
However, most of the biomarker studies in FTD-GRN have investigated one type of
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biomarker, i.e. fluid, neuroimaging, or cognition, leaving the temporal relations and ordering
of these biomarkers unknown. These temporal relations could potentially provide novel
insights into disease progression mechanisms in GRN mutation carriers. Moreover, because
of the fast progression of pathophysiological changes, determining the earliest abnormal
biomarker is crucial, as the optimal window of opportunity for treatment might be small.
Recently, novel data-driven methods for disease progression modelling have emerged,
focusing on the cascade of biomarker changes [52, 70]. Event-based models are a class of
disease progression models that estimate the cascade of biomarker changes derived from
cross-sectional data [53, 70, 86]. This is done without strong a priori assumptions regarding
the relationship between different biomarkers. A promising novel method that estimates the
cascade of biomarker change is Discriminative Event-Based Modelling (DEBM) [70, 93]. This
model is robust to disease phenotypic heterogeneity in a cohort and can handle missing data.
In this study, we use DEBM to estimate the temporal cascade of biomarker changes in
presymptomatic and symptomatic FTD-GRN mutation carriers, distinguishing between early
and late biomarkers. Furthermore, we determine phenotypic differences in patterns of
biomarker changes in nfvPPA and bvFTD, to gain more insights into their distinct disease
progression mechanisms.
4.2 Methods
4.2.1 Sample and study procedures
Subjects were recruited prospectively from three European centres of the Genetic
Frontotemporal dementia Initiative (GENFI): Rotterdam (the Netherlands), Brescia (Italy),
and Barcelona (Spain). We collected cognitive and clinical data, MRI, and serum samples
from 126 participants. We included 35 symptomatic GRN mutation carriers (Rotterdam:
n=11, Brescia: n=22, Barcelona: n=2), 56 presymptomatic GRN mutation carriers (Rotterdam:
n=33, Brescia: n=17, Barcelona: n=6), and 35 cognitively healthy non-carriers (Rotterdam:
n=34, Brescia: n=0, Barcelona: n=1). Local clinical genetics departments performed
DNA genotyping to confirm the presence of a GRN mutation. Non-carriers were first-
degree family members of GRN patients without a mutation. Symptomatic mutation
carriers were diagnosed based on the established clinical criteria for bvFTD [139] (n=17),
nfvPPA [140] (n=16), or cortico-basal syndrome [141] (n=2). Mutation carriers were defined
as presymptomatic when clinical criteria were not fulfilled, i.e., behavioural or cognitive
symptoms were absent [142]. Clinical questionnaires were administered to the caregiver,
spouse, or a family member, i.e. the Frontotemporal Lobar Degeneration Clinical Dementia
Rating scale sum of boxes (FTD-CDR-SB) [143], the Neuropsychiatric Inventory (NPI [144],
and the Frontotemporal Dementia Rating scale (FRS) [145]. The study was carried out
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according to the declaration of Helsinki, approved by the local medical ethics board at each
site, and all participants provided written informed consent.
4.2.2 Biomarker collection and processing
Biomarker selection
For biomarker selection, we performed a literature search using Pubmed. We included studies
that (i) performed research in presymptomatic GRN mutation carriers, and (ii) biomarker
studies that examined biomarkers in blood or CSF, neuroimaging biomarkers and cognition.
We selected serum NfL [137], MMSE, cognitive domains of attention and processing speed,
executive functioning, language, and social cognition [136, 146]; left and right grey matter
volumes of the insula, frontal lobe, parietal lobe and temporal lobe [10, 138]; left and
right white matter tracts of the anterior thalamic radiation, superior longitudinal fasciculus,
uncinate fasciculus, and the forceps minor [10, 147]. For detailed information about the
literature review and subsequent biomarker selection, please see Supplementary material 4A.
Neurofilament light chain
Serum samples were obtained through venepunctures and analysed with single molecular
assay technology, as described previously [30]. Samples were measured in a single laboratory,
in duplicate, with an intra-assay coefficient of variation below 5%. Inter-assay variation
between batches was below 8%. NfL concentrations were expressed in pg/ml.
Magnetic Resonance Imaging
3D T1-weighted and diffusion tensor imaging were acquired with 3T MRI scanners across the
three sites. MRI was missing in 25 participants due to unavailability (n=16) and insufficient
quality due to motion artefacts (n=9). Availability of MRI and an overview of the scanning
protocols are listed in Supplementary material, Table 4.ST1. Image processing was carried out
in FMRIB Software Library [148], using default pipelines for grey matter volumes and white
matter tracts. For grey matter volumetric regions of interest (ROI), we used the Montreal
Neurological Institute (MNI) atlas [149], and for the fractional anisotropy of white matter
tracts, we used the Johns Hopkins’ University atlas [150]. Left and right regions and tracts
were considered separately. Raw regional volumes and fractional anisotropy values were
transformed to z-scores, based on the mean and standard deviation from the non-carriers. A





Cognitive data were collected from all participants in four cognitive domains, described in
detail in supplementary material 4A. Raw cognitive test scores were transformed to z-scores
based on the mean and standard deviation in non-carriers, and then combined into cognitive
domain scores similar to previous studies [136].
Confounding factors correction
All selected biomarkers were tested for normality (see supplementary material 4A for details)
and log-transformed in case of a skewed distribution. As most non-carriers originated from
one centre, we used presymptomatic subjects for regressing out possible confounding effects
using multiple linear regression, before continuing with event-based modelling. NfL levels
were corrected for age and sex. Grey matter volumes and fractional anisotropy values were
corrected for age, sex, total intracranial volume and MRI scanning protocol. Cognitive domain
scores were corrected for confounding effects of age, sex and total years of education.
4.2.3 Temporal cascade of biomarker changes
The DEBM model introduced in Venkatraghavan et al. [70, 93] estimates the cascade of
biomarker changes in a three-step process. For each biomarker, it first estimates the
distributions of normal and pathological (or abnormal) values using Gaussian mixture
modelling (GMM), and uses these to compute, for each subject, the probability that the
biomarker is abnormal (explained in detail in supplementary material 4B). The method then
estimates the biomarker cascade independently for each subject based on the biomarker
values present for that subject. The mean cascade is estimated such that the sum of the
probabilistic Kendall’s Tau distances is minimized between the mean cascade and all the
subject-specific cascades. For subjects with missing biomarker values, only the corresponding
subset of the biomarker cascade present in the subject-specific cascade is used to compute the
probabilistic Kendall’s Tau distance. Lastly, the severity of disease as a summary measure
for each subject is computed by estimating the subject’s progression along the resulting
disease progression timeline. In this section, we describe the experiments we performed
for estimating the cascade of biomarker changes for non-imaging biomarkers, as well as for
neuroimaging and non-imaging biomarkers together.
DEBM model for non-imaging biomarkers
As imaging was missing in a lot of subjects (n=25), we first estimated the cascade of
biomarker changes procedure with solely NfL and cognitive biomarkers. Since the non-
carriers are healthy in this cohort, the normal Gaussians were fixed at the mean and standard
deviation of the biomarker values of the non-carriers. We used GMM only to estimate the
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abnormal Gaussian and the mixing parameter for each biomarker. In order to estimate the
positional variance in the estimated cascade, the entire dataset was randomly sampled using
bootstrap sampling with 100 different random seeds, and the cascade of biomarker change
was estimated for each of those randomly sampled datasets [70, 93].
DEBM model for neuroimaging and non-imaging biomarkers together
For the imaging biomarkers, we modified the GMM step in DEBM to make it better suited
for the FTD-GRN population, known for its asymmetric pattern of atrophy [135]. Abnormal
values of biomarkers that typically become abnormal late in the disease are usually under-
represented in a specific patient population as compared to the early biomarkers. This
could make the GMM of late biomarkers unstable, as previously reported [93]. Due to the
asymmetrical atrophy patterns of FTD-GRN [86, 135], lateralized neuroimaging biomarkers
that become abnormal early in the disease process may have a corresponding biomarker from
the other hemisphere that remains stable until much later in the disease process. To exploit
this, we assumed that the normal and abnormal Gaussians from the left and right hemispheric
biomarkers (expressed as z-scores) are the same, and the biomarkers from both hemispheres
only differ in their position along the disease progression timeline. With this assumption, we
proposed a novel modification to the GMM optimization called Siamese GMM, in which the
biomarkers of the same region from left and right hemispheres are jointly optimized. The
abnormal and normal Gaussians are shared between the left and right hemispheres, but the
mixing parameters are independently estimated (see supplementary material 4B for details).
In this way, the numerical stability of GMM optimization in the late neuroimaging biomarkers
improved.
For non-imaging biomarkers, GMM was performed as described in the previous section.
After GMM, further steps of DEBM modelling were carried out as usual, to estimate the
complete cascade of neuroimaging and non-imaging biomarker changes in presymptomatic
and symptomatic GRN mutation carriers. The positional variance in the estimated cascade
was again estimated using bootstrap sampling with 100 different random seeds. For brevity,
in the remainder of the paper we refer to this model, which integrates neuroimaging and
non-imaging biomarkers, as the multimodal DEBM.
Validation
To validate the DEBM models, we used 10-fold cross-validation. In each fold of the
cross-validation, the DEBM model was built in the training set and the disease severity
was estimated in the test set. We distinghuished symptomatic mutation carriers from
presymptomatic mutation carriers, and reported the corresponding sensitivity and specificity.
Furthermore, in bvFTD and nfvPPA subjects, the estimated disease severity was correlated
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with years since symptom onset and FTD-CDR-SB scores, using Pearson correlation.
Symptomatic carriers without imaging biomarkers were excluded for the validation of the
multimodal DEBM but were included in the non-imaging DEBM.
4.2.4 Differential phenotype analysis
In order to examine the differences between bvFTD and nfvPPA variants of FTD-GRN, we
built separate DEBM models. Presymptomatic subjects were excluded from this analysis as
no phenotype information is available. The numbers of symptomatic subjects in each group
(17 with bvFTD, 16 with nfvPPA) are too small to build complete DEBM models reliably.
As a solution, we assumed that the biomarkers for the two phenotypes shared the same
normal and abnormal biomarker distributions, and that they only differ in their position
along the disease progression timeline. We hence optimized the GMM such that the normal
and abnormal Gaussians were estimated without considering the phenotypes, whereas the
mixing parameters were estimated separately for each phenotype. As before, we estimated
the cascade of biomarker changes in the two phenotypes for non-imaging and multimodal
(neuroimaging and non-imaging together) biomarkers.
4.3 Results
4.3.1 Sample
A total of 126 subjects were included in this study. Availability and characteristics of the data
are presented in Table 4.1. Details on biomarker availability and characteristics can be found
in supplementary material 4A, Tables 4.ST2 and 4.ST3. Symptomatic mutation carriers were
older, had fewer years of education, and had higher scores on the NPI and FTD-CDR-SB,
and lower scores on the FRS than both presymptomatic mutation carriers and non-carriers.
There were no differences in demographic or clinical characteristics between presymptomatic
mutation carriers and non-carriers.
4.3.2 Cascade of biomarker changes
Non-imaging and multimodal DEBM models
In Figure 4.1a and 4.1b, we show the estimated mean cascade of biomarker changes and
the uncertainty within the model for non-imaging and multimodal biomarkers. Language
was the earliest biomarker to become abnormal followed by neurofilament light chain. It
can be seen in Figure 4.1b that, left anterior thalamic radiation, left insula, and bilateral
uncinate fasciculi were the earliest imaging biomarkers. It can also be observed that imaging
biomarkers from the left-hemisphere became abnormal earlier than their right counterpart.





































































































































































































































































































































































































































































































































































































































































where the estimated Gaussians are seen to fit the observed histograms well. Figure 4.1c shows
the positional variance of the cascade of multimodal biomarker changes obtained when GMM
of the imaging biomarkers was done without using Siamese GMM. Generally, the positional






Figure 4.1: Cascade of biomarker changes in FTD-GRN along with the uncertainty associated with it. (a)
Non-imaging biomarkers, (b) Multimodal biomarkers with Siamese GMM, (c) Multimodal biomarkers
without Siamese GMM. The biomarkers are ordered based on the position in the estimated cascade. The
color-map is based on the number of times a biomarker is at a position in 100 repetitions of bootstrapping.
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Figure 4.2: Gaussian mixture modelling distributions. The histogram bins are divided in three colours,
where the green part shows the proportion of non-carriers, the yellow part shows the proportion of
presymptomatic carriers and the red part shows the proportion of symptomatic carriers. The Gaussians
shown here are the ones that were estimated using Gaussian mixture modelling, where the green
Gaussian is the normal one estimated using non-carriers and the red Gaussian is the abnormal one
estimated using the carriers. The amplitudes of these Gaussians are based on the estimated mixing






Figure 4.3: Frequency of occurrence of subjects with different disease severities, estimated using cross-
validation. (a) results using non-imaging biomarkers in DEBM, (b) results using multimodal biomarkers
in DEBM.
Validation
Figure 4.3a and 4.3b shows the estimated disease severity when using non-imaging and
multimodal biomarkers respectively. It can be seen that estimated disease severity delineated
the symptomatic subjects from the pre-symptomatic subjects. The sensitivity and specificity
of this delineation were 1.0 and 0.982 respectively while using non-imaging biomarkers, and
1.0 and 0.961 respectively while using multimodal biomarkers.
Figure 4.4 shows the correlation of the estimated disease severity with years since symptom
onset and FTD-CDR-SB for nfvPPA and bvFTD subjects, when using multimodal DEBM.
It can be seen from Figure 4.4 that estimated disease severity strongly correlated with
years since symptom onset (R=0.95, p=0.0003), and the FTD-CDR-SB (R=0.84, p=0.0189),
in nfvPPA patients. However, estimated disease severity correlated poorly with years
since symptom onset (R=0.22, p=0.6331) and the FTD-CDR-SB (R=0.28, p=0.5866) in bvFTD
patients. Figure 4.SF2 in supplementary material 4B shows a similar plot when using non-







Figure 4.4: Correlation of disease severity (as estimated by multimodal DEBM using cross-validation)
with years since onset and FTD-CDR-SOB. The 2D scatter plots in figures (a) and (c) show the correlations
of disease severity with years since onset, for symptomatic nfvPPA and bvFTD subjects respectively. The
2D scatter plot in figures (b) and (d) show the correlations of disease severity with FTD-CDR-SOB. The
plot on top of each subfigure shows the probability density function of the disease stages. The plots on
the right of figures (a) and (c) show the probability density functions of years since symptom onset. The
plots on the right of figures (b) and (d) show the probability density function of FTD-CDR-SOB.
symptom onset and FTD-CDR-SB, neither for nfvPPA nor for bvFTD subjects.
Differential phenotype analysis
Figure 4.5 shows the multimodal biomarker cascade for nfvPPA and bvFTD phenotypes.
nfvPPA patients showed language and NfL as first abnormal biomarkers followed by
other cognitive domains. Left-hemispheric imaging biomarkers became abnormal before
right-hemispheric imaging biomarkers, starting with the uncinated fasciculus (white matter





Figure 4.5: Cascade of multimodal biomarker changes in nfvPPA (a) and bvFTD (b) subjects along with
the uncertainty associated with it. The biomarkers are ordered based on the position in the estimated
cascade. The color-map is based on the number of times a biomarker is at a position in 100 repetitions of
bootstrapping.
fasciculus was estimated as late biomarker, even later then its right-sided counterpart.
Interestingly, in bvFTD patients, the biomarker ordering also indicated that language and
NfL were the earliest abnormal biomarkers. In contrast to the nfvPPA, the left superior
longitudinal fasciculus (white matter integrity) was estimated as the first abnormal imaging
biomarker in bvFTD. However, the biomarker orderings in bvFTD were predominantly
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characterized by large uncertainty in the positioning of biomarkers in the disease timeline,
with hardly any observable distinction between early and late biomarkers. Figure 4.SF3
in supplementary material 4B presents the non-imaging biomarker cascade for the two
phenotypes, showing that the uncertainty in the mean cascade in bvFTD is more than in
nfvPPA.
4.4 Discussion
In this study, we estimated the cascade of biomarker changes in FTD-GRN. We validated our
model by delineating the symptomatic mutation carriers from the presymptomatic mutation
carriers using the estimated disease severity. We demonstrated that language and NfL levels
are the earliest biomarkers to become abnormal in the FTD-GRN spectrum. Other early
biomarkers were the white matter microstructure of the thalamic radiation and the cognitive
domain of attention and mental processing speed.
Our findings support other studies that proposed NfL as an early biomarker for disease
onset in FTD-GRN [30, 137]. We demonstrated that the left anterior thalamic radiation
also degenerated early. This is also supported by previous studies which suggested that
white matter microstructure markers may correlate with changes in NfL [137, 151]. Cognitive
changes in attention, mental processing speed, and executive functioning occurred relatively
early in the estimated disease progression timeline. This corresponds well with the early
white matter changes (i.e. NfL and fractional anisotropy changes), as attention and processing
speed are cognitive functions that highly depend upon the integrity of axons and their
myelin sheaths [152, 153]. The early involvement of these biomarkers point towards axonal
degeneration as one of the first pathological processes in GRN mutation carriers. However,
it must be noted that the estimated cascade shows the sequence of biomarker events when
they are detectably abnormal. One of the important factors that affects the detectability of
biomarker abnormality in a cross-sectional data set is the overlap between the normal and
abnormal biomarker distributions. Therefore, the presented cross-sectional model cannot
provide insight into the sequence of earliest (hardly detectable) changes in the carriers’
biomarker levels. Figure 4.2 showed that the overlap in cognitive biomarkers is was relatively
smaller than the overlap in neuroimaging biomarkers, which could explain the relative early
positioning of the cognitive biomarker events.
With the differential phenotypic analysis, we estimated the biomarker cascade for nfvPPA
and bvFTD patients. Strikingly, language functions deteriorated early in both nfvPPA and
bvFTD. While not currently embedded in the clinical criteria for bvFTD [139], our results
demonstrate the importance of decreased language functions in both phenotypes. This is
in line with multiple previous studies [154, 155, 156]. In addition, multiple determinants
of the complex language network were also affected early, for example the left insula, and
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uncinate fasciculus [157]. While language deficits were estimated as the first detectable
abnormal biomarker, the overlap with the second, the elevation in NfL levels, complicates
distinguishing the timeline of these disease events. Furthermore, as depicted in Figure 4.2,
(subtle) language deficits were less specific for disease onset than NfL levels. However,
the high sensitivity of the language biomarker in our study, and the relative uncomplicated
administration of language tests (compared to neuroimaging techniques, for example) offers
potential for longitudinal research in the preclinical stage of FTD-GRN ideally in combination
with NfL levels.
For nfvPPA, NfL levels and other cognitive domains became abnormal in early disease stages,
consistent with findings from previous studies [30, 137, 158]. In addition, we showed that
left hemispheric tracts and regions were affected in nfvPPA patients before right regions,
accordant with the previously reported strong involvement of the left hemisphere in primary
progressive aphasia [159, 160]. We showed that NfL levels and cognitive domains may be
possible biomarkers for disease onset, while neuroimaging markers were highly correlated
with clinical indicators of progression (years since onset, FTD-CDR-SB).
For bvFTD, however, the biomarker cascade was characterized by large uncertainty, and the
estimated disease severities did not correlate with actual years since onset or FTD-CDR-
SB. This uncertainty could indicate large neuroanatomical heterogeneities between bvFTD
patients. Differences in neuroanatomical atrophy patterns have been associated with FTD-
GRN patients before [86, 135]. Here, we demonstrated that this anatomical heterogeneity
is predominantly associated with the bvFTD phenotype, while nfvPPA patients showed a
clear pattern of left hemispheric degeneration before the right hemisphere was affected.
Furthermore, bvFTD patients present with cognitive symptoms such as impaired social
conduct and executive function but can also have severe memory problems. In summary,
within the group of bvFTD, spatial and temporal brain degeneration and cognitive changes
are more heterogeneous than in the nfvPPA group.
From a methodological point of view the strength of this paper lies in the introduction
of the Siamese GMM approach in DEBM. We showed that Siamese GMM reduces the
positional variance in neuroimaging biomarkers, most notably in the right insula, the right
anterior thalamic radiation and the right superior longitudinal fasciculus. This is because
GMM is known to be unstable in the presence of biomarkers with a large overlap between
the normal and abnormal Gaussians [93]. This is often the case in biomarkers becoming
abnormal late in the disease and having very few samples representative of the typical
abnormal values expected in the disease. The joint GMM in the Siamese counterpart
exploits the knowledge that FTD-GRN is generally an asymmetric brain disease, and uses the
neuroimaging biomarkers that become abnormal early in the disease process to aid the GMM
of its hemispheric counterpart that becomes abnormal far later in the disease process. Another
98
FTD-GRN: Siamese GMM
strong point about the DEBM model is that it infers disease progression from cross-sectional
data, which is more readily available than longitudinal data, especially in a rare disease as
FTD-GRN.
From the clinical point of view, a major strength of our study is the large, well-defined cohort
of presymptomatic and symptomatic GRN mutation carriers, and availability of multimodal
(i.e. fluid, imaging, and cognitive) biomarkers. Although we did not have FLAIR or T2
imaging data available for the current study, it would be interesting to incorporate white
matter lesions in a future version of the model, as a number of studies have indicated
the presence of white matter lesions in FTD-GRN carriers [161]. Additionally, including
functional neuroimaging measures in future studies possibly provides new insights into the
temporal biomarker sequence and underlying disease mechanism as well. Recent papers have
addressed functional changes in FTD-GRN, showing thalamic-cortical hyperconnectivity in
early preclinical stages [162] and presymptomatic abnormalities in neurophysiology [163].
A minor limitation in our study is the difference in mean age between the non-carrier,
presymptomatic, and symptomatic mutation carrier groups. We adjusted for this in the
analysis rather than matching the groups. It should be noted that the small sample size may
have caused a large part of the uncertainty of our model, especially in the case of missing
(neuroimaging) biomarkers. Our bvFTD and nfvPPA samples due to GRN mutations were
relatively large compared to previous studies [164]. However, the DEBM model would
improve substantially if the phenotypic samples were larger, as we could only include
symptomatic subjects for the phenotypic analysis. Uncertainties in the estimation of the
phenotypic biomarker cascades may be improved with upcoming longitudinal data, when
some of the converted mutation carriers can be included in the phenotypic models.
In conclusion, with this DEBM study in the FTD-GRN spectrum, we were able to demonstrate
that language functions and NfL levels are the earliest abnormal biomarkers, regardless
of phenotype. However, bvFTD show more heterogeneity and uncertainty in disease
progression, pointing towards more variability in biomarkers than nfvPPA. Our analyses
suggest axonal degeneration and damage to the language network as the earliest biomarkers
in GRN mutation carriers, which could potentially be used as endpoints in clinical trials
for disease modifying treatments. Future efforts should be directed at confirmation and
validation of these findings with longitudinal data. Future vValidation of these results in
an external cohort such as the LEFFTDS [165] could further aid in confirming these results
and elucidate any ethnic variations in the disease progression timeline. We expect that
DEBM modelling will benefit individual prediction of symptom onset in the future, and may
optimize selection of eligible mutation carriers for clinical trials.
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Supplementary material 4A: Biomarkers
Biomarker selection
For biomarker selection, we extensively searched for relevant literature about presymptomatic
FTD-GRN in Pubmed. We reviewed all empirical studies that included at least a
presymptomatic GRN mutation carrier group. Next, we determined which biomarkers were
frequently reported as abnormal in previous empirical studies and included these biomarkers
accordingly, restricted to fluid biomarkers, grey matter brain regions, white matter tracts, and
cognition. The selected biomarkers were: serum NfL [30, 137, 166], MMSE [136, 138, 163],
cognitive domains of language, attention and processing speed, executive functioning, and
social cognition [136, 146, 167, 168]; left and right volumes of the insula, frontal lobe, parietal
lobe and the temporal lobe [138, 163, 169, 170, 171] [10, 86, 142, 172, 173, 174, 175, 176, 177];
white matter tracts: left and right fractional anisotropy of anterior thalamic radiation, superior
longitudinal fasciculus, uncinate fasciculus, and forceps minor [10, 142, 147, 169, 175, 178].
Although the GRN mutation affects plasma progranulin protein levels, these levels were
not selected as biomarker, as research has shown that these remain stable in both the
presymptomatic and symptomatic stage [163, 179].
MRI processing and ROI calculation
An overview of MRI acquisition parameters is presented in supplementary material
Table 4.ST1. The standard voxel-based morphometry pipeline from FSL [148, 180, 181] was
used to process T1-weighted images. In brief, the brain was extracted from the images, and we
carefully checked the brain extraction for missing brain tissue and areas of non-brain tissue,
and adjusted the image accordingly. We corrected RF inhomogeneities by bias field correction
with a Markov random field model and subsequently segmented the brain in grey matter,
white matter, and cerebrospinal fluid images [182]. A study specific grey matter template was
created in standard space using a balanced set of subjects, and all grey matter segmentations
were registered to this template with non-linear registration, and then corrected for any local
expansion or contraction by modulation of the Jacobian warp field [148]. Last, an isotropic
Gaussian kernel with a sigma of 3mm was applied for smoothing of the grey matter images.
Total intracranial volume (TIV) was calculated as the sum of the volumes from grey matter,
white matter and cerebrospinal fluid in standard space. The structures from the MNI-atlas
were used as grey matter ROIs. We extracted volumetric measurements from the ROIs by
registering the structural MNI-atlas [149] to the grey matter images in standard space, and
multiplying the grey matter density of the ROI with the total volume of the ROI, resulting in
the grey matter volume within the ROI. Left and right regions were considered separately.
Diffusion tensor images were corrected for motion artefacts and eddy currents by alignment
to the b=0 image, and subsequently, the tensor was fitted at each voxel to create fractional
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anisotropy (FA) images. The FA images were processed with the tract-based spatial statistics
(TBSS) pipeline as implemented in FSL [183]. Using non-linear registration, the images were
aligned to the FMRIB58 FA template and then averaged into a mean FA image. The mean
FA image was thresholded at 0.2 and thinned into a white matter skeleton. All individual
FA images were projected onto this skeleton, resulting in skeletonized FA data for each
participant. The probabilistic tracts from the Johns Hopkins University atlas [150] were
applied as white matter ROIs to the skeleton mask, and the masked ROIs were used to extract
FA values from the individual tracts. Left and right tracts were considered separately.
Rotterdam 1 Rotterdam 2 Brescia Barcelona
N (s/p/nc) 3/22/24 5/9/6 7/17/0 1/6/1
Scanner Philips Achieva 3T Philips Achieva 3T Siemens Skyra Siemens Trio Tim
Head Coil 8 channel SENSE 32 channel SENSE 32 channel 64 channel
T1 weighted imaging
TR 9.8 ms 6.8 ms 2000 ms 2000 ms
TE 4.6 ms 3.1 ms 2.9 ms 2.9 ms
FOV 224× 168 mm 256× 256 mm 282× 282 mm 282× 282 mm
Voxel size 0.88× 0.88× 1.2
mm
1.1 mm3 1.1 mm 3 1.1mm 3
Flip angle 8 8 8 8
Slices 140 207 208 208
Diffusion tensor imaging
TR 8250 ms 7000 ms 7300 ms 7300 ms
TE 80 ms 69 ms 90 ms 90 ms
FOV 256× 256 mm 240× 240 mm 240× 240 mm 240× 240 mm
Voxel size 2× 2× 2 mm 2.5× 2.5× 2.5 mm 2.5× 2.5× 2.5 mm 2.5× 2.5× 2.5 mm
Slices 70 59 59 59
Directions 60 68 68 68
B-values 0/1000 s/mm2 0/1000 s/mm2 0/1000 s/mm2 0/1000 s/mm2
Table 4.ST1: MRI acquisition protocols. Numbers are subjects included after quality check.
Abbreviations: s = symptomatic, p = presymptomatic, nc = non-carrier, TR = repetition time, TE = echo
time, FOV = field of view.
Cognitive assessment
The following cognitive tests were performed, depending on the protocol from the local site.
For language, the Boston Naming Task [184] and semantic fluency (animals) [185] were used.
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Tests concerning attention and processing speed were the Trail making test part A [186],
Stroop part 1 and 2 [187], symbol substitution [188], letter digit substitution task [189], and
forward digit span [188]. For executive functioning, we used Trail making test part B [186],
Stroop task part 3 [187], phonological fluency [185] and digit span backwards [188]. Tests
for social cognition were the Ekman faces test [190], emotion recognition from the mini social
cognition and emotional assessment (MINI-SEA) [191], and Happé cartoon task [192]. Raw
scores from tests in which a higher score indicates worse performance were reversed (i.e. Trail
making test, Stroop). We transformed all raw test scores to z-scores, based on the mean and
standard deviation of the non-carriers. Subsequently, cognitive domains were composed as
the mean z-score of all available tests within that domain per individual, disregarding missing
tests.
Biomarker statistics
Before modelling, we checked skewed distributions in the biomarkers with the following
graphs and tests: histograms, q-q plots, skewness and kurtosis values (values between 2
and –2 indicate normality), Kolmogorov-Smirnov and Shapiro-Wilk’s tests (values above 0.05
indicate normality). When three or more tests indicated skewness, the distributions were
adjusted using log-transformations (log10), i.e. neurofilament light chain levels, MMSE,
BNT, Trail Making Test, Stroop, facial emotion recognition. In the case of cognitive tests,
log-transformation was performed before transforming raw scores to z-scores. Biomarker
characteristics and statistical differences between groups are presented in Table 4A.3.
Symptomatic mutation carriers had higher NfL levels, lower grey matter volumes, impaired
white matter microstructure, and worse cognitive functions than both presymptomatic
mutation carriers and non-carriers in all selected biomarkers. Post-hoc analysis revealed
that these differences in biomarkers were specifically driven by the bvFTD patients. For
nfvPPA patients, we found higher NfL levels and worse cognitive performance than both
presymptomatic mutation carriers and non-carriers. NfvPPA patients showed smaller grey
matter volumes than both presymptomatic mutation carriers and non-carriers, especially
in left-sided ROIs, and lower fractional anisotropy levels in the left anterior thalamic
radiation, left uncinate fasciculus, and the forceps minor. The volume of the right frontal
lobe was smaller in nfvPPA patients compared with presymptomatic mutation carriers.
Furthermore, bvFTD patients had smaller volumes of the right frontal and temporal lobe than
nfvPPA patients, and lower fractional anisotropy values in the forceps minor, left superior
longitudinal fasciculus and right uncinate fasciculus. There were no differences in any of the










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.90± 0.25A 1.89± 0.23A 1.91± 0.28B 1.10± 0.22
Left frontal lobe (GM) −2.75± 1.80A −3.42± 2.06A −2.46± 1.40B 0.30± 0.65
Right frontal lobe (GM) −1.72± 1.79A −2.76± 1.43A,C −0.93± 1.79D 0.30± 0.65
Left insula (GM) −2.32± 1.56A −2.45± 1.79A −2.35± 1.51B −0.32± 0.95
Right insula (GM) −1.02± 1.13A −1.47± 1.26A −0.74± 0.98 −0.08± 0.84
Left parietal lobe (GM) −1.87± 1.11A −2.18± 1.39A −1.74± 0.84B −0.03± 1.02
Right parietal lobe (GM) −1.19± 2.00A −1.42± 2.08A −0.89± 2.15 −0.06± 0.96
Left temporal lobe (GM) −2.97± 2.42A −3.21± 2.59A −2.98± 2.51B −0.19± 0.96
Right temporal lobe (GM) −1.14± 2.66A −2.22± 3.40A,C −0.12± 1.69 −0.08± 0.94
Left anterior thalamic
radiation (FA)
−2.28± 1.34A −2.73± 1.60A −1.77± 0.98B −0.33± 0.95
Right anterior thalamic
radiation (FA)
−1.24± 1.23A −1.78± 1.51A −0.66± 0.66 −0.27± 0.77








−1.14± 1.12A −1.47± 1.14A −0.74± 1.06 −0.11± 0.60
Left uncinate fasciculus
(FA)
−2.63± 1.15A −3.00± 1.43A −2.29± 0.88B −0.35± 0.86
Right uncinate fasciculus
(FA)
−1.92± 2.16A −3.19± 2.07A,C −0.77± 1.74 −0.51± 1.12
MMSE −2.71± 1.19A −2.71± 1.28A −2.71± 1.14B 0.06± 0.91
Attention and processing
speed
−2.06± 1.09A −2.11± 1.15A −2.05± 1.12B −0.22± 0.65
Executive functioning −2.12± 0.88A −2.00± 0.99A −2.24± 0.82B −0.14± 0.72
Social cognition −1.89± 0.64A −2.13± 0.74A −1.52± 0.42B −0.19± 0.96
Table 4.ST3: Biomarker characteristics. Abbreviations: bvFTD = behavioural variant frontotemporal
dementia, nfvPPA = non-fluent variant primary progressive aphasia, GM volume = grey matter volume,
FA = fractional anisotropy, MMSE = Mini Mental State Examination. Values are mean z-score (based
on non-carriers) ± standard deviation, after correction for confounding factors of age, gender, and
years of education. A Both the entire group of symptomatic mutation carriers and only bvFTD patients
significantly differed from presymptomatic mutation carriers as well as non-carriers (p < 0.05, Bonferroni
corrected). B Significant difference between nfvPPA patients and presymptomatic mutation carriers as
well as non-carriers (p < 0.05, Bonferroni corrected). C Significant difference between bvFTD patients
and nfvPPA patients (p < 0.05, Bonferroni corrected). D Significant difference between nfvPPA patients
and presymptomatic mutation carriers (p < 0.05, Bonferroni corrected).
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Supplementary material 4B: DEBM
Gaussian mixture modelling
DEBM uses Gaussian mixture modelling to transform biomarker values to posterior
probabilities of them being abnormal. This is done by assuming the probability density
functions of normal and abnormal values are represented by Gaussians N(µ¬E , σ¬E) and
N(µE , σE) respectively, where the occurrence of the biomarker abnormality event is denoted
by E and the absence of such an event is denoted by ¬E. Gaussian mixture modelling is
an optimisation task to estimate these normal and abnormal Gaussians as well as the mixing
parameter based on maximum log-likelihood, where the log-likelihood for biomarker B is





Figure 4.SF1: Illustrations of the Gaussian probability density functions for normal and abnormal values
of biomarker B.
Here, the likelihood f(B) is computed as follows:
f(B) = θ¬E × p(B|µ¬E , σ¬E) + θE × p(B|µE , σE)
Where θ¬E + θE = 1, and the mixing parameters θ¬E and θE show the relative proportions
of the two Gaussians in the dataset. The abnormal Gaussian is initialized using the mean
and standard deviation of the symptomatic subjects, while the normal Gaussian is initialized
using the non-carriers. Since non-carriers are healthy controls, we fix µ¬E and σ¬E to
their initialized values and only optimize the remaining parameters in the Gaussian mixture
model. The mixing parameter and the Gaussian parameters are optimized alternately until
convergence as detailed previously [93].
For imaging-biomarkers with left and right counter parts, we propose a novel modification to
the Gaussian mixture model optimization called Siamese Gaussian mixture model (Siamese
GMM). We propose to jointly optimize the parameters of these biomarkers, by taking
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advantage of symmetry in the brain. The log-likelihood for the joint optimization for the




log f(ILj ) + log f(I
R
j )
where f(ILj ) and f(IRj ) are expressed mathematically as:
f(ILj ) = θ
L
¬E × p(ILj |µ¬E , σ¬E) + θLE × p(ILj |µE , σE)
f(IRj ) = θ
R
¬E × p(IRj |µ¬E , σ¬E) + θRE × p(IRj |µE , σE)
θL¬E + θ
L












E ) and the abnormal
Gaussian parameters (µE , σE) are again optimized alternately until convergence [93]. This
joint optimization of the left and right counter parts by sharing the normal and abnormal
Gaussians reduces the number of parameters to be optimized, and thus improves the
robustness. In case of asymmetrical atrophy patterns, where one of the biomarkers is stronger






Figure 4.SF2: Correlation of disease severity (as estimated by non-imaging DEBM using cross-validation)
with years since onset and FTD-CDR-SOB. The 2D scatter plots in figures A and C show the correlations
of disease severity with years since onset, for symptomatic nfvPPA and bvFTD subjects respectively. The
2D scatter plot in figures B and D show the correlations of disease severity with FTD-CDR-SOB. The plot
on top of each subfigure shows the probability density function of the disease stages. The plots on the
right of figures A and C show the probability density functions of years since symptom onset. The plots
on the right of figures B and D show the probability density function of FTD-CDR-SOB.
A B
Figure 4.SF3: Cascade of non-imaging biomarker changes in nfvPPA (A) and bvFTD (B) subjects along
with the uncertainty associated with it. The biomarkers are ordered based on the position in the estimated





The sequence of structural, functional and cognitive
changes in multiple sclerosis
This chapter contains the content of the manuscript ‘The sequence of structural, functional
and cognitive changes in multiple sclerosis. Iris Dekker, Menno M. Schoonheim,
Vikram Venkatraghavan, Anand J.C. Eijlers, Iman Brouwer, Esther E. Bron, Stefan Klein,
Mike P. Wattjes, Alle M. Wink, Jeroen J.G. Geurts, Bernard M.J. Uitdehaag, Neil P. Oxtoby,
Daniel C. Alexander, Hugo Vrenken, Joep Killestein, Frederik Barkhof, Viktor Wottschel.
NeuroImage Clinical, Accepted, 2020’. An earlier version of this chapter was also presented
(oral) at the Computational approaches for ageing and age-related diseases (CompAge)
workshop 2020, and presented (poster) at the European Committee for Treatment and
Research in Multiple Sclerosis (ECTRIMS) conference 2019.





Background: As disease progression remains poorly understood in multiple sclerosis (MS), we aim to
investigate the sequence in which different disease milestones occur using a novel data-driven approach.
Methods: We analysed a cohort of 295 relapse-onset MS patients and 96 healthy controls, and considered
28 features, capturing information on T2-lesion load, regional brain and spinal cord volumes, resting-
state functional centrality (“hubness”), microstructural tissue integrity of major white matter (WM) tracts
and performance on multiple cognitive tests. We used a discriminative event-based model to estimate the
sequence of biomarker abnormality in MS progression in general, as well as specific models for worsening
physical disability and cognitive impairment.
Results: We demonstrated that grey matter (GM) atrophy of the cerebellum, thalamus, and changes in
corticospinal tracts are early events in MS pathology, whereas other WM tracts as well as the cognitive
domains of working memory, attention, and executive function are consistently late events. The models
for disability and cognition show early functional changes of the default-mode network and earlier
changes in spinal cord volume compared to the general MS population. Overall, GM atrophy seems
crucial due to its early involvement in the disease course, whereas WM tract integrity appears to be
affected relatively late despite the early onset of WM lesions.
Conclusion: Data-driven modelling revealed the relative occurrence of both imaging and non-imaging
events as MS progresses, providing insights into disease propagation mechanisms, and allowing fine-
grained staging of patients for monitoring purposes.
5.1 Introduction
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative
disease of the central nervous system (CNS) [16] frequently leading to physical disability
and cognitive decline [193]. The underlying pathological processes result in tissue damage,
leaving behind demyelinating lesions and white (WM) and grey matter (GM) atrophy that
can be visualised and quantified by brain and spinal cord imaging [18]. Alterations in
structural and functional networks of the brain also have clear clinical relevance [194]. Usually
considered in isolation, various studies have considered these features of MS. However, the
sequence in which these changes occur remains unclear, in part due to scarcity of longitudinal
data.
Event-based modelling (EBM) is a probabilistic data-driven approach to study disease
progression that uses cross-sectional data to estimate the temporal sequence of events and
subsequently stage patients within this sequence [53, 61]. This type of model has been applied
in Alzheimer’s disease [53, 57, 61], Huntington’s disease [53, 95] and a recent EBM study in
MS patients provided insights into the sequence of GM atrophy, but did not include features
derived from other modalities [94].
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In the present study we go beyond the aspect of atrophy in MS and consider a
broader set of structural, functional, and cognitive outcomes. We explored measures
quantifying demyelination (focal WM lesions) [193], neurodegeneration (GM atrophy) [195],
microstructural changes of WM tracts (fractional anisotropy) [196], and functional centrality
of key brain networks [194, 197] using a discriminative EBM (dEBM), which is more
accurate and computationally efficient than the original EBM implementation [93]. The
imaging biomarkers were supplemented with measures of cognitive performance [198]. Our
multimodal dEBM could improve the interpretation of studies using single biomarkers,
provide useful insights into disease propagation mechanisms, and aid in fine-grained staging
and precise monitoring of patients. Therefore, the primary aim was to build a model that
reflects a sequence of events in disease evolution in MS patients with a relapse onset. The
secondary aim was to explore the event sequence for patients in relation to worsening physical
and cognitive burden separately, because underlying disease processes could be different.
5.2 Methods
5.2.1 Participants
In this retrospective analysis study, we included data from the Amsterdam MS cohort based
on the availability of multimodal data, resulting in the inclusion of 96 healthy controls
(HC) and 295 patients with relapse-onset MS (ROMS) according to the 2011 revisions of
the McDonald criteria [199]. Patients with a primary progressive disease onset have been
excluded.
The institutional ethics review board of the VU University Medical Center approved the
protocol and written informed consent was obtained from all participants prior to inclusion.
5.2.2 Clinical assessments
The Expanded Disability Status Scale (EDSS) score [200] was assessed in all patients and was
used to classify patients into three groups according to having minimal (EDSS 0.0 – 2.5),
moderate (EDSS 3.0 – 3.5) or severe disability (EDSS ≥ 4.0) as defined in [200]. Cognitive
performance was assessed in all patients and HCs using an expanded Brief Repeatable
Battery of Neuropsychological tests [201] with different cognitive domains tested, as described
previously [198]. Raw test scores were corrected for the confounding effects of sex, age and
education trends seen in the HCs [202]. Cognitive domain-specific z-scores were calculated
using the mean and standard deviation (SD) of the HCs. Patients were sub-divided into three
cognitive-performance groups according to the z-scores obtained from the neuropsychological
tests. Patients with z ≤ −2 on at least 2 out of 7 cognitive domains of the neuropsychological
tests were labelled as cognitively impaired (CI), patients with z ≤ −1.5 on at least 2 cognitive
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domains but not fulfilling CI criteria were classified as mildly cognitively impaired (MCI) and
the remaining patients were classified as cognitively preserved (CP) [203]. Level of education
was measured using a scale ranging from 1 (unfinished primary school) to 7 (a university
degree or higher) [204].
5.2.3 Magnetic Resonance Imaging
A 3 Tesla whole-body MR system was used to scan all participants (GE Signa HDxt,
Milwaukee, WI) using an 8-channel phased-array head coil. The scan protocol included a
3D T1-weighted fast spoiled gradient-echo sequence for volume measures (TR: 7.8 ms, TE:
3 ms, 240 × 240 mm2 field of view (FOV), 176 sagittal slices of 1 mm thickness, 0.94 ×
0.94 mm2 in-plane resolution), a 3D fluid-attenuated inversion recovery (FLAIR) sequence
for lesion detection (TR: 8000 ms, TE: 125 ms, TI: 2350 ms, 250 × 250 mm2 FOV, 132 sagittal
slices of 1.2 mm thickness, 0.98× 0.98 mm2 in-plane resolution), a diffusion-weighted imaging
(DWI) sequence to detect microstructural changes in WM tracts (TR: 13 s, TE: 86 ms, 2.4 mm
contiguous axial slices, 2.0 × 2.0 mm2 in-plane resolution, 30 volumes with b-value = 900
s/mm2, 5 volumes with b-value = 0 s/mm2), and a whole-brain resting-state fMRI sequence
to measure eigenvector centrality (functional centrality; (200 volumes, TR: 2200 ms, TE: 35 ms,
3 mm contiguous axial slices covering the entire brain, 3.3 × 3.3 mm2 in-plane resolution)).
FLAIR images were generally only acquired for patient, not HCs. More details on the protocol
can be found in a previous report on this cohort [205].
FLAIR images were used to segment WM lesions in MS patients using a k-Nearest-
Neighbours approach with tissue type priors (kNN-TTP) [206]. Lesion maps were registered
to 3D T1-weighted images and filled using a validated patch-based approach [207].
Brain parcellation of cortical and subcortical regions was obtained using geodesic information
flows (GIF) [208] on the 3D T1-weighted MRI scans, a method that has been used previously
in applications of MS [209, 210], including a predecessor study on EBM-based atrophy
progression [94], and other neurological disorders [211], as well as a pre-processing tool
for segmenting WM hyperintensities [212]. GIF is an atlas-propagation-based method that
registers T1 scans of 160 subjects with manually delineated brain structures to each target
scan, then identifies the closest local matches and uses those matches for segmentation.
The atlas segmentations are based on the Desikan-Killiany-Tourville protocol, which was
designed to improve accuracy and consistency of brain labels compared to the classic Desikan-
Killiany atlas database [213]. To further quantify regional lesion loads, the white matter was
initially divided into 10 concentric bands between the ependyma of the ventricles and the pial
surface based on normalized subject-specific distance maps derived from Laplace equation
isolines [210, 214]. The bands were then grouped as inner (band 1-2), intermediate deep
(band 3-8), and outer bands (band 9-10) in order to obtain a data-driven approximation of the
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stratification used in (pre-)clinic. Infratentorial lesions were subsequently discarded because
they were only present in a small subset of patients.
Spinal cord atrophy was quantified as mean upper cervical cord area (MUCCA) using SCT-
PropSeg [215]. Analyses were performed on the 3D T1-weighted images of the brain, which
cover a sufficient length of the cervical spinal cord. We measured over a length of 30mm
along the central canal, starting at the top of the second cervical vertebra, C2. MUCCA
measurements on brain images have been shown to be as reproducible as those performed
on dedicated spinal cord MRI [216, 217].
Functional MRI processing steps for obtaining eigenvector centrality maps (ECM) have been
published previously [218]. The MELODIC pipeline (part of FSL [181], using standard
settings) was used to process resting-state fMRI images, followed by nonlinear registration
to Montreal Neurological Institute standard space, and resampling to a resolution of 4 mm
isotropic. The MELODIC outcomes were further processed using fastECM [219] to estimate
voxel-wise eigenvector centrality as a network measure of functional hubness (brain function)
in the default-mode network (DMN), basal ganglia and sensorimotor network.
DWI scans were pre-processed using FSL5, including motion- and eddy current correction on
images and gradient vectors, followed by diffusion tensor fitting for diffusion tensor imaging
(DTI). The resulting fractional anisotropy (FA) maps were then fed into the tract-based spatial
statistics (TBSS) pipeline [220], after which the skeleton was masked using the JHU white-
matter tractography atlas from FSL to define WM tracts.
There was only a minor amount of motion artefacts present in the advances imaging
sequences, and we did not observe any difference in artefact severity between groups.
5.2.4 Discriminative event-based model
The EBM uses cross-sectional data to estimate the ordered sequence of cumulative
abnormality in a disease, together with uncertainty in the ordering. Here, we used
the discriminative EBM (dEBM; https://github.com/EuroPOND/pyebm) described
previously as it has been shown to be more accurate and computationally efficient compared
to other EBM implementations [70, 93]. The dEBM estimates the probability for each
biomarker being normal or abnormal using a Gaussian mixture model (GMM) based on
data from a disease and a reference population. Based on the probability distributions of the
biomarkers in the two groups, an individual sequence of biomarker abnormality is calculated
for each patient. Finally, these individual sequences are combined statistically to give an
ordering for the whole population [93]. The uncertainty of this ordering is estimated by
bootstrapping, i.e. repeating the experiment with random subsets of subjects. Subjects can
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be staged within the event sequence by identifying the events that have already become
abnormal for each individual subject [61].
5.2.5 Selected biomarkers
We included multimodal biomarkers with relevance in MS whilst limiting the overall number
of features in the model to allow for better interpretability of results and faster computation.
The following 28 MS-related biomarkers were considered (before statistical post-selection as
described below):
GM volumes of the thalamus, hippocampus, basal ganglia (without thalamus and
hippocampus), cerebellar GM, cingulate, frontal lobe, insula, occipital lobe, parietal lobe and
temporal lobe. These regions cover the entire brain to allow for a rough estimate of the general
atrophy sequence.
MUCCA was included for all subjects as an indicator of spinal cord volume.
T2-hyperintense lesion loads on FLAIR images were considered only for patients and split
according to the inner (i.e., periventricular), outer (i.e., juxtacortical) and intermediate deep
WM bands in order to mimic (pre-)clinical use.
Functional centrality in the default mode network (DMN), sensorimotor cortex network and
basal ganglia network; the voxelwise ECM-measures were averaged within the respective
anatomical regions. The selected networks are linked to MS progression in the domains
cognition [218], fatigue [221] and clinical recovery [222].
Microstructural changes of WM tracts measured by fractional anisotropy (FA) in 3 major WM
tracts related to cognition (anterior thalamic radiation and cingulum [223, 224]) and motor
function (corticospinal tract [225]) and all other WM tracts combined (forceps minor, inferior
fronto-occipital fasciculus, inferior longitudinal fasciculus, superior longitudinal fasciculus,
uncinate fasciculus and superior longitudinal fasciculus); the voxelwise FA-measures were
averaged within the respective anatomical regions.
Cognitive function by cognitive domain: executive function, verbal memory, information
processing, verbal fluency, visuospatial, working memory and attention.
5.2.6 Statistics
Normality of data was checked by visual inspection of histograms combined with
Kolmogorov-Smirnov testing. Parametric (independent-samples t-test) and non-parametric
(Mann-Whitney U test and chi-square test) tests were used to compare groups (Tables 5.1, 5.2
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and 5.3) for demographic, clinical and imaging characteristics. All measures, except lesions,
which could only be obtained in patients, were corrected for the confounding effects of age,
sex and education seen in HCs using one linear regression model per biomarker. The residuals
of these fits were then transformed into z-scores using the mean and SD from HCs.
We used SPSS 22.0 and 24.0 (IBM Corp., Armonk, NY, USA) and the scipy python package
(version 1.2.1) for statistical analyses. The level of significance for demographic and clinical
data (Tables 5.1, 5.2 and 5.3) was set at p < 0.05.
5.2.7 Model fitting
The dEBM relies on a Gaussian Mixture of the biomarker distributions, and requires a
sufficient separation of the respective distributions from the control and disease groups.
Therefore, we performed a biomarker post-selection and included only those biomarkers that
passed a two-sided independent samples t-test at a significance level of p/leq0.1. We used
1000 bootstraps sampled from the same cohort in order to estimate the positional variance of
the event sequence. Individual subjects were finally staged within the model between stage 0
(no abnormal biomarkers) and stage N (all N biomarkers are abnormal).
Three dEBMs were built to characterize the structural, functional, and cognitive changes in
ROMS progression generally (Model 1), and specifically for disability worsening (Model 2)
and cognitive decline (Model 3).
• Model 1: Event sequence in all ROMS patients as a progression from HC.
• Model 2: Event sequence in ROMS patients progressing from low (EDSS 0.0 – 2.5) to
high disability level (EDSS≥ 4.0). Intermediate patients with an EDSS of 3.0 or 3.5 were
excluded from the GMM initialisation but used to estimate the event sequence. HCs
were excluded for this analysis.
• Model 3: Event sequence in MS patients progressing from cognitively preserved (CP)
to cognitively impaired (CI). Patients with mild cognitive impairment (MCI) were
excluded from the GMM initialisation but used to estimate the event sequence. HCs
were excluded for this analysis.
5.3 Results
At the time of data acquisition, 243 of ROMS patients were diagnosed with relapsing-remitting
MS (RRMS) and 52 patients with secondary progressive MS (SPMS). The average age was
46.7 (standard deviation 11.0) years and patients had their symptom onset 12.6 ± 1.6 years
prior to assessment. The proportion of women was higher in the patient group (71.5%) than
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Figure 5.1: Overview of diagnostic groups, and separation of ROMS subgroups.
in HCs (58.3%, p=0.016) and HCs had a higher educational level (p=0.017). The median
EDSS was 3.0 (IQR 2 – 4) with 120 patients having low disability (EDSS 0.0 – 2.5) and 102
patients having high disability (EDSS ≥ 4.0). Seventy-five patients were cognitively impaired
(CI), 52 patients were classified as MCI and 168 patients as CP (Figure 5.1). Demographics
and MRI metrics of patients and HCs are shown in Table 5.1. For the MRI measures, only
two functional networks (DMN and basal ganglia) were not significantly different between
patients and healthy controls after correction for confounding variables.
Biomarker post-selection resulted in 21, 25, and 17 biomarkers included in the final models 1
(general MS progression), 2 (disability in MS) and 3 (cognitive decline in MS), respectively.
We visualize the models using positional variance diagrams (PVD; see Figure 5.2, 5.4, 5.6).
The positional variance diagram shows the most likely sequence of events on the y-axis, while
the x-axis represents the event position within the sequence ranging from one to the number
of events. The intensity of each field represents the number of bootstraps where an event
appeared at that respective position. This indicates uncertainty in the sequence, such that a
strong confidence in the ordering results in a dark diagonal in the positional variance diagram.
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Clinical / Imaging measures Patients (n=295) Healthy controls (n=96) p-value
Clinical measures
Age [years] * 47.0 ± 10.7 45.9 ± 10.4 0.37a
Sex [female, %] ** 211 (71.5) 56 (58.3) 0.016b
Education level *** 5 (4 - 6) 6 (4 - 7) 0.017 c
Symptom duration [years] * 12.6 ± 1.6 N/A -
DMT ever used [%]** 173 (58.6) N/A -
EDSS *** 3.0 (2.0 - 4.0) N/A -
CP/MCI/CI [%] ** 25.4 / 17.6 / 56.9 N/A -
RRMS/SPMS 243/52 N/A -
Information processing speed [z-score] * -1.12 (1.4) 0.0 (1.0) <0.001a
Executive functioning [z-score] * -0.95 (1.7) 0.0 (0.8) <0.001a
Working memory [z-score] * -1.02 (1.5) 0.0 (0.9) <0.001a
Verbal memory [z-score] * -0.48 (1.2) 0.0 (0.9) <0.001a
Verbal fluency [z-score] * -0.44 (1.1) 0.0 (1.0) <0.001a
Visuospatial memory [z-score] * -0.61 (1.2) 0.0 (0.9) <0.001a
Attention [z-score] * -0.65 (1.1) 0.0 (0.7) <0.001a
MRI measures
T2-hyperintense lesion loads [mL]*
Total T2-hyperintense lesion load 14.2 (12.7) N/A -
Inner lesions 4.3 (3.3) N/A -
Deep lesions 6.5 (6.9) N/A -
Outer lesions 3.4 (3.5) N/A -
Infratentorial 0.02 (0.04) N/A -
Brain and spinal cord volumes [mL] *
Total brain volume 1135.3 (110.3) 1181.8 (128.8) <0.001 a
Basal Ganglia 34.3 (3.5) 36.7 (4.1) <0.001 a
Hippocampus 7.6 (0.7) 8.0 (0.8) <0.001 a
Thalamus 10.1 (1.0) 11.7 (1.4) <0.001 a
Cingulate 27.7 (3.3) 29.0 (3.6) 0.002 a
Frontal lobe 179.92 (18.8) 185.1 (20.8) 0.224 a
Insula 10.7 (1.2) 11.3 (1.4) <0.001 a
Occipital lobe 66.6 (8.0) 70.3 (8.2) <0.001 a
Parietal lobe 91.1 (10.2) 95.0 (9.6) 0.002 a
Temporal lobe 128.0 (13.4) 132.8 (15.0) 0.006 a
Cerebellar grey matter 94.6 (9.5) 99.0 (10.1) 0.003 a
MUCCA 64.7 (7.8) 68.6 (5.7) <0.001 a
Functional hubness (EC [z-scores])
Basal ganglia network -0.128 (0.23) 0 (0.26) 0.371 a
Default mode network 0.009 (0.21) 0 (0.22) 0.755 a
Sensorimotor cortex network -0.046 (0.22) 0 (0.22) 0.234 a
White matter tract integrity (FA [0-1])
Anterior thalamic radiation 0.453 (0.035) 0.479 (0.027) <0.001 a
Corticospinal tract 0.653 (0.028) 0.668 (0.028) <0.001 a
Cingulum 0.564 (0.047) 0.598 (0.041) <0.001 a
Other WM tracts 0.525 (0.035) 0.561 (0.026) <0.001 a
Table 5.1: Clinical and imaging measures of patients and healthy controls. The p-values of the MRI
measures are based on the z-scored comparisons. Biomarkers with a p < 0.1 were included in the model.
* Mean (standard deviation), ** number (percentage), *** median (IQR). a Independent-samples t-test, b
chi-square test, c Mann-Whitney U test.
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5.3.1 Model 1: Sequence of events in relapse-onset multiple sclerosis
progression.
The PVD of Model 1 is shown in Figure 5.2. Despite considerable uncertainty, ROMS tends to
starts with decreases in the corticospinal tract FA as well as cerebellar and thalamic atrophy.
Neurodegeneration continues to involve the occipital and parietal lobes (position 5 and 7 of
21), through the temporal lobe, spinal cord (MUCCA) and basal ganglia (position 10, 12 and
13 of 21), with the cingulate and insula being affected later (position 16-17 of 21). Deficiency in
visuospatial cognition is the earliest cognitive abnormality at position 4, shortly after thalamic
atrophy, followed by verbal fluency, verbal memory and information processing (position 6,
9 and 11 of 21). Other cognitive domains are estimated to be affected later. FA changes of
the cingulum and the non-specific WM-tracts appear in the last third of the event sequence
between the basal ganglia and the cingulate volume events. Anterior thalamic radiation FA
becomes abnormal late (position 18 of 21).
The staging reveals that healthy controls are mostly placed at earlier stages and no HC being
staged higher than stage 11 of 21 (median stage 2, mean stage 3) while ROMS patients are
spread across all stages with a median stage of 8 (mean 9.4) as shown in Figure 5.3.
The effect on leaving out individual biomarkers or groups of biomarkers from a certain
modality is very small as shown qualitatively in the Supplementary Materials. The PVD for
the main tracts of the JHU WM tractography atlas is shown in Figure 5.SF4.
5.3.2 Model 2: Sequence of events in the progression of low-to-high disability in
ROMS.
Table 5.2 shows the comparison between patients with high disability (EDSS of 4.0 or higher,
n = 102) and patients with low disability (EDSS of 2.5 or lower, n = 120). Patients with
high disability were older (average 53.1 versus 41.0 years, p < 0.001), had longer symptom
duration (average 18.8 versus 10.6 years, p < 0.001), had a lower level of education (5
versus 4, p=0.001), and a higher percentage of cognitive impairment (47.1% versus 13.3%,
p < 0.001) than patients with low disability. Not all MRI measures showed significant
differences (p < 0.1 was accepted in the biomarker post-selection) between patients with high
versus low disability. The included markers are listed in Figure 5.4.
The sequence for progression from low to high disability is shown in Figure 5.4. Insular and
cerebellar GM atrophy occur early in the event sequence together with changes in centrality
of the default-mode and basal-ganglia networks, and visuospatial perception (position 1-5 of
25). Atrophy continues to occur in the thalamus, temporal lobe, MUCCA, parietal lobe, basal
ganglia, while occipital and frontal lobe atrophy occur relatively late (position 19 and 21 of
25 respectively). Lesion load becomes abnormal first in the inner (periventricular) regions,
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Clinical / Imaging measures Total (n=222) EDSS ≤ 2.5 (n=120) EDSS ≥ 4.0 (n=102) p-value
Clinical measures
Age [years]* 46.5 (10.6) 41.0 (8.5) 53.1 (8.9) <0.001a
Sex [female, %]** 160 (72.1) 87 (72.5) 73 (71.6) 0.88b
Education level [median, IQR]*** 5 (4-6) 5 (4-6) 4 (3-6) 0.001c
Symptom duration [years]* 14.4 (8.4) 10.6 (5.7) 18.8 (8.8) <0.001a
DMT used** 126 (56.8) 67 (55.8) 59 (57.8) 0.76b
EDSS*** 2.5 (2.0 - 4.5) 2.0 (1.5 - 2.5) 5.0 (4.0 6.0) <0.001c
CP/MCI/CI [%]*** 53.6 / 17.6 / 28.8 68.3 / 18.3 / 13.3 36.3 / 16.7 / 47.1 <0.001b
RRMS/SPMS 176 / 46 119 / 1 57 / 45 <0.001b
Information processing speed [z-score] * -1.18 (1.4) -0.67 (1.2) -1.80 (1.4) <0.001a
Executive functioning [z-score] * -1.04 (1.8) -0.50 (1.0) -1.71 (2.4) <0.001a
Working memory [z-score] * -1.03 (1.4) -0.51 (1.0) -1.69 (1.6) <0.001a
Verbal memory [z-score] * -0.45 (1.1) -0.25 (1.0) -0.70 (1.2) 0.002a
Verbal fluency [z-score] * -0.52 (1.1) -0.22 (1.0) -0.86 (1.0) <0.001a
Visuospatial memory [z-score] * -0.63 (1.2) -0.28 (1.1) -1.04 (1.2) <0.001a
Attention [z-score] * -0.66 (1.1) -0.39 (0.9) -0.98 (1.3) <0.001a
MRI measures
T2-hyperintense lesion loads [mL]*
Total T2-hyperintense lesion load 14.7 (13.2) 11.2 (9.0) 18.9 (15.9) <0.001a
Inner lesions 4.3 (3.3) 3.6 (2.5) 5.2 (3.8) <0.001a
Deep lesions 6.9 (7.4) 5.1 (4.9) 9.1 (9.2) <0.001a
Outer lesions 3.5 (3.4) 2.6 (2.3) 4.6 (4.1) <0.001a
Infratentorial 0.01 (0.04) 0.01 (0.03) 0.02 (0.04) 0.31a
Brain and spinal cord volumes [mL] *
Total brain volume 1133.0 (111.3) 1153.1 (109.4) 1109.4 (109.4) 0.003a
Basal Ganglia 34.2 (3.6) 34.9 (3.6) 33.3 (3.5) <0.001a
Hippocampus 7.6 (0.7) 7.7 (0.8) 7.4 (0.7) 0.011a
Thalamus 10.1 (1.5) 10.6 (1.3) 9.4 (1.3) <0.001a
Cingulate 27.7 (3.3) 28.1 (3.2) 27.2 (3.4) 0.04a
Frontal lobe 180.1 (19.0) 185.4 (19.6) 173.9 (16.2) <0.001a
Insula 10.7 (1.3) 11.0 (1.3) 10.3 (1.2) <0.001a
Occipital lobe 66.3 (8.0) 68.3 (7.8) 64.0 (7.7) <0.001a
Parietal lobe 91.1 (10.2) 94.0 (10.2) 87.8 (9.3) <0.001a
Temporal lobe 127.7 (13.5) 130.7 (13.9) 124.1 (12.1) <0.001a
Cerebellar grey matter 94.3 (9.7) 96.6 (9.3) 91.6 (9.5) <0.001a
MUCCA 64.5 (8.3) 65.6 (8.3) 63.2 (8.2) 0.07a
Functional hubness (EC [z-scores])
Basal ganglia network -0.016 (0.24) -0.067 (0.235) 0.044 (0.224) <0.001a
Default mode network -0.004 (0.21) -0.035 (0.221) 0.033 (0.200) 0.017a
Sensorimotor cortex network -0.039 (0.22) -0.021 (0.216) -0.058 (0.216) 0.206a
White matter tract integrity (FA [0-1])
Anterior thalamic radiation 0.45 (0.03) 0.47 (0.02) 0.44 (0.04) <0.001a
Corticospinal tract 0.65 (0.03) 0.66 (0.02) 0.64 (0.03) <0.001a
Cingulum 0.56 (0.05) 0.58 (0.04) 0.55 (0.05) <0.001a
Other WM tracts 0.53 (0.04) 0.54 (0.03) 0.51 (0.04) <0.001a
Table 5.2: Demographics of high vs low EDSS. Biomarkers with a p < 0.1 were included in the model.
* Mean (standard deviation), ** number (percentage), *** median (IQR). a Independent-samples t-test, b
chi-square test, c Mann-Whitney U test.
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Figure 5.2: Positional variance diagram for the general ROMS population (Model 1).
The maximum-likelihood sequence of abnormality is shown on the y-axis (top to bottom). Colour
intensity in each row indicates positional variance: the darker the colour, the higher the confidence of the
event position across 1000 bootstraps (capped at 500 for visualisation). The biomarker ordering reflects
the sequence obtained from fitting all subjects.
EC = eigenvector centrality; EDSS: expanded disability status scale; FA: fractional anisotropy as a measure
for microstructural WM tract changes; MUCCA: mean upper cervical cord area.
then in the deep WM and the outer regions (i.e. juxtacortical). Changes in the FA biomarkers
appear in the last third of the sequence, and cognitive changes in attention, working memory
and executive function are last to become abnormal.
The patient staging shows that ROMS patients with all levels of disability can be found in all
25 stages (see Figure 5.5). However, there is a clear trend such that patients with low EDSS
have a median stage of 4 (mean 6.9), patients with medium disability have a median stage of 6
(mean 9.3), and patients with a high level of disability have a median stage of 16 (mean 14.6).
5.3.3 Model 3: Sequence of events in ROMS as cognition declines.
All 295 patients had complete cognitive tests: 75 patients were classified as CI, 52 as MCI, and
168 patients as CP. Patients with CI were older (average 50.4 versus 45.7 years; p = 0.001),
had a longer symptom duration (average 17.6 versus 13.3 years, p < 0.001), had a lower
educational level (4 versus 6, p < 0.001) and a higher EDSS score (median 4.0 versus 3.0;





Figure 5.3: Patient staging for Model 1 (ROMS). (a) Staging of HC and ROMS subjects within the 21
disease stages. (b) Boxplot of staging indicating median (solid orange line) and mean (dashed green line)
of the groups.
The ordering of events in the dEBM of cognitive impairment is shown in Figure 5.6. Similar
to Model 2, the progression in cognitive decline is accompanied by early insular atrophy
and increased functional DMN centrality. The event sequence continues with atrophy of the
hippocampus, cervical cord, frontal, parietal, occipital and temporal lobes, and the thalamus
(position 3-9 of 17) and finally the basal ganglia (position 14 of 17). Lesion events occur in
close succession after most atrophy measures (position 10-12 of 17). Changes in WM tract FA




Figure 5.4: Positional variance diagram for the progression from low to high disability in ROMS patients
(Model 2). The maximum-likelihood sequence of abnormality is shown on the y-axis (top to bottom).
Colour intensity in each row indicates positional variance: the darker the colour, the higher the confidence
of the event position across 1000 bootstraps (capped at 500 for visualisation). The biomarker ordering
reflects the sequence obtained from fitting all subjects.
EC = eigenvector centrality; EDSS: expanded disability status scale; FA: fractional anisotropy as a measure
for microstructural WM tract changes; MUCCA: mean upper cervical cord area.
As in Model 2, all three groups are spread across all stages (see Figure 5.7). Cognitively
preserved ROMS patients have a median stage of 5 (mean 5.3), patients with MCI have a
median stage of 7.5 (mean 7.8), and cognitively impaired patients have a median stage of 12
(mean 11.4).
5.3.4 Discussion
Current understanding of disease progression in MS is largely based on studies that each
considered a small number of MS pathology features in isolation. This body of work has
identified lesion number and location, regional atrophy, changes in functional centrality
of brain networks, or alterations in WM tract microstructure as features of interest. Until
now, the sequence of accumulated abnormality in these biomarkers relative to each other
remained largely undetermined. Our data-driven dEBM analysis suggests that changes of the
corticospinal tract, and GM volume changes of cerebellum, thalamus and occipital lobe are
early events; whereas microstructural changes in other WM tracts and changes in cognitive
domains attention, executive function and working memory are relatively late events in MS





Figure 5.5: Patient staging for Model 2 (disability). (a) Staging of subjects with different levels of disability
within the 25 disease stages. (b) Boxplot of staging indicating median (solid orange line) and mean
(dashed green line) of the groups.
impairment motivated to reveal new insight into the underlying mechanisms of each, and to
provide a quantitative template for patient assessment. The results of this secondary analysis
suggest that functional network centrality of the default mode network is involved early in
both, with DTI-related WM tract abnormality occurring later.
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Figure 5.6: Positional variance diagram for the progression in ROMS patients as cognition declines (Model
3). The maximum-likelihood sequence of abnormality is shown on the y-axis (top to bottom). Colour
intensity in each row indicates positional variance: the darker the colour, the higher the confidence of the
event position across 1000 bootstraps (capped at 500 for visualisation). The biomarker ordering reflects
the sequence obtained from fitting all subjects.
EC = eigenvector centrality; EDSS: expanded disability status scale; FA: fractional anisotropy as a measure
for microstructural WM tract changes; MUCCA: mean upper cervical cord area.
5.3.5 Model 1: Sequence of events in relapse-onset multiple sclerosis
progression.
The general ROMS model suggests that cerebellar atrophy is an early event. Although studies
in patients with a clinically isolated syndrome (CIS) have not been conclusive on the presence
of early cerebellar volume loss [226], a recent EBM study in MS patients also showed cerebellar
atrophy as part of the atrophy sequence [94]. Early thalamic and hippocampal atrophy in
our study are in accordance with findings in previous studies reporting atrophy in these
areas already in CIS patients [227, 228]. Insular and cingulate atrophy occur relatively late in
our study but the bootstrap analysis shows a bimodal distribution for these biomarkers with
clusters at the beginning and the end of the sequence (see Figure 5.2), which might indicate
heterogeneity in the population such that some patients have the event early whereas others
experience this later. Among the volumetric measurements, MUCCA abnormality occurs at
an intermediate position in the event ordering, while previous literature indicates that spinal
cord atrophy can be seen already in CIS patients on a group level and with high clinical
relevance [229]. This could be due to differences in measurement sensitivity or cohort size





Figure 5.7: Patient staging for Model 3 (cognition). Top: Staging of subjects with different levels of
cognitive abilities within the 17 disease stages. Bottom: Boxplot of staging indicating median (solid
orange line) and mean (dashed green line) of the groups.
A second marker of white matter abnormality, the FA of the corticospinal tract, appears as
the first event, which agrees with previous work [229]. In addition, research found that WM
changes occur early in the disease [196], whereas most FA markers other than corticospinal
tract damage included in this study were late events in the model. A probable explanation
could be that the WM damage from lesions within the tracts is relatively small compared to
overall sizes of the tract ROIs, so that the tract features mainly represent normal-appearing
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WM and hence have little disease signal. Additionally, there is substantial inter-patient
heterogeneity in the anatomical distribution of WM damage, which creates an unclear relation
between microstructural changes in specific WM tracts and progression along the disease
course.
The seven included cognitive domains are spread across the progression timeline but previous
literature does not provide many concrete indications regarding the true positioning of those
biomarkers given the lack of longitudinal data. However, the domains attention, executive
function, and working memory were consistently late events in our analyses, which is
supported by previous research [230]. Overall, we showed that the obtained event sequence
is well in line with previous work on individual features but provides additional insight in
the relative positioning of the multimodal features. The obtained sequence can potentially be
used to stage patients within the disease course and help with clinical monitoring of disease
progression beyond relapses and physical disability. However, the relatively high uncertainty
limits use for individual patients at this stage.
5.3.6 Model 2: Sequence of events in the progression of low-to-high disability in
relapse-onset multiple sclerosis.
The model for progression from low disability to high disability has many similarities to
the general MS event sequence (Model 1) such as the early occurrence of cerebellar atrophy
or visuospatial memory impairment, and the late events for white matter tract FA and the
cognitive domains of attention, working memory and executive function. This is somewhat
expected as minor impairment starts early in the disease course when brain structure is most
similar to healthy controls. The most notable difference with Model 1 is the early increase
of eigenvector centrality of the DMN and basal ganglia functional network, which supports
findings on functional centrality as a correlate of physical disability [197]. Similarly, basal
ganglia atrophy appears early in Model 2, supporting recent findings of deep GM atrophy
being a driving factor in disability worsening [209]. The insula appears to be the earliest event
but the considerable uncertainty suggests variability between individuals.
Changes of the MUCCA measurement appear earlier and FA changes of the corticospinal
tract appear later with respect to Model 1. This ostensibly contradictory finding could be
interpreted such that initial damage of the corticospinal tract already occurred in patients with
low disability (i.e. first event in the progression from HC to MS) and more severe damage (i.e.
spinal cord atrophy) will become apparent later. At the same time the cord area is not strongly
affected initially but changes become more detectable after MS onset has occurred as indicated
by previous studies that have shown the relevance of spinal cord atrophy in explaining long-
term disability [231, 232].
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The thalamus is broadly involved in cognitive and sensorimotor functions [233], which could
explain the very early position in Model 1 and an early position in Model 2, and can be
interpreted as a further increase in abnormality alongside the increase in disability.
MS lesions appear to become significant towards the cortex as disability progresses, i.e. first in
the periventricular white matter, then in the deep WM and finally closer to the cortex, which
is in line with other studies showing a larger lesion load around the ventricles with fewer
lesions juxtacortically [234, 235]. It should be noted, however, that this study does not include
measurements of cortical lesions, which needs to be addressed in subsequent studies.
5.3.7 Model 3: Sequence of events in relapsing-onset multiple sclerosis as
cognition declines.
In the dEBM sequence from CP to CI, early events were atrophy of the insula, hippocampus
and spinal cord, as well as the increased functional centrality of the DMN. The early
appearance of insular atrophy in this model is interesting in the light of previous studies
showing the fastest volume loss in these areas in patients with SPMS [209, 236]. We infer
that these volume changes are an early event in the general MS population, confirmed by
their respective positioning in a previous EBM study sequence [94].
A meaningful comparison of the functional centrality of networks is impeded by the exclusion
of the basal ganglia and sensorimotor network biomarkers from the model due to statistically
indistinguishable biomarker distributions between CP and CI groups, indicating that these
have limited relevance to cognitive decline in MS. However, the increased functional centrality
of the DMN was an early event in both model 2 and 3 suggesting that abnormality of DMN
functional centrality could be an early indication of future cognitive and physical decline, as
has been suggested extensively in MS literature [203, 218].
The interpretation and relevance of the early positioning of MUCCA in the cognitive model
is difficult to understand but might reflect the overlap between patients with CI and patients
with increased physical disability (64% of patients with CI in this cohort also have more severe
physical disability; see also Table 5.2 and Figure 5.1). Lesion events appear in direct succession
and the positional variance diagram (Figure 5.6) indicates that abnormal lesion volumes occur
in all three locations roughly at the same time, indicating that other measures such as atrophy
and brain function are more important for cognition.
Though thalamic atrophy has been associated with cognitive decline and disease
progression [198], it appears relatively later (mid-sequence) than expected in the dEBM
sequence. This could be the result of a floor-effect as there is already thalamic atrophy
present in CP patients [228] and further changes arise late in the progression from CP to CI.
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Microstructural WM changes appear late in model 3, which is consistent with model 2 and
could imply that these measures reflect advanced stages of disease progression. A previous
study showed that only CI patients with atrophy had microstructural WM changes and CP
patients without atrophy did not have WM tract abnormalities [205]. Alternatively, the order
in which different tracts become abnormal varies and more tracts are affected with advanced
disease [196].
5.3.8 Considerations regarding features in the models
White matter lesions are a sensitive indicator for MS diagnosis [237] and are used extensively
in daily clinical practice. We analysed lesion locations at three depths, with the inner band
including the lesions close to the ventricles, the outer band including those close to the
cortex, and the intermediate deep WM lesions in between [210]. While this definition is
not as stringent as the clinically used stratification into periventricular, juxtacortical and
deep lesions, it is a useful approximation that can be derived in a consistent and data-
driven fashion. Infratentorial lesions were only present in a small subset of patients and
were therefore discarded from further analysis despite their involvement in clinical disability.
Although minor (vascular) WM lesions could be present in controls, these lesions could
not be included due to the lack of FLAIR imaging in controls. As such, in the analysis of
general ROMS progression, Model 1, we did not include lesions. However, lesions would
be expected to occur very early in the MS sequence. MUCCA measurement was performed
using SCT-PropSeg on 3DT1 head images, which may have reduced sensitivity to change
compared to dedicated cervical cord imaging although several studies have shown good
agreement between MUCCA derived from head and cervical images [216, 217]. We note that
the considerable positional variance in the estimated ordering means that the exact positions
of events should be interpreted with caution. Additionally, the ordering does not imply
causation.
While we took care to include biomarkers of relevance to MS pathology, many more candidate
biomarkers could be included in the future. Features such as spinal cord lesions [238],
cerebrospinal fluid alterations [239], or (semi)quantitative MR measures of myelination such
as magnetization transfer ratio (MTR) have been shown to be sensitive to the MS pathogenesis
but were unavailable in this cohort.
5.3.9 Study limitations
MS is a heterogeneous disease with multiple concurrent disease processes, which are difficult
to model, especially with limited data. As a consequence, some biomarkers show clear
bimodal behaviour in the positional variance diagram (e.g., cingulate and insular atrophy in
Model 1), which suggests different orderings for subgroups of our cohort. While this impedes
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interpretation of some results, we believe that it is an important finding. An alternative way
to model heterogeneous trajectories is to use advanced data-driven subtyping models such
as SuStaIn [86], which could potentially identify clusters of subjects that share a differential
sequence of events and hence model the disease progression in MS more reliably. However,
this typically requires a larger dataset than is available here.
The effects of disease modifying treatment is very challenging to model due to the
heterogeneity in the disease progression and the resulting treatment options. In general,
we would expect a reduction of EDSS or lesion occurrence as these are the main outcome
measures for clinical trials. In this study, this would lead to a change in group assignments,
especially for Model 2, but we would not expect a strong effect on other biomarkers or their
event sequence. A comparison of sequences obtained from treated and untreated patients, as
well as the effect of a complex statistical correction for treatment effects, should be performed
in an independent and sufficiently large cohort.
EBM provides a temporal ordering of biomarker abnormality, but no actual information about
time as the intervals between subsequent events are not linear; this means that the division
into late and early events can only be interpreted relative to other markers within the overall
disease course. A combination of EBM-type models with longitudinal data and survival
models, however, could give an estimate of the timescales of disease progression [61, 93].
5.3.10 Conclusion
This study has revealed the sequence of observable (biomarker) changes in brain structure,
function, and cognition in the progression of ROMS, including specific sequences associated
with disability worsening and cognitive decline. In general, changes in GM volume, especially
of the thalamus, insula, hippocampus and cerebellum were the earliest events in MS and MS-
related physical disability and cognitive decline, which also showed strong involvement of
default-mode dysfunction. Microstructural changes in WM tracts were predominantly late
events, which deserves further investigation as it appears to contradict the early occurrence
of focal white matter lesions in many tracts, possibly indicating that overall tract integrity
is maintained for a longer period of time. The relatively high uncertainty could be reduced
using advanced models taking into account multiple concurrent disease trajectories within
one cohort. Future research should also include patients soon after first symptoms arise (i.e.
CIS) to determine the earliest disease pathologies in MS with high certainty.
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Clinical / Imaging measures Total (n=243) Cognitively preserved (n=168) Cognitively impaired (n=75) p-value
Clinical measures
Age [years]* 47.1 (10.6) 45.7 (10.3) 50.4 (10.5) 0.001a
Sex [female, %]** 174 (71.6) 125 (74.4) 49 (65.3) 0.15b
Education level [median, IQR]*** 5 (4 - 6) 6 (4 - 6) 4 (3 6) <0.001c
Symptom duration [years]* 14.6 (8.6) 13.3 (7.7) 17.6 (9.6) <0.001a
DMT used** 141 (58.0) 96 (57.1) 45 (60.0) 0.68b
EDSS*** 3.0 (2.0 - 4.0) 3.0 (2.0 - 3.5) 4.0 (3.0 6.0) <0.001c
RRMS/SPMS 197 / 46 148 / 20 49 / 26 <0.001b
Information processing speed [z-score] * -1.01 (1.4) -0.35 (1.0) -2.52 (1.2) <0.001a
Executive functioning [z-score] * -0.95 (1.8) -0.19 (0.8) -2.73 (2.3) <0.001a
Working memory [z-score] * -0.99 (1.6) -0.39 (0.8) -2.40 (2.0) <0.001a
Verbal memory [z-score] * -0.44 (1.2) 0.02 (0.9) -0.15 (1.1) <0.001a
Verbal fluency [z-score] * -0.38 (1.1) -0.04 (1.0) -1.2 (1.0) <0.001a
Visuospatial memory [z-score] * -0.56 (1.2) -0.14 (1.0) -1.49 (1.1) <0.001a
Attention [z-score] * -0.60 (1.2) -0.22 (0.7) -1.48 (1.6) <0.001a
MRI measures
T2-hyperintense lesion loads [mL]*
Total T2-hyperintense lesion load 13.7 (12.8) 10.3 (8.4) 21.4 (17.0) <0.001a
Inner lesions 4.1 (3.2) 3.3 (2.3) 5.9 (4.0) <0.001a
Deep lesions 6.3 (7.2) 4.6 (4.5) 10.3 (10.0) <0.001a
Outer lesions 3.3 (3.3) 2.4 (2.1) 5.3 (4.4) <0.001a
Infratentorial 0.01 (0.04) 0.01 (0.04) 0.01 (0.03) 0.95a
Brain and spinal cord volumes [mL] *
Total brain volume 1136.4 (110.9) 1147.5 (110.5) 1111.4 (108.3) 0.019a
Basal Ganglia 34.3 (3.5) 34.9 (3.3) 33.0 (3.7) <0.001a
Hippocampus 7.6 (0.7) 7.7 (0.7) 7.5 (0.8) 0.02a
Thalamus 10.1 (1.5) 10.5 (1.3) 9.2 (1.5) <0.001a
Cingulate 27.6 (3.3) 27.8 (3.3) 27.3 (3.3) 0.256a
Frontal lobe 180.4 (19.2) 182.9 (19.1) 174.8 (18.4) 0.002a
Insula 10.7 (1.3) 10.9 (1.3) 10.2 (1.1) <0.001a
Occipital lobe 66.9 (8.3) 68.3 (8.1) 63.9 (8.0) <0.001a
Parietal lobe 91.3 (10.6) 92.5 (10.6) 88.7 (10.1) 0.01a
Temporal lobe 128.2 (13.5) 129.5 (13.6) 125.0 (12.9) 0.02a
Cerebellar grey matter 94.5 (9.5) 95.4 (9.5) 92.6 (9.1) 0.031a
MUCCA 64.5 (7.9) 65.7 (7.6) 61.6 (8.0) 0.001a
Functional hubness (EC [z-scores])
Basal ganglia network -0.020 (0.242) -0.026 (0.252) -0.006 (0.216) 0.549a
Default mode network 0.007 (0.213) -0.013 (0.223) 0.052 (0.184) 0.027a
Sensorimotor cortex network -0.042 (0.222) -0.037 (0.227) -0.053 (0.209) 0.600a
White matter tract integrity (FA [0-1])
Anterior thalamic radiation 0.45 (0.04) 0.46 (0.03) 0.43 (0.04) <0.001a
Corticospinal tract 0.65 (0.03) 0.66 (0.03) 0.64 (0.03) 0.002a
Cingulum 0.56 (0.05) 0.58 (0.04) 0.54 (0.06) <0.001a
Other WM tracts 0.53 (0.04) 0.54 (0.03) 0.50 (0.05) <0.001a
Table 5.3: Demographics of cognitive preserved vs cognitive impaired. Biomarkers with a p < 0.1
were included in the model. * Mean (standard deviation), ** number (percentage), *** median (IQR). a




The combination of features from different domains, such as volumetric, FA or cognition, has
no effect on the general event ordering, except for small variations within the uncertainty
estimated by the bootstrap experiments. In the supplementary materials we present
additional data from experiments with subsets of the biomarkers used in Model 1 to support
this statement.
Exclusion of cognitive biomarkers
The event sequence obtained when using no cognitive biomarkers is almost identical
(Figure 5.SF1) to the original ordering of Model 1 as shown in Figure 5.2, except for the
excluded biomarkers, of course. The only difference is in the last three biomarkers Cingulate,
Insula and Anterior thalamic radiation, where Cingulate and Anterior thalamic radiation have
swapped position. This can be explained by the very high positional uncertainty of these
biomarkers.
Figure 5.SF1: Positional variance diagram for subjects and biomarkers from Model 1 but excluding
cognitive biomarkers. Please note that the colourbar is capped at 500 to improve visualisation.
Similarly, when creating an EBM using only cognitive biomarkers (Figure 5.SF2) we obtain
an ordering that is alike to the ordering of cognitive features within the more comprehensive
Model 1. Only ‘Verbal Memory’ and ‘Information Processing’, and ‘Executive Function’ and
‘Working Memory’ have swapped positions. These pairs of biomarkers are very close in event
position, so this change is within the uncertainty estimated from the bootstraps.
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Figure 5.SF2: Positional variance diagram for subjects from Model 1 using only cognitive biomarkers.
Variation of included tracts for FA biomarkers
The relative ordering of the four tract-related biomarkers, when modelled independently of
all other biomarkers as shown in Figure 5.SF3, is identical to the one obtained in Model 1 as
shown in Figure 5.2.
The biomarker ‘WM tracts’ includes several large tracts, which raises the question of their
relative positioning to the other three separately included features. In Figure 5.SF4 we show
the ordering and positional variance of all major tracts in the JHU WM tractography atlas. It
can be seen that the relative ordering of the original three separately included tracts from
Model 1 does not change when fitting an EBM using all main tracts from the JHU WM
tractography atlas (see Figure 5.SF4).
The FA of the uncinate fasciculus is positioned after the anterior thalamic radiation at the
end of the sequence, and only the inferior longitudinal fasciculus is positioned between the
corticospinal tract and the cingulum, albeit with some uncertainty. The other 3 tracts that
were previously bundles together as ‘WM tracts’ remain in between the cingulum and the




Figure 5.SF3: Positional variance diagram for subjects from Model 1 using only the four tract-based
biomarkers.
Figure 5.SF4: Positional variance diagram for subjects from Model 1 using individual from the JHU atlas
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Accurate prediction of progression in subjects at risk of Alzheimer’s disease is crucial for enrolling the
right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for
predicting disease onset and progression is currently lacking. We present the findings of The Alzheimer’s
Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge, which compared the performance of
92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk
of Alzheimer’s disease. Challenge participants were required to make a prediction, for each month of
a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer’s Disease Assessment
Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. No single submission
was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the
best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13
no single submitted prediction method was significantly better than random guessing. On a limited,
cross-sectional subset of the data emulating clinical trials, performance of best algorithms at predicting
clinical diagnosis decreased only slightly (3% error increase) compared to the full longitudinal dataset.
Two ensemble methods based on taking the mean and median over all predictions, obtained top scores
on almost all tasks. Better than average performance at diagnosis prediction was generally associated
with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor
imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated
with inclusion of summary statistics, such as patient-specific biomarker trends. The submission system
remains open via the website https://tadpole.grand-challenge.org, while code for submissions
is being collated by TADPOLE SHARE: https://tadpole-share.github.io/. Our work suggests
that current prediction algorithms are accurate for biomarkers related to clinical diagnosis and ventricle
volume, opening up the possibility of cohort refinement in clinical trials for Alzheimer’s disease.
6.1 Introduction
Accurate prediction of the onset of Alzheimer’s disease (AD) and its longitudinal progression
is important for care planning and for patient selection in clinical trials. Current opinion
holds that early detection will be critical for the successful administration of disease modifying
treatments during presymptomatic phases of the disease prior to widespread brain damage,
e.g. when pathological amyloid and tau start to accumulate [240]. Moreover, accurate
prediction of the progression of at-risk subjects will help select homogenous patient groups for
clinical trials, thus reducing variability in outcome measures that can obscure positive effects
on patients at the right stage to benefit.
Several mathematical and computational methods have been developed to predict the onset
and progression of AD. Traditional approaches leverage statistical regression to model
relationships between target variables (e.g. clinical diagnosis or cognitive/imaging markers)
with other known markers [241, 242] or measures derived from these markers such as the
rate of cognitive decline [243]. More recent approaches involve supervised machine learning
techniques such as support vector machines, random forests and artificial neural networks.
These approaches have been used to discriminate AD patients from cognitively normal
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individuals [244, 245], and for discriminating at-risk individuals who convert to AD in a
certain time frame from those who do not [246, 247]. The emerging approach of disease
progression modelling aims to reconstruct biomarker trajectories or other disease signatures
across the disease progression timeline, without relying on clinical diagnoses or estimates
of time to symptom onset. Examples include models built on a set of scalar biomarkers to
produce discrete [53, 61] or continuous [51, 52, 57, 68, 248] biomarker trajectories; spatio-
temporal models that focus on evolving image structure [249, 250], potentially conditioned
by non-imaging variables [251]; and models that emulate putative disease mechanisms to
estimate trajectories of change [60, 252, 253]. All these models show promise for predicting AD
biomarker progression at group and individual levels. However, previous evaluations within
individual publications provide limited information because: (1) they use different data sets
or subsets of the same dataset, different processing pipelines, and different evaluation metrics
and (2) over-training can occur due to heavy use of popular training datasets. Currently, the
field lacks a comprehensive comparison of the capabilities of these methods on standardised
tasks relevant to real-world applications.
Community challenges have consistently proved effective in moving forward the state of
the art in technology to address specific data-analysis problems by providing platforms for
unbiased comparative evaluation and incentives to maximise performance on key tasks [254].
In medical image analysis, for example, such challenges have provided important benchmarks
in tasks such as registration [255] and segmentation [256], and revealed fundamental insights
about the problem studied, for example in structural brain-connectivity mapping [257].
Previous challenges in AD include the CADDementia challenge [258], which aimed to identify
clinical diagnosis from MRI scans. A similar challenge, the International challenge for automated
prediction of MCI from MRI data [259], asked participants to predict diagnosis and conversion
status from extracted MRI features of subjects from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study [260]. Yet another challenge, The Alzheimer’s Disease Big Data DREAM
Challenge [261], asked participants to predict cognitive decline from genetic and MRI data.
These challenges have however several limitations: (i) they did not evaluate the ability of
algorithms to predict biomarkers at future timepoints (with the exception of one sub-challenge
of DREAM), which is important for patient stratification in clinical trials; (ii) the test data
was available to organisers when the competitions were launched, leaving room for potential
biases in the design of the challenges; (iii) the training data was drawn from a limited set of
modalities.
The Alzheimer’s Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge (https:
//tadpole.grand-challenge.org) aims to identify the data, features and approaches
that are the most predictive of future progression of subjects at risk of AD. In contrast to
previous challenges, our challenge is designed to inform clinical trials through identification
of patients most likely to benefit from an effective treatment, i.e., those at early stages of
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disease who are likely to progress over the short-to-medium term (1-5 years). The challenge
focuses on forecasting the trajectories of three key features: clinical status, cognitive decline,
and neurodegeneration (brain atrophy), over a five-year timescale. It uses ”rollover” subjects
from the ADNI study [260] for whom a history of measurements (imaging, psychology,
demographics, genetics) is available, and who are expected to continue in the study, providing
future measurements for testing. TADPOLE participants were required to predict future
measurements from these individuals and submit their predictions before a given submission
deadline. Since the test data did not exist at the time of forecast submissions, the challenge
provides a performance comparison substantially less susceptible to many forms of potential
bias than previous studies and challenges. The design choices were published [69] before
the test set was acquired and analysed. TADPOLE also goes beyond previous challenges
by drawing on a vast set of multimodal measurements from ADNI which might support
prediction of AD progression.
This article presents the results of the TADPOLE Challenge and documents its key findings.
We summarise the challenge design and present the results of the 92 prediction algorithms
contributed by 33 participating teams worldwide, evaluated after an 18-month follow-
up period. We discuss the results obtained by TADPOLE participants, which represent
the current state-of-the-art in Alzheimer’s disease prediction. To understand what key
characteristics of algorithms were important for good predictions, we also report results on
which input data features were most informative, and which feature selection strategies, data
imputation methods and classes of algorithms were most effective.
6.2 Results
6.2.1 Predictions
TADPOLE Challenge asked participants to forecast three key biomarkers: (1) clinical
diagnosis, which can be either cognitively normal (CN), mild cognitive impairment (MCI),
or probable AD; (2) Alzheimer’s Disease Assessment Scale Cognitive Subdomain (ADAS-
Cog13) score; and (3) ventricle volume (divided by intra-cranial volume) from MRI. The
exact time of future data acquisitions for any given individual was unknown at forecast
time, so participants submitted month-by-month predictions for every individual. Predictions
of clinical status comprise relative likelihoods of each option (CN, MCI, and AD) for each
individual at each month. Predictions of ADAS-Cog13 and ventricle volume comprise a best-
guess estimate as well as a 50% confidence interval for each individual at each month. Full

















AlgosForGood manual 16+5* forward-filling Aalen model linear regression 1 min. 1 sec.
Apocalypse manual 16
population
average SVM linear regression 40 min. 3 min.
ARAMIS-Pascal manual 20
population
average Aalen model - 16 sec. 0.02 sec.
ATRI-Biostat-JMM automatic 15 random forest random forest
linear mixed effects
model 2 days 1 sec.
ATRI-Biostat-LTJMM automatic 15 random forest random forest DPM 2 days 1 sec.
ATRI-Biostat-MA automatic 15 random forest random forest
DPM + linear mixed
effects model 2 days 1 sec.
BGU-LSTM automatic 67 none feed-forward NN LSTM 1 day millisec.
BGU-RF/ BGU-RFFIX automatic ≈ 67+1340* none semi-temporal RF semi-temporal RF a fewmin. millisec.
BIGS2 automatic all
Iterative
Thresholded SVD RF linear regression 2.2 sec. 0.001 sec.
Billabong (all) manual 15-16 linear regression linear scale non-parametric SM 7 hours 0.13 sec.
BORREGOSTECMTY automatic ≈100 + 400* nearest-neighbour regression ensemble ensemble of regression+ hazard models 18 hours 0.001 sec.
BravoLab automatic 25 hot deck LSTM LSTM 1 hour a few sec.
CBIL manual 21 linear interpolation LSTM LSTM 1 hour one min.
Chen-MCW manual 9 none linear regression DPM 4 hours < 1 hour
CN2L-NeuralNetwork automatic all forward-filling RNN RNN 24 hours a few sec.
CN2L-RandomForest manual >200 forward-filling RF RF 15 min. < 1 min.
CN2L-Average automatic all forward-filling RNN/RF RNN/RF 24 hours < 1 min.
CyberBrains manual 5
population





+ DPM DPM 290 sec. 0.025 sec.
DIVE manual 13 none KDE+DPM DPM 20 min. 0.06 sec.
EMC1 automatic 250 nearest neighbour
DPM + 2D spline +
SVM DPM + 2D spline 80 min. a few sec.
EMC-EB automatic 200-338 nearest-neighbour SVM classifier SVM regressor 20 sec. a few sec.
FortuneTellerFish-Control manual 19 nearest neighbour multiclass ECOC SVM
linear mixed effects
model 1 min. < 1 sec.
FortuneTellerFish-SuStaIn manual 19 nearest neighbour
multiclass ECOC SVM +
DPM
linear mixed effects
model + DPM 5 hours < 1 sec.





fill/nearest-neigh. multi-state model DPM + regression 15 min. 2 min.
GlassFrog-SM manual 7 linear model multi-state model parametric SM 93 sec. 0.1 sec.
GlassFrog-Average
semi-
automatic all forward-fill/linear multi-state model
DPM + SM +
regression 15 min. 2 min.









ridge regression 20 min. 0.3 sec.







model 20 min. 1.3 sec.












model 1 min. a few sec.
SPMC-Plymouth (all) automatic 20 none unknown - unknown 1 min.




NN 40 min. 0.06 sec.
SmallHeads-LinMixedEffects automatic unknown nearest neighbour -
linear mixed effects





average SVM linear model 30 min. < 1 min.
Threedays manual 16 none RF - 1 min. 3 sec.
Tohka-Ciszek-SMNSR manual ≈ 32 nearest neighbour - SMNSR severalhours a few sec.
Tohka-Ciszek-RandomForestLin manual 32 mean patient value RF linear model a fewmin. a few sec.
VikingAI (all) manual 10 none
DPM + ordered logit
model DPM 10 hours 8 sec.
BenchmaskLastVisit None 3 none constant model constant model 7 sec. millisec.
BenchmarkMixedEffects None 3 none Gaussian model
linear mixed effects
model 30 sec. 0.003 sec.





regressor (SVR) 20 sec. 0.001 sec.
Table 6.1: Summary of prediction methods used in the TADPOLE submissions. Keywords: SVM – Support Vector
Machine, RF – random forest, LSTM – long short-term memory network, NN – neural network, RNN – recurrent neural
network, SMNSR – Sparse Multimodal Neighbourhood Search Regression, DPM – disease progression model, KDE –
kernel density estimation, LDA – linear discriminant analysis, SM – slope model, ECOC – error-correcting output codes,
SVD – singular value decomposition (*) Augmented features, or summary statistics, such as trends, slope, min/max,
moments, generally derived patient-wise using longitudinal data. Color tags denote prediction method category:
regression/proportional hazards model, random forest, neural networks, disease progression model,
machine learning (other), benchmark, other. The left-side box denotes the category for diagnosis prediction




We had a total of 33 participating teams, who submitted a total of 58 predictions from
the longitudinal prediction set (D2), 34 predictions from the cross-sectional prediction set
(D3), and 6 predictions from custom prediction sets (see Online Methods section 6.5.1 for
description of D2/D3 datasets). A total of 8 D2/D3 submissions from 6 teams did not have
predictions for all three target variables, so we computed the performance metrics for only
the submitted target variables. Another 3 submissions lacked confidence intervals for either
ADAS-Cog13 or ventricle volume, which we imputed using default low-width confidence
ranges of 2 for ADAS-Cog13 and 0.002 for Ventricles normalised by intracranial volume (ICV).
Table 6.1 summarises the methods used in the submissions in terms of feature selection,
handling of missing data, predictive models for clinical diagnosis and ADAS/Ventricles
biomarkers, as well as training and prediction times. A detailed description of each method is
in Online Methods Section 6.5.4. In particular, some entries constructed augmented features
(i.e. summary statistics), which are extra features such as slope, min/max or moments that
are derived from existing features.
In addition to the forecasts submitted by participants, we also evaluated four benchmark
methods, which were made available to participants during the submission phase of the
challenge: (i) BenchmaskLastVisit uses the measurement of each target from the last available
clinical visit as the forecast, (ii) BenchmarkMixedEffects uses a mixed effects model with age
as predictor variable for ADAS and Ventricle predictions, and Gaussian likelihood model
for diagnosis prediction, (iii) BenchmarkMixedEffectsAPOE is as (ii) but adds APOE status as
a covariate and (iv) BenchmarkSVM uses an out-of-the-box support vector machine (SVM)
classifier and regressor (SVR) to provide forecasts. More details on these methods can be
found in Online Methods section 6.5.4. We also evaluated two ensemble methods based on
taking the mean (ConsensusMean) and median (ConsensusMedian) of the forecasted variables
over all submissions.
To control for potentially spurious strong performance arising from multiple comparisons,
we also evaluated 100 random predictions by adding Gaussian noise to the forecasts of the
simplest benchmark model (BenchmarkLastVisit). In the subsequent results tables we will
show, for each performance metric, only the best score obtained by any of these 100 random
predictions (RandomisedBest) – See end of Online Methods section 6.5.4 for more information
on RandomisedBest.
6.2.3 Forecasts from the longitudinal prediction set (D2)
Table 6.2 compiles all metrics for all TADPOLE submitted forecasts, as well as benchmarks
and ensemble forecasts, from the longitudinal D2 prediction set. For details on datasets
140
TADPOLE
Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
ConsensusMedian - - 0.925 0.857 - 5.12 5.01 0.28 - 0.38 0.33 0.09
Frog 1 1 0.931 0.849 4 4.85 4.74 0.44 10 0.45 0.33 0.47
ConsensusMean - - 0.920 0.835 - 3.75 3.54 0.00 - 0.48 0.45 0.13
EMC1-Std 2 8 0.898 0.811 23-24 6.05 5.40 0.45 1-2 0.41 0.29 0.43
VikingAI-Sigmoid 3 16 0.875 0.760 7 5.20 5.11 0.02 11-12 0.45 0.35 0.20
EMC1-Custom 4 11 0.892 0.798 23-24 6.05 5.40 0.45 1-2 0.41 0.29 0.43
CBIL 5 9 0.897 0.803 15 5.66 5.65 0.37 13 0.46 0.46 0.09
Apocalypse 6 7 0.902 0.827 14 5.57 5.57 0.50 20 0.52 0.52 0.50
GlassFrog-Average 7 4-6 0.902 0.825 8 5.26 5.27 0.26 29 0.68 0.60 0.33
GlassFrog-SM 8 4-6 0.902 0.825 17 5.77 5.92 0.20 21 0.52 0.33 0.20
BORREGOTECMTY 9 19 0.866 0.808 20 5.90 5.82 0.39 5 0.43 0.37 0.40
BenchmarkMixedEffects - - 0.846 0.706 - 4.19 4.19 0.31 - 0.56 0.56 0.50
EMC-EB 10 3 0.907 0.805 39 6.75 6.66 0.50 9 0.45 0.40 0.48
lmaUCL-Covariates 11-12 22 0.852 0.760 27 6.28 6.29 0.28 3 0.42 0.41 0.11
CN2L-Average 11-12 27 0.843 0.792 9 5.31 5.31 0.35 16 0.49 0.49 0.33
VikingAI-Logistic 13 20 0.865 0.754 21 6.02 5.91 0.26 11-12 0.45 0.35 0.20
lmaUCL-Std 14 21 0.859 0.781 28 6.30 6.33 0.26 4 0.42 0.41 0.09
RandomisedBest - - 0.800 0.803 - 4.52 4.52 0.27 - 0.46 0.45 0.33
CN2L-RandomForest 15-16 10 0.896 0.792 16 5.73 5.73 0.42 31 0.71 0.71 0.41
FortuneTellerFish-SuStaIn 15-16 40 0.806 0.685 3 4.81 4.81 0.21 14 0.49 0.49 0.18
CN2L-NeuralNetwork 17 41 0.783 0.717 10 5.36 5.36 0.34 7 0.44 0.44 0.27
BenchmarkMixedEffectsAPOE 18 35 0.822 0.749 2 4.75 4.75 0.36 23 0.57 0.57 0.40
Tohka-Ciszek-RandomForestLin 19 17 0.875 0.796 22 6.03 6.03 0.15 22 0.56 0.56 0.37
BGU-LSTM 20 12 0.883 0.779 25 6.09 6.12 0.39 25 0.60 0.60 0.23
DIKU-GeneralisedLog-Custom 21 13 0.878 0.790 11-12 5.40 5.40 0.26 38-39 1.05 1.05 0.05
DIKU-GeneralisedLog-Std 22 14 0.877 0.790 11-12 5.40 5.40 0.26 38-39 1.05 1.05 0.05
CyberBrains 23 34 0.823 0.747 6 5.16 5.16 0.24 26 0.62 0.62 0.12
AlgosForGood 24 24 0.847 0.810 13 5.46 5.11 0.13 30 0.69 3.31 0.19
lmaUCL-halfD1 25 26 0.845 0.753 38 6.53 6.51 0.31 6 0.44 0.42 0.13
BGU-RF 26 28 0.838 0.673 29-30 6.33 6.10 0.35 17-18 0.50 0.38 0.26
Mayo-BAI-ASU 27 52 0.691 0.624 5 4.98 4.98 0.32 19 0.52 0.52 0.40
BGU-RFFIX 28 32 0.831 0.673 29-30 6.33 6.10 0.35 17-18 0.50 0.38 0.26
FortuneTellerFish-Control 29 31 0.834 0.692 1 4.70 4.70 0.22 50 1.38 1.38 0.50
GlassFrog-LCMEM-HDR 30 4-6 0.902 0.825 31 6.34 6.21 0.47 51 1.66 1.59 0.41
SBIA 31 43 0.776 0.721 43 7.10 7.38 0.40 8 0.44 0.31 0.13
Chen-MCW-Stratify 32 23 0.848 0.783 36-37 6.48 6.24 0.23 36-37 1.01 1.00 0.11
Rocket 33 54 0.680 0.519 18 5.81 5.71 0.34 28 0.64 0.64 0.29
BenchmarkSVM 34-35 30 0.836 0.764 40 6.82 6.82 0.42 32 0.86 0.84 0.50
Chen-MCW-Std 34-35 29 0.836 0.778 36-37 6.48 6.24 0.23 36-37 1.01 1.00 0.11
DIKU-ModifiedMri-Custom 36 36-37 0.807 0.670 32-35 6.44 6.44 0.27 34-35 0.92 0.92 0.01
DIKU-ModifiedMri-Std 37 38-39 0.806 0.670 32-35 6.44 6.44 0.27 34-35 0.92 0.92 0.01
DIVE 38 51 0.708 0.568 42 7.10 7.10 0.34 15 0.49 0.49 0.13
ITESMCEM 39 53 0.680 0.657 26 6.26 6.26 0.35 33 0.92 0.92 0.43
BenchmarkLastVisit 40 44-45 0.774 0.792 41 7.05 7.05 0.45 27 0.63 0.61 0.47
Sunshine-Conservative 41 25 0.845 0.816 44-45 7.90 7.90 0.50 43-44 1.12 1.12 0.50
BravoLab 42 46 0.771 0.682 47 8.22 8.22 0.49 24 0.58 0.58 0.41
DIKU-ModifiedLog-Custom 43 36-37 0.807 0.670 32-35 6.44 6.44 0.27 47-48 1.17 1.17 0.06
DIKU-ModifiedLog-Std 44 38-39 0.806 0.670 32-35 6.44 6.44 0.27 47-48 1.17 1.17 0.06
Sunshine-Std 45 33 0.825 0.771 44-45 7.90 7.90 0.50 43-44 1.12 1.12 0.50
Billabong-UniAV45 46 49 0.720 0.616 48-49 9.22 8.82 0.29 41-42 1.09 0.99 0.45
Billabong-Uni 47 50 0.718 0.622 48-49 9.22 8.82 0.29 41-42 1.09 0.99 0.45
ATRI-Biostat-JMM 48 42 0.779 0.710 51 12.88 69.62 0.35 54 1.95 5.12 0.33
Billabong-Multi 49 56 0.541 0.556 55 27.01 19.90 0.46 40 1.07 1.07 0.45
ATRI-Biostat-MA 50 47 0.741 0.671 52 12.88 11.32 0.19 53 1.84 5.27 0.23
BIGS2 51 58 0.455 0.488 50 11.62 14.65 0.50 49 1.20 1.12 0.07
Billabong-MultiAV45 52 57 0.527 0.530 56 28.45 21.22 0.47 45 1.13 1.07 0.47
ATRI-Biostat-LTJMM 53 55 0.636 0.563 54 16.07 74.65 0.33 52 1.80 5.01 0.26
Threedays - 2 0.921 0.823 - - - - - - - -
ARAMIS-Pascal - 15 0.876 0.850 - - - - - - - -
IBM-OZ-Res - 18 0.868 0.766 - - - - 46 1.15 1.15 0.50
Orange - 44-45 0.774 0.792 - - - - - - - -
SMALLHEADS-NeuralNet - 48 0.737 0.605 53 13.87 13.87 0.41 - - - -
SMALLHEADS-LinMixedEffects - - - - 46 8.09 7.94 0.04 - - - -
Tohka-Ciszek-SMNSR - - - - 19 5.87 5.87 0.14 - - - -
Table 6.2: Ranked scores for all TADPOLE submissions and benchmarks using the longitudinal prediction data set (D2).
Best scores in each category are bolded. Missing numerical entries indicate that submissions did not include forecasts
for the corresponding target variable. The “Diagnosis” ranking uses multiclass area under the receiver operating
characteristic curve (MAUC), those of ADAS-Cog13 and Ventricles use mean absolute error (MAE). The overall ranking
on the left uses the sum of the ranks from the three target variables. The table also lists the secondary metrics: BCA –
balanced classification accuracy, WES – weighted error score, CPA – coverage probability accuracy. See Online Methods
section 6.5.2 for details on performance metrics.
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D2 and D3, see Online Methods section 6.5.1, while for details on performance metrics see
Online Methods section 6.5.2. Box-plots showing the distribution of scores, computed on 50
bootstraps of the test set, are shown in Supplementary Fig. 6.SF1, while the distribution of
ranks is shown in Supplementary Figs. 6.SF8 – 6.SF10. Among the benchmark methods,
BenchmarkMixedEffectsAPOE had the best overall rank of 18, obtaining rank 35 on clinical
diagnosis prediction, rank 2 on ADAS-Cog13 and rank 23 on Ventricle volume prediction.
Removing the APOE status as covariate proved to significantly increase the predictive
performance (BenchmarkMixedEffects), although we do not show ranks for this entry as it was
found during the evaluation phase. Among participant methods, the submission with the
best overall rank was Frog, obtaining rank 1 for prediction of clinical diagnosis, rank 4 for
ADAS-Cog13 and rank 10 for Ventricle volume prediction.
For clinical diagnosis, the best submitted forecasts (team Frog) scored better than all
benchmark methods, reducing the error of the best benchmark methods by 58% for the
multiclass area under the receiver operating characteristic curve (MAUC) and by 38% for
balanced classification accuracy (BCA). Here, the best benchmarks obtained a MAUC of
0.846 (BenchmarkMixedEffects) and a BCA of 0.792 (BenchmarkLastVisit). Among participant
methods, Frog had the best MAUC score of 0.931, significantly better than all entries other
than Threedays according to the bootstrap test (p-value = 0.24, see Supplementary section
6.5.4 for details on significance testing). Supplementary Figure 6.SF8 further shows the
variability in performance ranking over bootstrap samples and highlights that the top two
entries consistently remain at the top of the ranking. In terms of BCA, ARAMIS-Pascal
had the best score of 0.850. Moreover, ensemble methods (ConsensusMedian) achieved the
second best MAUC score of 0.925 and the best BCA score of 0.857. In contrast, the best
randomised prediction (RandomisedBest) achieved a much lower MAUC of 0.800 and a BCA of
0.803, suggesting entries below these scores did not perform significantly better than random
guessing according to the bootstrap test (p-value = 0.01). MAUC and BCA performance
metrics had a relatively high correlation across all submissions (r = 0.88, Supplementary Fig.
6.SF3).
For Ventricle volume, the best submitted forecasts among participants (team EMC1) also
scored considerably better than all benchmark methods, reducing the error of the best
benchmark methods by almost one third (29%) for mean absolute error (MAE) and
around one half (51%) for weighted error score (WES). Here, the best benchmark method
(BenchmarkMixedEffects) had an overall Ventricle MAE and WES of 0.56. Among participant
submissions, EMC1-Std/-Custom had the best MAE of 0.41 (% ICV), significantly lower than all
entries other than lmaUCL-Covariates/-Std/-half-D1, BORREGOTECMTY and SBIA according
to the Wilcoxon signed-rank test (see Supplementary section 6.5.4) – this is also confirmed in
Supplementary Fig. 6.SF10 by the variability in performance ranking over bootstrap samples.
Team EMC1 also had the best Ventricle WES of 0.29, while DIKU-ModifiedMri-Custom/-Std
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had the best Ventricle coverage probability accuracy (CPA) of 0.01. Ensemble methods
(ConsensusMean) achieved the best Ventricle MAE of 0.38. In contrast, the best randomised
prediction (RandomisedBest) achieved a higher MAE of 0.46, WES of 0.45 and CPA of 0.33.
MAE and WES scores showed high correlation (r = 0.99, Supplementary Fig. 6.SF3) and were
often of equal value for many submissions (n = 24), as teams set equal weights for all subjects
analysed. CPA did not correlate (r ≈ −0.01, Supplementary Fig. 6.SF3) with either MAE or
WES.
For ADAS-Cog13, the best submitted forecasts did not score significantly better than the
simple benchmarks. Here, the simple BenchmarkMixedEffects model obtained the second-best
MAE of 4.19, which was significantly lower than all other submitted entries according to
the Wilcoxon signed-rank test. BenchmarkMixedEffects also had the best ADAS-Cog13 WES
of 4.19, while VikingAI-Sigmoid had the best ADAS-Cog13 CPA of 0.02. Among participants’
submissions, FortuneTellerFish-Control ranked first in ADAS-Cog13 prediction with a MAE of
4.70, which is 11% higher than the error of the best benchmark. Moreover, all participants’
forecasts scored worse than the best randomised prediction (RandomisedBest), which here
achieved a MAE of 4.52 and WES of 4.52. Nevertheless, the ensemble method ConsensusMean
obtained the best ADAS scores for MAE (3.75), WES (3.54) and CPA (0.0), which along with
BenchmarkMixedEffects were the only entries that performed significantly better than random
guessing (p-value = 0.01). The MAE and WES scores for ADAS-Cog13 had relatively high
correlation (r = 0.97, Supplementary Fig. 6.SF3) and were often of equal value for many
submissions (n = 25). CPA had a weak but significant correlation with MAE (r = 0.37,
p-value < 0.02) and WES (r = 0.35, p-value < 0.02).
6.2.4 Forecasts from the cross-sectional prediction set (D3) and custom prediction
sets
Table 6.3 shows the ranking of the forecasts from the cross-sectional D3 prediction set. Box-
plots showing the distribution of scores, computed on 50 bootstraps of the test set, are shown
in Supplementary Fig 6.SF2, while the distribution of ranks is shown in Supplementary
Figs. 6.SF11 – 6.SF13. Due to the lack of longitudinal data, most submissions had lower
performance compared to their equivalents from the D2 longitudinal prediction set. Among
submitted forecasts, GlassFrog-Average had the best overall rank, as well as rank 2-4 on
diagnosis prediction, rank 5 on ADAS-Cog13 prediction and rank 3 on ventricle prediction.
For clinical diagnosis prediction on D3, the best prediction among TADPOLE participants
(team IBM-OZ-Res) scored considerably better than all benchmark methods, reducing the
error of the best benchmark method by 40% for MAUC and by 25% for BCA, and achieving
error rates comparable to the best predictions from the longitudinal prediction set D2.
The best benchmark methods obtained a MAUC of 0.839 (BenchmarkMixedEffects) and a
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BCA of 0.771 (BenchmarkLastVisit). Among participant methods, IBM-OZ-Res had the best
MAUC score of 0.905, significantly better than all entries other than GlassFrog-SM/-Average/-
LCMEM-HDR, BGU-RF/-RFFIX/-LSTM, VikingAI-Logistic, EMC-EB, Rocket and Tohka-Ciszek-
RandomForestLin according to the bootstrap hypothesis test (same methodology as in D2).
This is further confirmed in Supplementary Fig. 6.SF11 by the variability of ranks under
boostrap samples of the dataset, as these teams often remain at the top of the ranking. IBM-
OZ-Res also had the best BCA score of 0.830 among participants. Among ensemble methods,
ConsensusMean obtained the best Diagnosis MAUC of 0.917. In contrast, the best randomised
prediction (RandomisedBest) obtained an MAUC of 0.811 and a BCA of 0.783. MAUC and
BCA performance metrics had a relatively high correlation across all submissions (r = 0.9,
Supplementary Fig. 6.SF4).
For Ventricle volume prediction on D3, the best prediction (GlassFrog-LCMEM-HDR) scored
considerably better than all benchmark methods, reducing the error of the best benchmark
methods by 58% for MAE and 41% for WES, and achieving error rates comparable to the
best predictions of D2. Here, the best benchmark methods had an overall Ventricle MAE
of 1.13 (BenchmarkMixedEffects) and WES of 0.64 (BenchmarkLastVisit). Among participant
submissions, GlassFrog-LCMEM-HDR had the best MAE of 0.48, significantly lower than all
other submitted entries according to the Wilcoxon signed-rank test – this is also confirmed
in Supplementary Fig. 6.SF13 by the rank distribution under dataset boostraps. GlassFrog-
LCMEM-HDR also had the best Ventricle WES of 0.38, while submissions by team DIKU
had the best Ventricle CPA of 0.05. Among ensemble methods, ConsensusMedian obtained
a Ventricle MAE of 0.71 (4th best) and WES of 0.65 (7th best). In contrast, the best randomised
prediction (RandomisedBest) obtained a Ventricle MAE of 0.92, WES of 0.50 and CPA of 0.
As in D2, MAE and WES scores in D3 for Ventricles had very high correlation (r = 0.99,
Supplementary Fig. 6.SF4), while CPA showed weak correlation with MAE (r = 0.24, p-value
= 0.17) and WES (r = 0.37, p-value < 0.032).
For ADAS-Cog13 on D3, the predictions submitted by participants again did not perform
better than the best benchmark methods. BenchmarkMixedEffects had the best MAE of 4.23,
which was significantly lower than all entries by other challenge participants. Moreover, the
MAE of 4.23 was only marginally worse than the equivalent error (4.19) by the same model
on D2. BenchmarkMixedEffects also had the best ADAS-Cog13 WES of 4.23, while ATRI-Biostat-
MA had the best ADAS-Cog13 CPA of 0.04. Among participants’ submissions, CyberBrains
ranked first in ADAS-Cog13 prediction with a MAE of 4.72, an error 11% higher than the
best benchmark. Among ensemble methods, ConsensusMean obtained an ADAS-Cog13 MAE
of 4.58, WES of 4.34, better than all participants’ entries. As in D2, the best randomised
predictions (RandomisedBest) obtained an ADAS-Cog13 MAE of 4.54 (2nd best) and WES of
4.50 (3rd best). As in D2, MAE and WES scores for ADAS-Cog13 had high correlation (r =
0.97, Supplementary Fig. 6.SF4), while CPA showed weak, non-significant correlation with
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MAE (r = 0.34, p-value ≈ 0.052) or WES (r = 0.33, p-value ≈ 0.057).
Results on the custom prediction sets are presented in Supplementary Table 6.ST1.
6.2.5 Algorithm characteristics associated with increased performance
To understand what characteristics of algorithms could have yielded higher performance, we
show in Figure 6.1 associations from a general linear model between predictive performance
and feature selection methods, different types of features, methods for data imputation,
and methods for forecasting of target variables. For each type of feature/method and each
target variable (clinical diagnosis, ADAS-Cog13 and Ventricles), we show the distribution of
estimated coefficients from a general linear model, derived from the approximated inverse
Hessian matrix at the maximum likelihood estimator (see Online Methods section 6.5.3). From
this analysis we removed outliers, defined as submissions with ADAS MAE higher than 10
and Ventricle MAE higher than 1.15 (%ICV). For all plots, distributions to the right of the
gray dashed vertical line denote increased performance compared to baseline (i.e. when those
characteristics are not used).
For feature selection, Figure 6.1 shows that methods with manual selection of features tend
to be associated with better predictive performance in ADAS-Cog13 and Ventricles. In
terms of feature types, CSF and DTI features were generally associated with an increase in
predictive performance for clinical diagnosis, while augmented features were associated with
performance improvements for ventricle prediction. In terms of data imputation methods,
while some differences can be observed, no clear conclusions can be drawn. In terms of
prediction models, the only positive association that indicates increased performance is in
the neural networks for ventricle prediction. However, given the small number of methods
tested (<50) and the large number of degrees of freedom, these results should be interpreted
with care.
6.3 Discussion
In this work, we presented the results of the TADPOLE Challenge. The results of the challenge
provide important insights into the current state of the field, and how well current algorithms
can predict progression of AD diagnoses and markers of disease progression both from rich
longitudinal data sets and, comparatively, from sparser cross-sectional data sets typical of
a clinical trial scenario. The challenge further highlights the algorithms, features and data-
handling strategies that tend to lead to improved forecasts. In the following sections we
discuss the key conclusions that we draw from our study and highlight important limitations.
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Figure 6.1: Associations between the prediction of clinical diagnosis, ADAS-Cog13 and Ventricle volume
and different strategies of (top) feature selection, (upper-middle) types of features, (lower-middle)
data imputation strategies and (bottom) prediction methods for the target variables. For each type
of feature/method (rows) and each target variable (columns), we show the distribution of estimated
coefficients from a general linear model. Positive coefficients, where distributions lie to the right of the
dashed vertical line, indicate better performance than baseline (vertical dashed line). For ADAS-Cog13
and Ventricle prediction, we flipped the sign of the coefficients, to consistently show better performance
to the right of the vertical line.
6.3.1 TADPOLE pushed forward performance on AD clinical diagnosis
prediction
When comparing to previous state-of-the-art results in the literature, the best TADPOLE
methods show similar or higher performance in AD diagnostic classification while also
tackling a harder problem than most previous studies of predicting future, rather than
estimating current, classification. A comparison of 15 studies presented by [262] reported
lower performance (maximum AUC of 0.902 vs 0.931 obtained by the best TADPOLE
method) for the simpler two-class classification problem of separating MCI-stable from MCI-
converters in ADNI. A more recent method by [263] reported a maximum AUC of 0.932
and accuracy of 0.88 at the same MCI-stable vs -converter classification task. However, a)
TADPOLE’s discrimination of CN-converters from CN-stable subjects is harder as disease
signal is weaker at such early stages, and b) the predictive performance drops in three-class
problems like TADPOLE compared to two-class. Furthermore, the best out of 19 algorithms
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in the CADDementia Challenge [258] obtained an MAUC of 0.78.
We are unaware of previous studies forecasting future ventricle volume or ADAS-Cog13, so
TADPOLE sets a new benchmark state-of-the-art performance on these important prediction
tasks.
6.3.2 No one-size-fits-all prediction algorithm
The results on the longitudinal D2 prediction set suggest no clear winner on predicting all
target variables – no single method performed well on all tasks. While Frog had the best
overall submission with the lowest sum of ranks, for each performance metric individually
we had different winners: Frog (clinical diagnosis MAUC of 0.931), ARAMIS-Pascal (clinical
diagnosis BCA of 0.850), BenchmarkMixedEffects (ADAS-Cog13 MAE and WES of 4.19),
VikingAI-Sigmoid (ADAS-Cog13 CPA of 0.02), EMC1-Std/EMC1-Custom (ventricle MAE of 0.41
and WES or 0.29), and DIKU-ModifiedMri-Std/-Custom (ventricle CPA of 0.01). Moreover, on
the cross-sectional D3 prediction set, the methods by Glass-Frog had the best performance.
Associations of method-type with increased performance in Fig. 6.1 confirm no clear increase
in performance for any types of prediction methods (with the exception of neural networks for
ventricle volume prediction). This raises an important future challenge to algorithm designers
to develop methods able to perform well on multiple forecasting tasks and also in situations
with limited data, such as D3.
6.3.3 Ensemble methods perform strongly
Consistently strong results from ensemble methods (ConsensusMean/ConsensusMedian
outperformed all others on most tasks) might suggest that different methods over-estimate
future measurements for all subjects while others under-estimate them, likely due to the
underlying assumptions they make. This is confirmed by plots of the difference between
true and estimated measures (Supplementary Figures 6.SF5–6.SF7), where most methods
systematically under- or over-estimate in all subjects. However, even if methods were
completely unbiased, averaging over all methods could also help predictions by reducing
the variance in the estimated target variables.
6.3.4 Predictability of ADAS-Cog13 scores
ADAS-Cog13 scores were more difficult to forecast than clinical diagnosis or ventricle volume.
The only single method able to forecast ADAS-Cog13 better than informed random guessing
(RandomisedBest) was the BenchmarkMixedEffects, a simple mixed effects model with no
covariates and age as a regressor. The difficulty could be due to variability in administering
the tests or practice effects. A useful target performance level comes from the 4 points change
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generally used to identify responders to a drug treatment [264]. With the exception of the
ensemble method, all submitted forecasts failed to produce mean error below 4, highlighting
the substantial challenge of estimating change in ADAS-Cog13 over the 1.4 year interval –
although over longer time periods, non-trivial forecasts are likely to improve in comparison
to RandomisedBest, which is independent of time period. Nevertheless, for the longitudinal D2
prediction set, the MAE in ADAS-Cog13 from ConsensusMean was 3.75, which restores hope
in forecasting cognitive score trajectories even over relatively short timescales.
6.3.5 Prediction errors from limited cross-sectional dataset mimicking clinical
trials are similar to those from longitudinal dataset
For clinical diagnosis, the best performance on the limited, cross-sectional D3 prediction set
was similar to the best performance on the D2 longitudinal prediction set: 0.917 vs 0.931 for
MAUC (p-value = 0.14), representing a 3% error increase for D3 compared to D2. Slightly
larger and significant differences were observed for ADAS MAE (3.75 vs 4.23, p-value < 0.01)
and Ventricle MAE (0.38 vs 0.48, p-value < 0.01). It should be noted that Ventricle predictions
for D3 were extremely difficult, given that only 25% of subjects to be forecasted had MRI data
in D3. This suggests that, for clinical diagnosis, current forecast algorithms are reasonably
robust to lack of longitudinal data and missing inputs, while for ADAS and Ventricle volume
prediction, some degree of performance is lost. Future work is also required to determine the
optimal balance of input data quality and quantity versus cost of acquisition.
6.3.6 DTI and CSF features appear informative for clinical diagnosis prediction,
augmented features appear informative for ventricle prediction
DTI and CSF features are most associated with increases in clinical diagnosis forecast
performance. CSF, in particular, is well established as an early marker of AD [5] and
likely to help predictions for early-stage subjects, while DTI, measuring microstructure
damage, may be informative for middle-stage subjects. On the other hand, for prediction of
ventricle volume, augmented features had the highest association with increases in prediction
performance. Future work is required to confirm the added value of these features and others
in a more systematic way.
6.3.7 Challenge design and limitations
TADPOLE Challenge has several limitations that future editions of the challenge may consider
addressing. One limitation is the reliability of the three target variables: clinical diagnosis,
ADAS-Cog13 and Ventricle volume. First of all, clinical diagnosis has only moderate
agreement with gold-standard neuropathological post-mortem diagnosis. In particular, one
study [265] has shown that a clinical diagnosis of probable AD has sensitivity between
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70.9% and 87.3% and specificity between 44.3% and 70.8%. With the advent of post-mortem
confirmation in ADNI, future challenges might address this by evaluating the algorithms on
subjects with pathological confirmation. Similarly, ADAS-Cog13 is known to suffer from low
reliability across consecutive visits [264], and TADPOLE algorithms fail to forecast it reliably.
However, this might be related to the short time-window (1.4 years), and more accurate
predictions might be possible over longer time-windows, when there is more significant
cognitive decline. Ventricle volume measurements depend on MRI scanner factors such as
field strength, manufacturer and pulse sequences [266], although these effects have been
removed to some extent by ADNI through data preprocessing and protocol harmonization.
TADPOLE Challenge also assumes all subjects either remain stable or convert to Alzheimer’s
disease, whereas in practice some of them might develop other types of neurodegenerative
diseases.
For performance evaluation, we elected to use very simple yet reliable metrics as the primary
performance scores: the multiclass area under the curve (mAUC) for the clinical categorical
variable and the mean absolute error (MAE) for the two numerical variables. While the
mAUC accounts for decision confidence, the MAE does not, which means that the confidence
intervals submitted by participants do not contribute to the rankings computed in Tables 6.2
and 6.3. While the weighted error score (WES) takes confidence intervals into account, we
consider it susceptible to “hacking”, e.g. participants might assign high confidence to only
one or two data points and thereby skew the score to ignore most of the predictions – in
practice, we did not observe this behaviour in any submission. For clinical relevance, we
believe that confidence intervals are an extremely important part of such predictions and urge
future studies to consider performance metrics that require and take account of participant-
calculated confidence measures.
TADPOLE has other limitations related to the algorithms’ comparability and generalisability.
First of all, the evaluation and training were both done on data collected by ADNI – in
future work, we plan to assess how the models will generalise on different datasets. Another
limitation is that we can only compare full methods submissions and not different types
of features, and strategies for data imputation and prediction used within the full method.
While we tried to evaluate the effect of these characteristics in Figure 6.1, in practice the
numbers were small and hence most effects did not reach statistical significance. Moreover,
the challenge format does not provide an exhaustive comparison of all combinations of data
processing, predictive model, features, etc., so does not lead to firm conclusions on the best
combinations but rather provides hypotheses for future testing. In future work, we plan to
test inclusion of features and strategies for data imputation and prediction independently, by
changing one such characteristic at a time.
Another limitation is that the number of controls and MCI converters in the D4 test set is
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low (9 MCI converters and 9 control converters). However, these numbers will increase over
time as ADNI acquires more data, and we plan to re-run the evaluation at a later stage with
the additional data acquired after April 2019. A subsequent evaluation will also enable us to
evaluate the TADPOLE methods on longer time-horizons, over which the effects of putative
drugs would be higher.
6.4 Conclusion
In this work we presented the results of the TADPOLE Challenge. The results of the
challenge provide important insights into the current state of the art in AD forecasting, such as
performance levels achievable with current data and technology as well as specific algorithms,
features and data-handling strategies that support the best forecasts. The developments and
outcomes of TADPOLE Challenge can aid refinement of cohorts and endpoint assessment
for clinical trials, and can support accurate prognostic information in clinical settings.
The challenge website (https://tadpole.grand-challenge.org) will stay open for
submissions, which can be added to our current ranking. The open test set remains available
on the ADNI LONI website and also allows individual participants to evaluate future
submissions. Through TADPOLE-SHARE https://tadpole-share.github.io/, we
further plan to implement many TADPOLE methods in a common framework, to be made




Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
ConsensusMean - - 0.917 0.821 - 4.58 4.34 0.12 - 0.73 0.72 0.09
ConsensusMedian - - 0.905 0.817 - 5.44 5.37 0.19 - 0.71 0.65 0.10
GlassFrog-Average 1 2-4 0.897 0.826 5 5.86 5.57 0.25 3 0.68 0.55 0.24
GlassFrog-LCMEM-HDR 2 2-4 0.897 0.826 9 6.57 6.56 0.34 1 0.48 0.38 0.24
GlassFrog-SM 3 2-4 0.897 0.826 4 5.77 5.77 0.19 9 0.82 0.55 0.07
Tohka-Ciszek-RandomForestLin 4 11 0.865 0.786 2 4.92 4.92 0.10 10 0.83 0.83 0.35
RandomisedBest - - 0.811 0.783 - 4.54 4.50 0.26 - 0.92 0.50 0.00
lmaUCL-Std 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
lmaUCL-Covariates 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
lmaUCL-halfD1 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
Rocket 5-9 10 0.865 0.771 3 5.27 5.14 0.39 23 1.06 1.06 0.27
VikingAI-Logistic 5-9 8 0.876 0.768 6 5.94 5.91 0.22 22 1.04 1.01 0.18
EMC1-Std 10 30 0.705 0.567 7 6.29 6.19 0.47 4 0.80 0.62 0.48
BenchmarkMixedEffects - - 0.839 0.728 - 4.23 4.23 0.34 - 1.13 1.13 0.50
SBIA 11 28 0.779 0.782 10 6.63 6.43 0.40 8 0.82 0.75 0.18
BGU-LSTM 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BGU-RFFIX 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BGU-RF 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BravoLab 15 18 0.813 0.730 28 8.02 8.02 0.47 2 0.64 0.64 0.42
BORREGOTECMTY 16-17 15 0.852 0.748 8 6.44 5.86 0.46 30 1.14 1.02 0.49
CyberBrains 16-17 17 0.830 0.755 1 4.72 4.72 0.21 35 1.54 1.54 0.50
ATRI-Biostat-MA 18 19 0.799 0.772 26 7.39 6.63 0.04 11 0.93 0.97 0.10
DIKU-GeneralisedLog-Std 19-20 20 0.798 0.684 20-21 6.99 6.99 0.17 16-17 0.95 0.95 0.05
EMC-EB 19-20 9 0.869 0.765 27 7.71 7.91 0.50 21 1.03 1.07 0.49
DIKU-GeneralisedLog-Custom 21 21 0.798 0.681 20-21 6.99 6.99 0.17 16-17 0.95 0.95 0.05
DIKU-ModifiedLog-Std 22-23 22-23 0.798 0.688 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedMri-Std 22-23 22-23 0.798 0.688 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedMri-Custom 24-25 24-25 0.798 0.691 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedLog-Custom 24-25 24-25 0.798 0.691 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
Billabong-Uni 26 31 0.704 0.626 11-12 6.69 6.69 0.38 19-20 0.98 0.98 0.48
Billabong-UniAV45 27 32 0.703 0.620 11-12 6.69 6.69 0.38 19-20 0.98 0.98 0.48
ATRI-Biostat-JMM 28 26 0.794 0.781 29 8.45 8.12 0.34 18 0.97 1.45 0.37
CBIL 29 16 0.847 0.780 33 10.99 11.65 0.49 29 1.12 1.12 0.39
BenchmarkLastVisit 30 27 0.785 0.771 19 6.97 7.07 0.42 33 1.17 0.64 0.11
Billabong-MultiAV45 31 33 0.682 0.603 30-31 9.30 9.30 0.43 24-25 1.09 1.09 0.49
Billabong-Multi 32 34 0.681 0.605 30-31 9.30 9.30 0.43 24-25 1.09 1.09 0.49
ATRI-Biostat-LTJMM 33 29 0.732 0.675 34 12.74 63.98 0.37 32 1.17 1.07 0.40
BenchmarkSVM 34 36 0.494 0.490 32 10.01 10.01 0.42 31 1.15 1.18 0.50
DIVE 35 35 0.512 0.498 35 16.66 16.74 0.41 34 1.42 1.42 0.34
IBM-OZ-Res - 1 0.905 0.830 - - - - 36 1.77 1.77 0.50
Table 6.3: Ranked prediction scores for all TADPOLE submissions that used the cross-sectional prediction data set
(D3). Best scores in each category are bolded. Missing numerical entries indicate that submissions did not include
predictions for the corresponding target variable. The “Diagnosis” ranking uses multiclass area under the receiver
operating characteristic curve (MAUC), those of ADAS-Cog13 and Ventricles use mean absolute error (MAE). The overall
ranking on the left uses the sum of the ranks from the three target variables. The table also lists the secondary metrics:
BCA – balanced classification accuracy, WES – weighted error score, CPA – coverage probability accuracy.
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6.5 Online Methods – Challenge design and prediction algorithms
6.5.1 Data
The challenge uses data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [260].
Specifically, the TADPOLE Challenge made four key data sets available to the challenge
participants:
• D1: The TADPOLE standard training set draws on longitudinal data from the entire
ADNI history. The data set contains measurements for every individual that has
provided data to ADNI in at least two separate visits (different dates) across three
phases of the study: ADNI1, ADNI GO, and ADNI2.
• D2: The TADPOLE longitudinal prediction set contains as much available data as we
could gather from the ADNI rollover individuals for whom challenge participants are
asked to provide predictions. D2 includes data from all available time-points for these
individuals. It defines the set of individuals for which participants are required to
provide forecasts.
• D3: The TADPOLE cross-sectional prediction set contains a single (most recent) time
point and a limited set of variables from each rollover individual in D2. Although
we expect worse predictions from this data set than D2, D3 represents the information
typically available when selecting a cohort for a clinical trial.
• D4: The TADPOLE test set contains visits from ADNI rollover subjects that occurred
after 1 Jan 2018 and contain at least one of the three outcome measures: diagnostic
status, ADAS-Cog13 score, or ventricle volume.
While participants were free to use any training datasets they wished, we provided the D1-D3
datasets in order to remove the need for participants to pre-process the data themselves, and
also to be able to evaluate the performance of different algorithms on the same standardised
datasets. Participants that used custom training data sets were asked also to submit results
using the standard training data sets to enable direct performance comparison. We also
included the D3 cross-sectional prediction set in order to simulate a clinical trial scenario.
For information on how we created the D1-D4 datasets, see Supplementary section 6.5.4.
The software code used to generate the standard datasets is openly available on Github:
https://github.com/noxtoby/TADPOLE.
Table 6.4 shows the demographic breakdown of each TADPOLE data set as well as the
proportion of biomarker data available in each dataset. Many entries are missing data,
especially for certain biomarkers derived from exams performed on only subsets of subjects,
such as tau imaging (AV1451). D1 and D2 also included demographic data typically available
in ADNI (e.g. education, marital status) as well as standard genetic markers (e.g. Alipoprotein




D1 D2 D3 D4
Overall number of subjects 1667 896 896 219
Controls†
Number (% all subjects) 508 (30.5%) 369 (41.2%) 299 (33.4%) 94 (42.9%)
Visits per subject 8.3 ± 4.5 8.5 ± 4.9 1.0 ± 0.0 1.0 ± 0.2
Age 74.3 ± 5.8 73.6 ± 5.7 72.3 ± 6.2 78.4 ± 7.0
Gender (% male) 48.6% 47.2% 43.5% 47.9%
MMSE 29.1 ± 1.1 29.0 ± 1.2 28.9 ± 1.4 29.1 ± 1.1
Converters* 18 9 - -
MCI†
Number (% all subjects) 841 (50.4%) 458 (51.1%) 269 (30.0%) 90 (41.1%)
Visits per subject 8.2 ± 3.7 9.1 ± 3.6 1.0 ± 0.0 1.1 ± 0.3
Age 73.0 ± 7.5 71.6 ± 7.2 71.9 ± 7.1 79.4 ± 7.0
Gender (% male) 59.3% 56.3% 58.0% 64.4%
MMSE 27.6 ± 1.8 28.0 ± 1.7 27.6 ± 2.2 28.1 ± 2.1
Converters* 117 37 - 9
AD†
Number (% all subjects) 318 (19.1%) 69 (7.7%) 136 (15.2%) 29 (13.2%)
Visits per subject 4.9 ± 1.6 5.2 ± 2.6 1.0 ± 0.0 1.1 ± 0.3
Age 74.8 ± 7.7 75.1 ± 8.4 72.8 ± 7.1 82.2 ± 7.6
Gender (% male) 55.3% 68.1% 55.9% 51.7%
MMSE 23.3 ± 2.0 23.1 ± 2.0 20.5 ± 5.9 19.4 ± 7.2
Converters* - - - 9
Number of clinical visits for all subjects with data available (% of total visits)
D1 D2 D3 D4
Cognitive 8862 (69.9%) 5218 (68.1%) 753 (84.0%) 223 (95.3%)
MRI 7884 (62.2%) 4497 (58.7%) 224 (25.0%) 150 (64.1%)
FDG-PET 2119 (16.7%) 1544 (20.2%) - -
AV45 2098 (16.6%) 1758 (23.0%) - -
AV1451 89 (0.7%) 89 (1.2%) - -
DTI 779 (6.1%) 636 (8.3%) - -
CSF 2347 (18.5%) 1458 (19.0%) - -
Table 6.4: Summary of TADPOLE datasets D1-D4. (†) Diagnosis at first visit with available data. For D3 and D4, 192
and 6 subjects respectively did not have a diagnosis at any clinical visit, so numbers don’t add up to 100%. (*) For D4,
converters are ADNI3 subjects who are MCI, but were previously CN, or who are AD, but were previously CN or MCI
in their last visit in ADNI2. For D1, D2 and D3, converters are CN or MCI at their earliest available visit, who progress
to a later classification of MCI/AD within 1.4 years (same duration as D4)
.
6.5.2 Forecast Evaluation
For evaluation of clinical status predictions, we used similar metrics to those that proved
effective in the CADDementia challenge [258]: (i) the multiclass area under the receiver
operating characteristic curve (MAUC) and (ii) the overall balanced classification accuracy
(BCA). For ADAS-Cog13 and ventricle volume, we used three metrics: (i) mean absolute
error (MAE), weighted error score (WES) and coverage probability accuracy (CPA). BCA and
MAE focus purely on prediction accuracy ignoring confidence, MAUC and WES account for
accuracy and confidence, while CPA assesses the confidence interval only. The formulas
for each performance metric are summarised in Table 6.5. See the TADPOLE white paper
[69] for further rationale for choosing these performance metrics. In order to characterise
the distribution of these metric scores, we compute scores based on 50 bootstraps with










j=1 Â(ci|cj) + Â(cj |ci)
where Â(ci|cj) = Si−ni(ni+1)/2ninj
ni, nj – number of points from class i and j. Sij – the
sum of the ranks of the class i test points, after ranking
all the class i and j data points in increasing likelihood










] TPi, FPi, TNi, FNi – the number of true positives,
false positives, true negatives and false negatives for





∣∣∣M̃i −Mi∣∣∣ Mi is the actual value in individual i in future data. M̃iis the participant’s best guess at Mi and N is the





Mi, M̃i and N defined as above. C̃i = (C+ − C−)−1,
where [C−, C+] is the 50% confidence interval
CPA = |ACP − 0.5|
actual coverage probability (ACP) - the proportion of
measurements that fall within the 50% confidence
interval.
Table 6.5: TADPOLE performance metric formulas and definitions for the terms.
6.5.3 Statistical Analysis of Method Attributes with Performance
To identify which features and types of algorithms enable good predictions, we annotated
each TADPOLE submission with a set of 21 attributes related to (i) feature selection
(manual/automatic and large vs. small number of features), (ii) feature types (e.g. “uses
Amyloid PET”), (iii) strategy for data imputation (e.g. “patient-wise forward-fill”) and
(iv) prediction method (e.g. “neural network”) for clinical diagnosis and ADAS/Ventricles
separately. To understand which of these annotations were associated with increased
performance, we applied a general linear model [267], Y = Xβ + ε, where Y is the
performance metric (e.g. diagnosis MAUC), X is the nr submissions x 21 design matrix
of binary annotations, and β show the contributions of each of the 21 attributes towards
achieving the performance measure Y .
6.5.4 Prediction Algorithms*
Team: EMC1 (Members: Vikram Venkatraghavan, Esther Bron, Stefan Klein, Institution:
Erasmus MC, The Netherlands)
Feature selection: Automatic – Only the subjects who had converted to AD were used for
feature selection. Features with the largest changes over time after correcting for age, gender,
education and ICV were selected
Selected features: 250 features from the set of FDG, AV45, DTI, MRI (cross-sectional
Freesurfer volumes), Arterial Spin Labelling (ASL) MRI, CSF and cognitive tests.
*This part of the manuscript has been edited to provide only the details of Vikram Venkatraghavan’s
algorithm. For details of the other submitted methods, please read the pre-print of the manunscript
published on arxiv: https://arxiv.org/abs/2002.03419
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Missing data: Imputed using nearest-neighbour interpolation. For D2, visits with missing
diagnosis were excluded. For the D3 subjects with no known diagnosis, this was estimated
using a nearest-neighbour search based on disease severity
Confounder correction: Corrected for age, gender, education and ICV using linear regression
based on data from controls.
Method category: Data-driven disease progression model and machine learning
Prediction method: Authors hypothesize that aging and progression of AD are the primary
causes for the change in biomarker values with time and that these changes eventually lead
to a change in clinical status. To predict biomarker values at future timepoints, the rate of
AD progression is estimated in each subject. This is followed by estimating the interactions of
aging and AD progression in the progression of different biomarkers. Lastly, authors use the
biomarkers estimated at the future timepoint to predict the change in clinical status. These
steps are elaborated below:
Rate of Progression of AD: To assess the severity of AD, we estimated the sequence in which
the selected features became abnormal in AD using a Discriminative Event-Based Model [93]
and used it to estimate the disease severity at all the timepoints for each subject. A linear
mixed effect model was fit to estimate the rate of change of disease severity for different
subjects. This model was used for predicting the disease severity at all the future timepoints.
Interactions of aging and AD progression: For predicting the biomarker values at the future
timepoint, we fit linear mixed effect models for each biomarker considering interactions
between the estimated disease severity and age, with gender and ICV as additional covariates.
This model was used to forecast the future values of all 250 selected features, including ADAS-
Cog13 scores and Ventricle volumes.
Predicting the change in clinical status: For the diagnosis prediction, the forecasted values of
the biomarkers and the last known clinical diagnosis of the subject were used as inputs for a
soft-margin SVM classifier with a radial basis function kernel. Two separate submissions were
made:
• EMC1-Std (ID 1): ASL based features were excluded in this model
• EMC1-Custom (ID 2): ASL based features were included in this model
Confidence Intervals: Standard errors of the predicted values of Ventricles and ADAS-Cog-
13 were estimated by repeating the prediction procedure, including the estimation of disease








Creating the D1-D4 datasets
The data used from ADNI consists of: (1) CSF markers of amyloid-beta and tau deposition;
(2) various imaging modalities such as magnetic resonance imaging (MRI), positron emission
tomography (PET) using several tracers: Fluorodeoxyglucose (FDG, hypometabolism), AV45
(amyloid), AV1451 (tau) as well as diffusion tensor imaging (DTI); (3) cognitive assessments
acquired in the presence of a clinical expert; (4) genetic information such as alipoprotein
E4 (APOE4) status extracted from DNA samples; and (5) general demographic information.
Extracted features from this data were merged together into a final spreadsheet and made
available on the LONI ADNI website.
The imaging data has been pre-processed with standard ADNI pipelines. For MRI
scans, this included correction for gradient non-linearity, B1 non-uniformity correction
and peak sharpening. [ADNI MRI pre-processing]. Meaningful regional features
such as volume and cortical thickness were extracted using the Freesurfer cross-
sectional and longitudinal pipelines [268]. Each PET image (FDG, AV45, AV1451)
had their frames co-registered, averaged across the six five-minute frames, standardised
with respect to the orientation and voxel size, and smoothed to produce a uniform
resolution of 8mm full-width/half-max (FWHM) (see http://adni.loni.usc.edu/
methods/pet-analysis/pre-processing/). Standardised uptake value ratio (SUVR)
measures for relevant regions-of-interest were extracted after registering the PET images to
corresponding MR images using the SPM5 software [269]. Further details have been provided
in the ADNI procedures manual. DTI scans were corrected for head motion and eddy-current
distortion, skull-stripped, EPI-corrected, and finally aligned to the T1 scans using the pipeline
from [270]. Diffusion tensor summary measures were estimated based on the Eve white-
matter atlas [271].
In addition to the standard datasets, we also created three leaderboard datasets LB1, LB2 and
LB2 which mimick the D1, D2 and D4 datasets. These datasets were used by participants
to preliminarily evaluate their algorithms before the competition deadline, and to compare
their results on the leaderboard system (https://tadpole.grand-challenge.org/
Leaderboard/).
Statistical testing
Differences in MAUC scores
For analysing whether the MAUC scores obtained by top algorithms are significantly
different, we performed a bootstrapped hypothesis test [272], since the significance test for
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comparing two AUC scores [112] does not extend to multiple classes. For two TADPOLE
entriesA andB, whereA scored better thanB on the full D4 test set, we want to confirm either
the null hypothesis H0 : mauc(A) = mauc(B) or the alternative hypothesis H1 : mauc(A) >
mauc(B). We then proceed as follows:
• Sample N = 50 random bootstraps Di of the D4 test set with replacement.
• Compute themauc(A,Di) andmauc(B,Di) based on the bootstrapped dataset. Repeat
for all N bootstraps.
• Compute the p-value as
∑
i I[mauc(A,Di) < mauc(B,Di)]/N , which is the proportion
of bootstrapped datasets where A performed worse than B.
• Accept/reject H0 based on a 5% significance level.
Differences in MAE scores
For comparing differences in MAE scores, we applied the non-parametric Wilcoxon signed-
rank test on paired samples of absolute errors across all visits of the D4 subjects. We chose the
non-parametric Wilcoxon test because the input samples are not normally distributed, as they
represent absolute errors and are always positive. We report results based on a 5% significance
level.
Differences between D2 and D3 forecasts
For comparing differences between the scores obtained by two algorithms on D2 vs D3
forecasts, we use an approach similar to comparing MAUC scores (section 8.4.2).
Supplementary Results
Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
Billabong-UniAV45 1 1 0.719 0.624 1-2 8.71 8.55 0.33 3-4 3.49 3.40 0.50
Billabong-Uni 2 2 0.717 0.621 1-2 8.71 8.55 0.33 3-4 3.49 3.40 0.50
Billabong-MultiAV45 3 3 0.661 0.562 3-4 12.95 12.71 0.42 1-2 3.16 3.08 0.47
Billabong-Multi 4 4 0.658 0.552 3-4 12.95 12.71 0.42 1-2 3.16 3.08 0.47
Simple-SPMC-Plymouth2 - 5 0.500 0.504 - - - - - - - -
Simple-SPMC-Plymouth1 - 6 0.500 0.499 - - - - - - - -
Table 6.ST1: Results on custom prediction sets from two teams: Billabong and SPMC-Plymouth. SPMC-Plymouth
predicted fewer subjects due to an incomplete submission, while Billabong used a prediction set similar to D3, but
filled in missing data for cognitive tests and MRI with the last available measurement. SPMC-Plymouth only submitted
predictions for clinical diagnosis, and obtained an MAUC score of 0.5. Results from Billabong show higher MAUC and
BCA in diagnosis prediction compared to D3, but lower performance for ADAS-Cog13 and Ventricle volume prediction.



























































































Figure 6.SF1: Distribution of performance metrics for clinical diagnosis (MAUC and BCA), ADAS-Cog13
(MAE, WES and CPA) and ventricle volume (MAE, WES and CPA) on the longitudinal D2 prediction
set. For each entry, we plot the distribution of performance metrics derived using 50 bootstrap data sets
drawn from the D4 test set. The submissions (rows) are in the same order as in Table 6.2. Entries are



































































Figure 6.SF2: Box plots of performance metrics for clinical diagnosis (MAUC and BCA), ADAS-Cog13
(MAE, WES and CPA) and ventricle volume (MAE, WES and CPA) on the cross-sectional D3 prediction
set. The submissions (rows) are in the same order as in Table 6.3. Some entries are missing because teams
did not make predictions for those target variables.
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Figure 6.SF3: For D2 submissions, we show scatter plots of pairs of performance metrics for (top row)
clinical diagnosis, (middle row) ADAS-Cog13 and (bottom row) Ventricles. Each dot is a participant
submission, coloured according to the type of prediction algorithm used. Correlation coefficients and p-
values are given above each subplot. A few outlier submissions with ADAS MAE > 20, ADAS WES > 40
































































































Figure 6.SF4: For D3 submissions, we show scatter plots of pairs of performance metrics for (top row)
clinical diagnosis, (middle row) ADAS-Cog13 and (bottom row) Ventricles. Each dot is a participant
submission, coloured according to the type of prediction algorithm used. Correlation coefficients and p-
values are given above each subplot. A few outlier submissions with ADAS MAE > 20, ADAS WES > 40
or Ventricle WES > 3 were excluded from the analysis.
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bias towards CN MCI bias towards AD
Bias in MCI prediction
Figure 6.SF5: Bias in prediction of clinical diagnosis for MCI subjects only. X-axis shows individual
subjects with designated MCI status at the clinical visit in D4, while the Y-axis shows TADPOLE
algorithms. Red represents subjects which were predicted as CN with true diagnosis of MCI, while blue
represents subjects predicted as AD with true diagnosis of MCI. Some algorithms show systematic biases
either towards CN or AD.
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−6 −4 −2 0 2 4 6
ADAS-Cog 13: Difference between true and predicted scores
Figure 6.SF6: Bias in prediction of ADAS-Cog13. X-axis shows individual subjects with ADAS-Cog
measurements in D4, while Y-axis shows TADPOLE algorithms. Red represents under-estimates while
blue represents over-estimates. Most algorithms under-estimate ADAS-Cog measurements.
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Ventricles: Difference between true and predicted volumes, as %ICV
Figure 6.SF7: Bias in prediction of ventricle volume. X-axis shows individual subjects with Ventricle
volume measurements in D4, while Y-axis shows TADPOLE algorithms. Red represents under-estimates


































































Figure 6.SF8: Distribution of ranks in clinical diagnosis MAUC for TADPOLE submissions using the
longitudinal prediction set (D2), obtained from N = 50 bootstraps of the test set (D4). More precisely,
we computed the MAUC ranks given a specific bootstrap of the test set, and then for each TADPOLE


































































Figure 6.SF9: Distribution of ranks in ADAS-Cog13 MAE for TADPOLE submissions using the
longitudinal prediction set (D2)
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Figure 6.SF10: Distribution of ranks in Ventricle Volume MAE for TADPOLE submissions using the
longitudinal prediction set (D2).
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Figure 6.SF11: Distribution of ranks in clinical diagnosis MAUC for TADPOLE submissions using the
cross-sectional prediction set (D3).
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Figure 6.SF12: Distribution of ranks in ADAS-Cog13 MAE for TADPOLE submissions using the cross-
sectional prediction set (D3).
169
Chapter 6






































Figure 6.SF13: Distribution of ranks in Ventricle Volume MAE for TADPOLE submissions using the cross-
sectional prediction set (D3).
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Extensions of DEBM: high-dimensional biomarkers,




Event-based modeling with high-dimensional imaging
biomarkers for estimating spatial progression of
dementia
This chapter contains the content of the manuscript ‘Event-based modeling with high-
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Event-based models (EBM) are a class of disease progression models that can be used to estimate temporal
ordering of neuropathological changes from cross-sectional data. Current EBMs only handle scalar
biomarkers, such as regional volumes, as inputs. However, regional aggregates are a crude summary
of the underlying high-resolution images, potentially limiting the accuracy of EBM. Therefore, we
propose a novel method that exploits high-dimensional voxel-wise imaging biomarkers: n-dimensional
discriminative EBM (nDEBM). nDEBM is based on an insight that mixture modeling, which is a key
element of conventional EBMs, can be replaced by a more scalable semi-supervised support vector
machine (SVM) approach. This SVM is used to estimate the degree of abnormality of each region
which is then used to obtain subject-specific disease progression patterns. These patterns are in turn
used for estimating the mean ordering by fitting a generalized Mallows model. In order to validate
the biomarker ordering obtained using nDEBM, we also present a framework for Simulation of Imaging
Biomarkers’ Temporal Evolution (SImBioTE) that mimics neurodegeneration in brain regions. SImBioTE
trains variational auto-encoders (VAE) in different brain regions independently to simulate images at
varying stages of disease progression. We also validate nDEBM clinically using data from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI). In both experiments, nDEBM using high-dimensional features
gave better performance than state-of-the-art EBM methods using regional volume biomarkers. This
suggests that nDEBM is a promising approach for disease progression modeling.
7.1 Introduction
In 2015, approximately 46.8 million people were estimated to be living with dementia, and by
2050 this number is expected to have increased to 131.5 million [62]. Dementia is characterized
by a cascade of neuropathological changes which are quantified using several imaging and
non-imaging biomarkers. Understanding how the different biomarkers progress from normal
to abnormal state after disease onset enables precise estimation of disease severity in an
objective and quantitative way. This can help in identifying individuals at risk of developing
dementia as well as monitor the effectiveness of preventive and supportive therapies.
Event-based models (EBM) are a class of disease progression models that estimate the order
in which biomarkers become abnormal during disease progression using cross-sectional
data [53, 59, 61, 93]. It was reported in a recent paper on discriminative EBM (DEBM) [93]
that the EBMs are very sensitive to the quality of biomarkers used for building the model.
Hence, to infer the neuropathological changes that occur during dementia accurately, good
quality biomarkers are important.
An essential step in an EBM involves mixture modeling to obtain biomarker distributions
in normal and abnormal classes [53, 93]. This restricts the current EBMs to only handle
scalar biomarkers. In case of imaging biomarkers, regional volumes from structural MRIs
are often used [53, 61, 80, 86, 93]. However, regional volumes are a crude summary of the
high-dimensional information available from structural MRI, resulting in suboptimal EBM
performance, as shall be demonstrated later in this paper. Therefore, we propose a novel
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method that exploits voxel-wise imaging biomarkers: n-dimensional discriminative EBM
(nDEBM).
Estimating the accuracy of ordering obtained by EBMs is not feasible as ground-truth ordering
is not known for a disease. In order to validate the proposed method and compare its
accuracy with that of existing state-of-the-art EBM methods, we also present a framework
for Simulation of Imaging Biomarkers’ Temporal Evolution (SImBioTE). SImBioTE uses
variational auto-encoders (VAE) to simulate neurodegeneration in brain regions. These
regions are represented by a vector in the latent space of the VAE. Synthetic brain regions were
created by sampling latent representations corresponding to target degrees of abnormality
which were determined by a ground-truth ordering of disease progression. The generated
synthetic brain regions were used as inputs for nDEBM, and the regional aggregates were
used as inputs for state-of-the-art EBMs to evaluate the accuracies.
7.2 nDEBM
In Section 8.2.1, a brief introduction to the current DEBM [93] model is given. Section 7.2.2,
presents a novel framework to use semi-supervised SVMs in DEBM for estimating posterior
probabilities of abnormality for high-dimensional biomarkers. In Section 7.2.3, we use these
posterior probabilities to estimate severity of disease progression in an individual.
7.2.1 DEBM
In a cross-sectional dementia dataset (X) ofM subjects (consisting of cognitively normal (CN)
and patients with dementia (DE)), let Xj denote a measurement of biomarkers for subject
j ∈ [1,M ], consisting of N scalar biomarker values xj,i. As dementia is characterized by a
cascade of neuropathological changes that occurs over several years, even CN subjects can
show some abnormal biomarker values. On the other hand, in DE subjects, a proportion
of biomarkers may still have normal values, especialy in patients at an early disease stage.
This leads to label noise in the data and hence clinical labels cannot directly be propagated to
individual biomarkers. The DEBM model introduced in [93], similar to previously proposed
EBMs [53, 59, 61], fits a Gaussian mixture model (GMM) to construct the normal and abnormal
distributions. These are used to compute pre-event and post-event likelihoods p(xj,i|¬Ei)
and p(xj,i|Ei) respectively, where an event Ei is defined as the corresponding biomarker
becoming abnormal. The mixing parameters are used as prior probabilities to convert these
likelihoods to posterior probabilities p(¬Ei|xj,i) and p(Ei|xj,i).
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p(Ei|xj,i)∀i are used to estimate the subject-specific orderings sj . sj is established such that:
sj 3 p(Esj(1)|xj,sj(1)) > p(Esj(2)|xj,sj(2)) > ... > p(Esj(N)|xj,sj(N)) (7.1)
Finally, DEBM computes the central event ordering S from the subject-specific estimates sj .
To describe the distribution of sj , a generalized Mallows model is used. The central ordering
is defined as the ordering that minimizes the sum of distances to all subject-specific orderings
sj , with probabilistic Kendall’s Tau being the distance measure.
7.2.2 n-Dimensional Biomarker Progression
It was reported in [93] that the accuracy of EBMs depends on the quality of biomarkers used
to build the model. Greater separability of individual biomarkers results in estimation of
more accurate event ordering. We hypothesize that high-dimensional imaging biomarkers
can increase the separability between the normal and abnormal groups, thus improving the
accuracy when used as inputs to EBMs. The use of GMM in EBMs however restricts it to using
only scalar or low-dimensional biomarkers as GMMs do not scale well to high-dimensional
features. SVMs do scale well to high-dimensional features, but a supervised soft-margin SVM
cannot be used because of the large amounts of label noise (upto one third of the elderly CN
population could be in pre-symptomatic stages of DE [71]). In this section, we present a way
in which scalable semi-supervised SVM classifiers can be used within the DEBM framework
with high-dimensional inputs.
Let Xj,i denote the high-dimensional imaging biomarker for brain region i. Since the clinical
diagnosis of the subject cannot be propagated to each region, the labels cannot be trusted while
training a classifier. If we were to train a classifier trusting these labels, independently on each
biomarker (X∀j,i), we hypothesize that labels of the data close to the decision boundary or on
either side of it cannot be completely trusted for that biomarker. For identifying the labels that
cannot be trusted for a biomarker, we propose to train a linear classifier assuming equal class-
priors. Fitting a non-linear classifier risks over-fitting to the wrongly-labeled data whereas
class-priors derived from labeled data could be misleading as some of the labels might be
wrong, for that biomarker.
For biomarkerX∀j,i, subjects whose labels are preserved are considered as labeled data (XL,i).
Subjects whose labels have been rejected, along with any prodromal subjects in the dataset are
considered as unlabeled data (XU,i). Semi-supervised classifiers can be used in this context
for obtaining the decision boundary for each biomarker.
To identify the subjects for whom labels can be trusted when considering X∀j,i, we first train
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a linear SVM (f0;i) based on CN and DE subjects. After rejecting labels that cannot be trusted
(with distance d0;i < |dt| from the decision boundary), we use semi-supervised learning with
EM [273] using linear SVM with subject-specific costs [274] (f1;i, ..., fk+1;i) to iteratively refine
the decision boundary. The algorithm for this semi-supervised classification is given below:
Algorithm 2 Semi-Supervised SVM Learning with Subject-specific weights
1: for i ∈ {1...N} do
2: Train f0;i with X∀j∈{CN,DE},i as inputs
3: d0;∀j,i ← prediction of X∀j,i using f0;i
4: for j ∈ {1...M} do
5: if d0;j,i > |dt| then: XL,i ← Xj,i
6: else: XU,i ← Xj,i
7: Estimate p̂0(Ei|XU,i) from d0;U,i (using Platt scaling [275]).
8: Train f1;i using X∀j,i using |p̂0(Ei|XU,i) - p̂0(¬Ei|XU,i)| as weights of XU,i.
9: Estimate p̂1(Ei|XU,i) from d1;U,i
10: k ← 1
11: while ||p̂k(Ei|XU,i)− p̂k−1(Ei|XU,i)||2 < ε do
12: Train fk+1;i using X∀j,i 3 |p̂k(Ei|XU,i) - p̂k(¬Ei|XU,i)| are weights of XU,i.
13: Estimate p̂k+1(Ei|XU,i) from dk+1;U,i.
14: k ← k + 1
15: Estimate p̂k+1(Ei|X∀j,i) from dk+1;∀j,i
16: p(Ei|Xj,i)← p̂k+1(Ei|Xj,i)
dt was chosen such that such that 5% of correctly classified data closest to decision boundary
are treated as unlabeled. Weighing XU,i based on |p̂k(Ei|XU,i) - p̂k(¬Ei|XU,i)| is motivated
based on [276]. It is done because unlabeled data close to the decision boundary are not the
ideal support vectors. The samples which are farther away from the decision boundary of the
previous iteration can be trusted more as support vectors for the next iteration of training.
7.2.3 Patient Staging
Patient staging refers to the process of positioning individuals on a disease progression
timeline characterized by the obtained event ordering. Patient stage (Υj) is computed as
an expectation of event-centers (λn) with respect to p(n, S,Xj), where n denotes the possible
discrete stages in the timeline characterized by N biomarker events. Event-centers are the
positions of the biomarker events on a normalized disease progression timeline [0, 1], that
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p(k, S,Xj) can be expressed in-terms of posterior probabilities of events obtained from semi-
supervised SVM as:















7.3 SImBioTE: A Validation Framework
For validating classical EBMs and nDEBM in a unified framework, we extend the framework
developed in [79] for simulating datasets consisting of scalar biomarkers, to be capable
of generating datasets with realistic voxel-wise imaging biomarkers. It was built on the
assumption that the trajectory of biomarker progression follows a sigmoid. Using a similar




1 + exp(−ρi(Ψ− ξj,i))
+ ε (7.4)
Ψ denotes disease stage of a subject which we take to be a random variable distributed
uniformly throughout the disease timeline. ε is the equivalent of measurement noise, which
represents randomness in the measurement of abnormality. ρi signifies the rate of progression
of a biomarker, which we take to be equal for all subjects for all biomarkers. It was shown
in [93] that the performance of EBMs is similar for equal ρi∀i and unequal ρi. ξj,i denotes the
disease stage at which the biomarker becomes abnormal.
After randomly choosing degrees of abnormalities for different regions, we use a variational
autoencoder (VAE) [277] for each region i, to generate 3D images of these brain regions at
a target degree of abnormality aj,i(Ψ). VAEs are neural networks consisting of two main
components: an encoder E which projects input images into a lower dimensional space
RK called the latent space, and a decoder D which generates images from their hidden
representation in the latent space Z ∈ RK . Once the VAE has been trained using a
large dementia dataset, a latent representation Zj,i;t corresponding to the target degree of
abnormality aj,i(Ψ) can be sampled in the latent space. The decoder D then generates a 3D
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image D(Zj,i;t) corresponding to aj,i(Ψ). Below we describe the VAE used in this work, and
the sampling strategy in the latent space.
7.3.1 Implementation of the Convolutional Variational Autoencoder
Figure 7.1 summarizes the architecture of our VAE. We use a ReLU activation after each
convolutional layer, except after the last 1*1*1 convolutional layer. We implemented the
loss function as proposed by Kingma and Welling [277], with mean-square-error (MSE) and
Kullback-Leibler divergence. We optimized the network with Adadelta [278].
Figure 7.1: Architecture of the Variational Autoencoder.
7.3.2 Sampling Strategy in the Latent Space
To navigate in the latent space RKi of region i, we use Euclidean geometry. We first build a
scale vector Ui in the latent space to describe the range of the disease from CN to DE. In order
to generate a point Zj,i;t ∈ RKi at the target degree of abnormality aj,i(Ψ), we first randomly
sample a point Zj,i;s ∈ RKi , and translate it along the direction of the scale vector Ui until we
reach the target abnormality aj,i(Ψ).
Scale Vector from Cognitively Normal to Dementia.
To build the scale vector Ui, we first compute the latent representations of all the images of
region i in the training dataset by projecting these images in the latent space RKi using the
encoder E. Then we use the binary labels – CN and DE – of each subject j to compute the
means µi;CN ∈ RKi and µi;DE ∈ RKi , and standard deviations σi;CN ∈ RKi and σi;DE ∈ RKi
for each of the two categories respectively.
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This is followed by computing the vector joining the two mean points as ui = µi;DE − µi;CN .
The idea is to create a vector Ui spanning the range of the disease progression, from CN to
DE. However, ui joins only the means, if we want to capture the whole distribution, we need
to lengthen this vector by a multiple of the standard deviations, on both sides: for instance
by 3σi;CN in the CN side, and 3σi;DE on the DE side. To do so, we compute the scalar
projections of the standard deviations as σi;CNp = |σi;CN .ûi| and σi;DEp = |σi;DE .ûi|, where
ûi = ui/||ui||2. Now we can compute the new origin point (CN) as O = µi;CN − 3σi;CNpûi,
and the new end point (DE) asM = µi;DE + 3σi;DEpûi. Finally, we can compute Ui = M −O.
Note that Ûi = Ui/||Ui||2 = ûi.
Navigation for generation
We first randomly sample a point Zj,i;s using the mean and standard deviation of the latent
representations of all subjects j for region i. The degree of abnormality aj,i;s of this randomly
sampled point Zj,i;s can be computed as aj,i;s = OZj,i;s.Ûi/||Ui||2. To reach the target point
Zj,i;t, we need to translate the randomly sampled point Zj,i;s. This now can be done by
computing Zj,i;t = Zj,i;s + (aj,i;t − aj,i;s)Ui. To generate the corresponding brain region we
can now use the decoder and compute D(Zj,i;t).
7.4 Experiments and Results
This section describes the experiments performed to validate the proposed nDEBM algorithm
and also compare it with classical EBM [53] and DEBM [93] algorithms.
7.4.1 ADNI Data
We considered 1737 ADNI subjects (417 CN, 106 with significant memory concern (SMC), 872
with mild cognitive impairment (MCI) and 342 AD subjects) who had a 1.5T structural MRI
(T1w) scan at baseline. This was followed by multi-atlas brain extraction using the method
described in [9]. Gray matter (GM) volumes of segmented regions were regressed on age, sex
and intra-cranial volume (ICV) and the effects of these factors were subsequently corrected for.
Student’s t-test between CN and AD was performed on these confounding factor corrected
GM volumes and 15 regions with smallest p-values were retained. They were subsequently
used as inputs for DEBM and EBM [53] models. The optimization routine proposed in [93]
was used to train the GMM in these two models.
The T1w images were registered to a common template space based on the method used
in [9]. Probabilistic tissue segmentations were obtained for white matter (WM), GM, and
cerebrospinal fluid on the T1w image using the unified tissue segmentation method [77]. The
voxel-wise GM density maps were computed based on the Jacobian of the local deformation
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map and the probabilistic GM volume. The GM density maps from the corresponding 15
regions were used as inputs for nDEBM.
Model Validation
Since the groundtruth ordering is not known in a clinical setting, validation of these models
was done based on the resulting patient stages for classifying AD subjects from CN as well as
for classifying MCI non-converters (MCI-nc) from converters (MCI-c)*. We performed 10-fold
cross-validation with 10 repetitions. The training set was used to train the three models. The
disease timeline created during training was used to stage the patients in the test-set.
Figure 7.2: AUC measures when patient stages of nDEBM, DEBM and EBM were used for classifying AD
vs CN (left) and MCI-c vs MCI-nc (right). The error bar represents the standard deviation in 10 random
repetitions.
Figure 7.2 shows the results of 10 random repetitions of 10-fold cross-validation on ADNI
dataset. The error-bar shows the standard deviation of the AUCs when the patient stages
obtained from nDEBM, DEBM and EBM were used to classify AD vs CN and MCI-c vs MCI-
nc.
Uncertainty in Estimation
Variation of the positions of the biomarker events on a normalized disease progression
timeline (event-centers) estimated by nDEBM and DEBM was studied by creating 50
bootstrapped samples of the data and applying nDEBM on those samples †.
Figure 7.3 shows event-centers estimated by nDEBM and DEBM along with the uncertainty
in their estimations. The biomarkers are ordered along the y-axis based on the event-ordering
obtained by nDEBM. 3D visualization of the estimated central ordering is shown in Figure 7.4.
*MCI converters are subjects who convert to AD within 3 years of baseline measurement
†EBM was left out of this experiment as the concept of event-centers was not introduced for EBM.
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Figure 7.3: Variation of event-centers estimated by nDEBM and DEBM in 50 bootstrapped samples of the
ADNI data. The error bar represents the standard deviation of the respective event-centers.
Figure 7.4: 3D visualization of the central ordering estimated by nDEBM. The position of a region in the
estimated ordering is encoded using a distinct color. The color-map used for this purpose is on the right-
side of the figure, where the early biomarkers are at the top of the color-map and late biomarkers are at
the bottom.
7.4.2 Simulation Data
In our experiments, ξj,i ∀j are random variables with Normal distribution N(µξi ,Σξi). µξi
were equally spaced for different i. The value of Σξi was set to be ∆ξ where ∆ξ is the
difference in µξi of adjacent events. ρi was considered to be equal for all biomarkers. Ψ of
the simulated subjects were distributed uniformly throughout the disease timeline.
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We first trained 15 VAEs (one per selected region) on the GM density maps of the ADNI
dataset. Then we generated - as detailed in Section 7.3 - images for these 15 regions and
for 1737 artificial subjects according to pre-computed degrees of abnormality as defined in
Equation 7.4. These degrees of abnormality are different for each region and each subject. We
repeated this process 10 times, with different random simulations. The voxel-wise GM density
maps of regions were used for obtaining the ordering using nDEBM. The GM volume of the
simulated regions (computed by integrating the GM density map over the region of interest)
were used as biomarkers for DEBM and EBM.
SimBioTE results depicting Lateral occipitotemporal gyrus atrophy in simulated images is
shown in Figure 7.5. The images thus generated were used for validating different EBM
methods.
Figure 7.5: An example of Lateral occipitotemporal gyrus (right) atrophy as simulated by SImBioTE. The
interpolation spans the full rangeUi, as described in section 7.3. Left is normal (CN) and right is abnormal
(DE). The two rows shows disease progression in two different simulated subjects.
Figure 7.6: Inaccuracies, as measured by Kendall’s Tau distance from groundtruth, of nDEBM, DEBM and
EBM. The error bar represents the standard deviation of the errors made in 10 repetitions of simulations.
The errors made by different EBM methods on SImBioTE data are shown in Figure 7.6.





We proposed a novel method (nDEBM) that exploits high-dimensional voxel-wise imaging
biomarkers for event-based modeling using semi-supervised SVM. This was validated based
on ADNI dataset, where the spatial spread of structural abnormality was estimated based on
a cross-sectional dataset. However this is an indirect validation of the orderings based on
accuracy of the estimated patient stages, since the ground-truth ordering for clinical data is
unknown.
To unambiguously validate the orderings obtained, we also proposed a new simulation
framework (SImBioTE) to simulate voxel-wise imaging biomarkers based on training VAEs
on different regions. It is known that GM tissue is lost in AD progression. Therefore
the voxel-wise GM density maps will become darker as the disease progresses, as can be
observed in Figure 7.5. It was also observed in Figure 7.5 that simulated regions for different
subjects shows considerable variations. This shows that the simulation framework is capable
of generating datasets with realistic atrophy and with good inter-subject variability. This,
in combination with the scalar biomarkers’ simulation framework, results in images where
the disease progression in different regions can be controlled. However, a more thorough
validation of the simulation framework by comparing the atrophy patterns of the simulated
data with that of real-life longitudinal data is needed to understand the effect of different
model parameters. Possible extensions of SImBioTE includes simulating whole brain images
from these independent regions, which can be used to validate wider range of disease
progression models.
The datasets simulated by SImBioTE were used for inputs for different EBMs. It was observed
in Figure 7.6 that the orderings obtained by nDEBM are much closer to the ground-truth
as compared to DEBM and EBM. It was also observed in Figure 7.2 that the patient stages
obtained by nDEBM delineates AD and CN subjects much better than the ones obtained by
DEBM and EBM. The AUCs of classifying MCI-c vs MCI-nc are also marginally better for
nDEBM as compared to the other two methods. These experiments serve as a validation
for our initial hypothesis that increasing the dimensionality of the inputs helps in better
delineation of normal and abnormal regions, which increases the accuracy of the resulting
ordering. It can hence be concluded that the voxel-wise data helps nDEBM in estimating the
disease progression more accurately than regional volumes. However, the choice of hyper-
parameters in nDEBM (for e.g. dt, SVM slack parameters) was done ad-hoc. The effect they
have on the accuracy of the resulting ordering needs to be studied through more rigorous
validation experiments.
The difference in event orderings obtained by nDEBM and DEBM as observed in Figure 7.3
suggests that the two types of inputs can lead to very different results. Hence, computing
regional aggregates, such as volumes, and using that as inputs for EBMs as done in [53, 61, 80,
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86, 93] is not an optimal choice for estimating the spatial progression of disease.
7.6 Conclusion
We hypothesized that high-dimensional imaging biomarkers would result in better
delineation of normal and abnormal regions thus leading to more accurate event-based
models. We hence proposed a novel method (nDEBM) that exploits high-dimensional voxel-
wise imaging biomarkers based on semi-supervised SVM to estimate temporal ordering
of neuropathological changes in the brain structure using cross-sectional data. We also
proposed a simulation framework (SImBioTE) using variational auto-encoders that mimics
neurodegeneration in brain regions to validate nDEBM. Furthermore, we applied nDEBM
framework to a set of 1737 subjects from ADNI dataset for clinically validating the method.
In both experiments, nDEBM using high-dimensional features gave better performance than
state-of-the-art EBM methods using regional volume biomarkers. This served as a validation
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Alzheimer’s disease (AD) is the most common form of dementia and is phenotypically heterogeneous.
APOE is a triallelic gene which correlates with phenotypic heterogeneity in AD. In this work, we
determined the effect of APOE alleles on the disease progression timeline of AD using a discriminative
event-based model (DEBM). Since DEBM is a data-driven model, stratification into smaller disease
subgroups would lead to more inaccurate models as compared to fitting the model on the entire dataset.
Hence our secondary aim is to propose and evaluate novel approaches in which we split the different
steps of DEBM into group-aspecific and group-specific parts, where the entire dataset is used to train
the group-aspecific parts and only the data from a specific group is used to train the group-specific
parts of the DEBM. We performed simulation experiments to benchmark the accuracy of the proposed
approaches and to select the optimal approach. Subsequently, the chosen approach was applied to the
baseline data of 417 cognitively normal, 235 mild cognitively impaired who convert to AD within 3
years, and 342 AD patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset to
gain new insights into the effect of APOE carriership on the disease progression timeline of AD. In the
ε4 carrier group, the model predicted with high confidence that CSF Amyloidβ42 and the cognitive score
of Alzheimer’s Disease Assessment Scale (ADAS) are early biomarkers. Hippocampus was the earliest
volumetric biomarker to become abnormal, closely followed by the CSF Phosphorylated Tau181 (PTAU)
biomarker. In the homozygous ε3 carrier group, the model predicted a similar ordering among CSF
biomarkers. However, the volume of the fusiform gyrus was identified as one of the earliest volumetric
biomarker. While the findings in the ε4 carrier and the homozygous ε3 carrier groups fit the current
understanding of progression of AD, the finding in the ε2 carrier group did not. The model predicted,
with relatively low confidence, CSF Neurogranin as one of the earliest biomarkers along with cognitive
score of Mini-Mental State Examination (MMSE). Amyloid β42 was found to become abnormal after
PTAU. The presented models could aid understanding of the disease, and in selecting homogeneous
group of presymptomatic subjects at-risk of developing symptoms for clinical trials.
8.1 Introduction
Dementia affects roughly 5% of the world’s elderly population of whom 60 − 70% are affected by
Alzheimer’s Disease (AD), which is the most common form of dementia [279]. There are several
neurobiological subtypes of AD [38] and each subtype potentially needs a different strategy to prevent
or slow the progression of AD. Understanding the pathophysiological processes in AD is thus crucial
for selecting novel preventive or therapeutic targets for clinical trials of disease modifying treatments,
identifying target groups for such trials and tracking the disease progression in patients.
While several studies have looked into the pathophysiology of AD [82, 117, 280], it is still not completely
understood. Although it has been observed that AD is phenotypically heterogeneous [281, 282, 283] with
potentially different pathways for disease progression, these pathways remain unclear. There is hence
a need to understand the phenotypic heterogeneity in AD while leveraging neuroimaging, fluid and
cognitive biomarkers.
APOE is a triallelic gene in which the ε2 allele reduces the risk of AD [284], the ε3 allele acts as a reference
allele and the ε4 allele is a major genetic risk factor of AD [285, 286, 287]. APOE has been shown to
correlate with phenotypic heterogeneity in AD [288]. Hence we hypothesize that the pathophysiology of
AD can be better understood when considering the effect of APOE carriership on biomarker changes.
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In the context of data-driven methods for understanding AD pathophysiology, disease progression
models have been used to study the trajectories of individual biomarkers [51, 67, 68] as well as their
progression with respect to each other [53, 59, 61, 70]. Unlike typical machine learning approaches,
these models are interpretable by design and provide insight for understanding the mechanisms of
disease progression. Event-based models (EBMs) are a class of such interpretable disease progression
models that estimate the timeline of neuropathologic change during AD progression using cross-sectional
data [53, 93].
Our primary aim is to use the discriminative event-based model (DEBM), which was shown to be more
accurate than previously proposed EBMs [93], to understand the effect of different APOE alleles on the
disease timeline of AD. To shed light on different aspects of neurodegeneration and identify the earliest
brain regions affected, we included commonly studied cerebrospinal fluid (CSF) biomarkers, cognitive
scores, and volumetric biomarkers from neuroimaging.
The default approach for estimating the disease progression timeline would be to stratify the population
based on their APOE ε2 − 4 carrier status and independently train the DEBM model on the stratified
populations [61]. However, since DEBM is a data-driven model, stratification into smaller groups would
lead to less accurate models than those obtained by the original method on the entire dataset. Hence
our secondary aim is to propose and evaluate a novel approach in which we split the different steps of
DEBM into group-aspecific and group-specific parts, where the entire dataset is used to train the group-
aspecific parts and only the data from a specific group is used to train the group-specific parts of the
DEBM. We present two different variations of this approach and we hypothesize that the optimal split
of the DEBM steps into the group-aspecific and group-specific parts would result in better accuracy of
the estimated disease progression timeline. Since the ground-truth timelines are unknown in a clinical
setting, we evaluate the accuracy of the proposed variations using simulation experiments and we select
the optimal method for the analysis on the effect of APOE on the AD progression timeline on patient data.
To summarize, our contributions in this paper include proposing and evaluating a novel approach for
using DEBM in stratified populations and estimating a comprehensive timeline of AD progression, in
terms of biomarker changes, in the presence of different APOE alleles.
8.2 Methods
An introduction to the DEBM model [93] is provided in Section 8.2.1. In Section 8.2.2 we propose our
novel approach for using DEBM in stratified populations with its two variations.
8.2.1 Discriminative event-based modeling
In a cross-sectional dataset (X) of M subjects, including cognitively normal individuals (CN), subjects
with mild cognitive impairment (MCI) and patients with AD, letXj denote a measurement of biomarkers
for subject j ∈ [1,M ], consisting of scalar biomarker values xj,i for i ∈ [1, N ]. x·,i denotes the i-th
biomarker for any unspecified j. DEBM estimates the posterior probabilities of individual biomarkers
being abnormal. These posterior probabilities are used to estimate the ordering of biomarker changes for
each subject independently. The central ordering and disease progression timeline for the entire dataset
are estimated based on these subject-specific orderings. The resulting disease progression timeline is used
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Figure 8.1: Overview of the steps involved in DEBM. Input for the DEBM model is a cross-sectional
datasetX withM subjects and various biomarkers (A,B,C andD) representing different aspects of neuro-
degeneration. Using Gaussian mixture modeling (GMM), mixing parameters (θi) and probability density
functions of normal (p(x·,i|¬Ei)) and abnormal (p(x·,i|Ei)) levels are estimated for each biomarker. This
is followed by the estimation of subject-specific orderings (sj), for each subject in the dataset. Disease
progression timeline consisting of central ordering (S) and event-centers (λ) are estimated based on these
subject-specific orderings. Based on the constructed disease progression timeline, patient stages (Υj) of
subjects in an independent test-set can be estimated.
for assessing the severity of disease in an individual based on his/her biomarker values. Figure 8.1 shows
the different steps involved in DEBM.
Step 1 - Mixture Modeling: As AD is characterized by a cascade of neuropathological changes that occurs
over several years, presymptomatic CN subjects can have some abnormal biomarker values. On the
other hand, in some clinically diagnosed AD subjects, a proportion of biomarkers may still have normal
values, as they might not have an underlying AD pathology or could have atypical AD. Hence clinical
labels cannot directly be propagated to individual biomarkers to label normal and abnormal biomarker
values. We shall refer to this as biomarker label noise in the rest of the paper. In order to estimate the
posterior probabilities of individual biomarkers being abnormal, DEBM, similar to previously proposed
EBMs [53, 59, 61], fits a Gaussian mixture model (GMM) to construct the normal / pre-event probability
density function (PDF), p(x·,i|¬Ei), and abnormal / post-event PDF, p(x·,i|Ei). EventEi in this notation
is used to denote the corresponding biomarker becoming abnormal and ¬Ei denotes the corresponnding
biomarer being normal. The aforementioned PDFs can be expressed as:
p(x·,i|¬Ei) = N (µi,¬E ;σi,¬E) (8.1)
p(x·,i|Ei) = N (µi,E ;σi,E) (8.2)
Where,N (µ, σ) is the normal distribution with mean µ and standard deviation σ.
For estimating these parameters robustly in the presence of biomarker label noise, the normal and
abnormal PDF estimates are first initialized using the mean and standard deviations after truncating
the overlapping tails of the observed distributions in CN and AD subjects. This can be observed in
Figure 8.2, where the initialization is performed only based on the non-overlapping parts of green and red
curves, while the overlapping part is left out to account for biomarker label noise. At this stage of GMM
initialization, MCI subjects are left out as well, because it is unsure a priori whether their biomarkers are
normal or abnormal. The resulting initialized PDFs are denoted as p̂(x·,i|¬Ei)) and p̂(x·,i|Ei).
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This is followed by an alternating GMM maximum likelihood optimization scheme until both the
Gaussian parameters as well as the mixing parameters converge. All the subjects, including MCI, are used
for GMM optimization. After convergence, these Gaussians are used to represent the PDFs p(x·,i|¬Ei)
and p(x·,i|Ei). The mixing parameters (θi) are used as prior probabilities to convert these PDFs to
posterior probabilities p(¬Ei|x·,i) and p(Ei|x·,i). Figure 8.2 shows an overview of this optimization
scheme.
Figure 8.2: Overview of GMM optimization in DEBM.
Step 2 - Subject-specific Orderings: p(Ei|xj,i)∀i are used to estimate the subject-specific orderings sj .
sj is established such that:
sj 3 p(Esj(1)|xj,sj(1)) > ... > p(Esj(N)|xj,sj(N)) (8.3)
Step 3 - Central Ordering: DEBM computes the central event ordering S from the subject-specific
estimates sj . To describe the distribution of sj , a generalized Mallows model is used [72]. The central
ordering is defined as the ordering that minimizes the sum of distances to all subject-specific orderings
sj , with probabilistic Kendall’s Tau being the distance measure [93]. While S denotes the sequence of
biomarker events, the relative position of these events (event-centers) in a normalized scale of [0, 1] is
denoted by the vector λ. The pair {S, λ} together forms a disease progression timeline.
Step 4 - Patient Staging: Once the disease progression timeline is created, subjects in an independent
test set (T ) can be placed on this timeline to estimate disease severity. This is achieved by converting
the biomarker values of the test subjects to posterior probabilities p(Ei|xj,i), ∀j ∈ T . These can be used
to estimate disease severities in test subjects by first estimating the conditional distribution p(i|S,Xj),


























8.2.2 Group-specific and group-aspecific parts of DEBM
We propose extensions of DEBM for stratified populations, i.e., when the dataset X can be subdivided in
groups g ∈ [1, G], based on, e.g., genotype or phenotype of the subjects. Since DEBM is a data-driven
model, data stratification into smaller groups would lead to more inaccurate models [93]. To obtain better
DEBM accuracies in such scenario, we propose to co-train DEBM for estimating disease timelines ∀g by
splitting DEBM into group-aspecific and group-specific parts. The group-aspecific parts of DEBM are
estimated using the entire dataset and group-specific parts are estimated for each group independently.
We first discuss the default way of independently training DEBM in the different groups and then propose
two different approaches for splitting DEBM into group-aspecific and group-specific parts.
Approach 1: Independent DEBM
In this default approach, each group is considered as an independent dataset and the disease progression
timeline in each group is estimated independently. GMM in such a scenario is illustrated in Figure 8.3a.
Approach 2: Coupled DEBM
DEBM→
p(x·,i|¬Ei), p(x·,i|Ei) group-aspecificθi,g , {Sg , λg}, group-specific (8.6)
In this approach, we assume that the different groups share the normal and abnormal PDFs, but the
ordering in which these biomarkers become abnormal are different. The mixing parameters (θi,g) are
considered as group-specific part of the DEBM algorithm because the proportion of subjects with normal
and abnormal biomarker values in each group g is correlated with the position of the biomarker along the
ordering Sg , which we expect to be different in each group.
Hence, in our approach, we modify the alternating GMM optimization scheme to jointly optimize the
GMM parameters of multiple groups. First, the GMM algorithm is initialized without considering the
groups, as explained in Section 8.2.1. Secondly, as with the default DEBM, Gaussian parameters and
mixing parameters are alternately optimized. In contrast in coupled DEBM, the Gaussian parameters are
estimated jointly for all groups, while mixing parameters are estimated separately for each group. This
has been illustrated in Figure 8.3b.
Once the GMM optimization has been performed, Sg and λg are estimated in each group. Patient staging
(Υj) of the test-subjects in group g are computed based on the disease progression timeline {Sg , λg}.









In this approach, we assume that the different groups do not share the normal and abnormal PDFs, but
that they are close to each other. Hence, in co-init DEBM, we relax the constraint on p(x·,i|¬Ei) and
p(x·,i|Ei) and instead consider the initialized values of normal and abnormal PDFs (p̂(x·,i|¬Ei) and
p̂(x·,i|Ei)) to be group-aspecific part of DEBM. We estimate pg(x·,i|¬Ei) and pg(x·,i|Ei) independently
for each group. This is illustrated in Figure 8.3c.
As with the previous approach, Sg , λg and the patient staging of the test-subjects in group g are computed
independently for each group.
(a) GMM in independent DEBM
(b) GMM in Coupled DEBM
(c) GMM in Co-init DEBM
Figure 8.3: Overview of GMM optimization strategies in the different approaches for DEBM analysis in
stratified populations. (a) The default approach in which GMM in each group is trained independently.
(b) GMM in coupled DEBM, where the different groups share the Gaussian parameters, but the mixing
parameters are estimated independently. (c) GMM in co-init DEBM in which the different groups are





Section 8.3.1 describes the experiments to evaluate the proposed DEBM approaches on a stratified
population. Since ground-truth orderings are unknown in real clinical data, we use simulated datasets
for evaluating the methods. After evaluating the proposed approaches, we select the best approach
for analyzing the effect of APOE on AD progression using subjects from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database. Section 8.3.2 descibes the details of these experiments.
8.3.1 Simulation Experiments
We used the framework developed by [79] for simulating cross-sectional data consisting of scalar
biomarker values for CN, MCI and AD subjects in two groups. In this framework, disease progression in
a subject is modeled by a series of biomarker changes representing the temporal cascade of biomarker
abnormality as estimated by an EBM. Individual biomarker trajectories are represented by sigmoids
varying from the biomarker’s normal value to its abnormal value. To account for inter-subject variability,
the normal and abnormal values for different subjects are drawn randomly from Gaussian distributions.
The simulation dataset used in our experiments are based on a set of seven biomarkers as described in
the simulation experiments of [93]. The simulated datasets were stratified into two groups, with each
group having its own distinct disease progression patterns. There are two ways in which the progression
of disease in the groups can differ: 1. difference in ground-truth orderings S1 and S2; 2. difference in the
abnormal biomarker PDFs in the two groups i.e. p1(x·,i|Ei) and p2(x·,i|Ei). Each of these differences
could affect the accuracy of the proposed approaches. Hence, we evaluated the proposed approaches
in the presence of each of these differences. Normalized Kendall’s Tau distance between the estimated







where K(A,B) is the number of swaps required to obtain ordering B from ordering A.
The normalization ensures that εS falls in the range [0, 1], with 0 as the distance when the two orderings
are the same, and 1 as the distance when the two orderings are the reverse of each other.
Experiment 1: The first simulation experiment studied the effect of the difference in ordering between
the two groups. The ordering in the first group (Group 1) was fixed and the ordering in the second
group (Group 2) was selected randomly such that the normalized Kendall’s Tau distance between the
two groups was a fixed number, say εO . εO was varied from 0 to 1 in steps of 0.2. The number of subjects
in Group 2 was kept constant at 900. The number of subjects in Group 1 was varied from 100 to 900 in
steps of 200, to study how the different approaches perform in small as well as large groups. The normal
and abnormal biomarkers levels in the two groups were sampled from the same Gaussian distribution for
this experiment. We generated 50 random repetitions of the simulated datasets, and reported mean and
standard deviation of εS for independent DEBM, coupled DEBM, and co-init DEBM in groups 1 and 2.
Experiment 2: This experiment studied the performance of the proposed approaches with the µg,i,E
parameter of the pg(x·,i|Ei) distribution being different in the two groups. µ1,i,E was fixed, and
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µ2,i,E was varied such that the difference µ2,i,E − µ1,i,E (εG) was one of {−0.2d, 0,+0.2d} where
d = µ1,i,E − µ1,i,¬E . 0 is considered the reference level, where the abnormal Gaussians are the same in
the two groups. µg,i,¬E were kept the same in the two groups. Hence, when εG = −0.2d, the abnormal
biomarker levels are closer to the normal biomarker levels in Group 2 than in Group 1. This results in
Group 2 biomarkers being weaker than their Group 1 counterparts when εG = −0.2d and stronger when
εG = +0.2d. The number of subjects in Group 2 was kept a constant at 900, while the subjects in Group
1 increased from 100 to 900. εO between the two groups was fixed at 0.4. We again generated 50 random
repetitions of the simulated datasets, and reported mean and standard deviation of εS for coupled DEBM,
co-init DEBM and DEBM.
These experiments were used to evaluate the different approaches mentioned in Section 9.2 and select the
best method for analyzing the effect of APOE alleles in AD progression.
8.3.2 Studying the effect of APOE
We considered the baseline measurements from 417 CN, 235 MCI converters and 342 AD subjects in
ADNI1, ADNIGO and ADNI2 studies*. The MCI converters are subjects who had MCI at baseline but
converted to AD within 3 years of baseline measurement. We excluded subjects with significant memory
concerns (without a diagnosis of AD or MCI) and MCI non-converters in our experiments to select a more
phenotypically homogeneous group of subjects with prevalent or incident AD. In each of the experiments,
the dataset was divided into three groups (ε2 carriers, homozygous ε3 carriers, and ε4 carriers) based on
the subject’s APOE carriership [284]. Subjects with APOE ε2, 4 (n=34) were not included in either group
because of the presence of both ε2 and ε4 alleles.
Subject demographics and their APOE carrierships are summarized in Table 8.1. The modalities
considered were structural imaging biomarkers, biomarkers extracted from cerebrospinal fluid (CSF), and
cognitive biomarkers. Structural imaging biomarkers were obtained from T1-weighted MRI acquired at
1.5T or 3T. Details of the MRI acquisition protocols of ADNI can be found in [289, 290].
Imaging biomarkers were estimated from T1-weighted MRI scans analysed with FreeSurfer software v6.0
cross-sectional stream and outputs were visually checked. We assumed a symmetric pattern of atrophy
in AD and averaged imaging biomarkers between the left and right hemisphere.
Experiment 3: For this experiment, the selected imaging biomarkers were: hippocampal volume, volume
of the entorhinal cortex, fusiform gyrus volume, middle-temporal gyrus volume, precuneus volume,
together with whole brain volume and volume of the ventricles [105, 106, 291]. The selected CSF based
biomarkers were: CSF concentrations of Amyloid-β42 (ABETA), total Tau (TAU) and phosphorylated
Tau181 (PTAU) proteins [23, 103], Neurogranin [292] and Neurofilament light chain [293, 294]. Mini
mental state examination (MMSE) and Alzheimer’s Disease Assessment Scale - Cognitive (13 items)
(ADAS13) were used as cognitive biomarkers. The availability of these multimodal biomarkers in the
*The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure the progression of mild cognitive





Diagnosis CN MCIc AD




Sex M/F 209/208 145/90 189/153
Age [yrs.]
(µ± σ)
74.8± 5.7 73.7± 7.0 75.0± 7.8
Edu [yrs.]
(µ± σ)
16.3± 2.7 15.9± 2.7 15.2± 3.0
Table 8.1: Demographics for the used population. 2? represents the subjects with APOE alleles ε2, 2 and ε2, 3. 33
represents the subjects with reference APOE allele ε3, 3. ?4 represents the subjects with APOE alleles ε3, 4 and ε4, 4.
Subjects with both ε2 and ε4 alleles were excluded from this study (n=34). Edu. is an abbreviation used for Education.
ADNI database is summarized in Table 2.
We downloaded the CSF measurements from the ADNI database. The measurements of ABETA, TAU
and PTAU had been made using the microbead-based multiplex immunoassay, the INNO-BIA AlzBio3
RUO [295]. The measurement of NFL had been made with enzyme-linked immunosorbent assay NF-
light ELISA kit [296]. NG had been measured by electrochemiluminescence technology (Meso Scale
Discovery) using a monoclonal antibody specific for NG (Ng7) for coating together with a detector
antibody polyclonal neurogranin anti-rabbit (ab 23570, Upstate) [297]. As described previously in [93],
the TAU and PTAU measurements were transformed to logarithmic scales to make the distributions less
skewed and more suitable for DEBM analysis.
The volumes of the selected regions were regressed with age, sex and intra-cranial volume (ICV) and the
effects of these factors were subsequently corrected for, before being used as biomarkers. The effects of
age and sex were regressed out of CSF features, whereas effects of age, sex and education were regressed
out of cognitive scores.
For the 12 selected biomarkers, we estimated the disease timelines in the three aforementioned groups
using the method selected after simulation experiments. We studied the positional variance of the
estimated orderings by creating 100 bootstrapped samples of the data. In order to evaluate if the estimated
orderings in the three groups were significantly different from one another, we used permutation testing
and estimated the distribution of the Kendall’s Tau distance under the null hypothesis. To compute this
distribution, we generated 10, 000 random permutations of the three groups. We then computed the one-
sided p-values for the actual Kendall’s Tau distances between the orderings of the three groups, calculated
as the proportion of sampled permutations where the distance was greater than or equal to the actual
distance, and using Bonferroni correction to account for multiple testing.
Experiment 4: In this experiment, we validated the disease stage (Υj) by computing its correlation with
the subjects’ MMSE and ADAS13 values. We used a 10-fold cross validation, where the training set was
used to estimate the disease timeline in the aforementioned groups and the test subjects’ disease stage was











Imaging 74 408 481
ABETA 57 301 357
PTAU 57 301 357
TAU 57 299 348
NG 21 113 131
NFL 23 118 137
MMSE 75 411 485
ADAS 74 410 477
Table 8.2: Biomarker availability in number of subjects in the APOE based groups of ε2 carriers, homozygous ε3 carriers,
and ε4 carriers
from Experiment 3, but excluded MMSE and ADAS13 scores from the model.
8.4 Results
8.4.1 Simulations
Experiment 1: Figures 8.4 (a) and (b) show the ordering errors (εS) in Group 1 of the simulation datasets
for DEBM, coupled DEBM and co-init DEBM as a function of number of subjects in Group 1, when εO
between the two groups changes from 0 to 1. Figures 8.4 (c), (d) and (e) show εS in Group 2 of the
simulation datasets for the aforementioned methods, as a function of number of subjects in Group 1. In
our experiments, Group 1 dataset remains the same while Group 2 dataset changes as εO increase. Hence
DEBM results do not change with change in εO in Figure 8.4 (a) and (b), whereas in Figure 8.4 (c), DEBM
results do not change with increase in number of subjects in Group 1.
It can be seen that both coupled-training methods (i.e., co-init DEBM and coupled DEBM) outperform
the default method of independently training DEBM models. It can also be observed that in both co-
init DEBM and coupled DEBM the ordering errors decrease as εO increases and that co-init DEBM
outperforms coupled DEBM for lower values of εO , whereas the performance is on par with coupled
DEBM for higher values of εO .
Experiment 2: Figures 8.5 (a) and (b) show εS in Group 1 and Figures 8.5 (c), (d) and (e) show the same in
Group 2, when varying εG. Even with εG 6= 0, coupled training (i.e., co-init DEBM and coupled DEBM)
outperformed the default method of independently training DEBM models. Co-init DEBM showed
negligible change in the errors when εG 6= 0. The performance of coupled DEBM in Group 1 worsened





Figure 8.4: Experiment 1: The effect of εO (the difference in groundtruth event orderings in the two
groups) on the performance of the proposed methods. The shaded region in these plots represents
standard deviation of the error in estimation of the proposed methods in 50 random iterations of
simulations. The plots in (a) and (b) show the ordering errors in Group 1 using Coupled DEBM and
Co-init DEBM with independent DEBM shown in both (a) and (b), as a function of number of subjects
in Group 1. The plots in (c), (d) and (e) show the ordering errors in Group 2 using independent DEBM,
Coupled DEBM and Co-init DEBM respectively as a function of number of subjects in Group 1.
8.4.2 Studying the effect of APOE
The results in Experiments 1 and 2 show that the performance of co-init DEBM is more accurate and
robust than coupled DEBM in most scenarios. We hence analyzed Experiments 3 and 4 using co-init
DEBM.
Experiment 3: Figure 8.6 shows orderings of CSF, global cognition and volumetric biomarkers in the
APOE based groups of ε2 carriers, homozygous ε3 carriers, and ε4 carriers along with their uncertainty
estimates. It can be seen that the uncertainty of the ordering in the ε2 carriers group was high. Despite this






Figure 8.5: Experiment 2: The effect of εG (difference in abnormal biomarker levels in the two groups),
on the performance of the proposed methods. The shaded region represents standard deviation of the
error in 50 random iterations. The plots in (a) and (b) show the ordering errors in Group 1 using Coupled
DEBM and Co-init DEBM with independent DEBM shown in both (a) and (b), as a function of number of
subjects in Group 1. The plots in (c), (d) and (e) show the ordering errors in Group 2 using independent
DEBM, Coupled DEBM and Co-init DEBM respectively as a function of number of subjects in Group 1.
In the homozygous ε3 carrier group, ABETA was very prominently the earliest biomarker, followed by
cognitive scores of MMSE and ADAS13. Among the CSF biomarkers, PTAU followed immediately after
ABETA, which was inturn followed by TAU. NFL and NG were late biomarkers. Among the structural
biomarkers, volumes of fusiform and middle-temporal gyri were the first to become abnormal, followed
by ventricular volume and wholebrain volume. Hippocampus, precuneus and entorhinal volumes were
late biomarkers in this group.
In the ε4 carrier group, the CSF biomarkers followed a pattern that was similar to that of the homozygous
ε3 carrier group. The cognitive biomarkers were early biomarkers in this group as well. However the
ordering in structural biomarkers was very different from that in the homozygous ε3 carrier group.
Hippocampus and entorhinal volumes were early biomarkers in this group, followed by middle-temporal
and fusiform gyri volumes. Wholebrain, ventricular and precuneus volumes were late biomarkers.
The ordering of the ε2 carrier group was significantly different from that of the homozygous ε3 carrier
group (p = 0.0156, after Bonferroni correction for multiple testing). Similarly, the orderings for the other
two groups were significant as well: p = 0.0147 for the difference between ε2 carrier group and ε4 carrier




(b) Homozygous ε3 carriers
(c) ε4 carriers
Figure 8.6: Experiment 3: Orderings of CSF, global cognition and volumetric biomarkers in the APOE
based groups of ε2 carriers, homozygous ε3 carriers, and ε4 carriers along with their uncertainty
estimates. Uncertainty in the estimation of the ordering was measured by 100 repetitions of
bootstrapping, in the three APOE based groups. The color-map is based on the number of times a
biomarker is at a position in 100 repetitions of bootstrapping. The number of subjects in the three groups
were 75, 411 and 485 respectively. The orderings were obtained using Co-init DEBM.
Experiment 4: The variation of MMSE and ADAS13 scores with respect to the estimated disease stages
has been plotted in Figure 8.7, for all three groups. The patient stages showed a significant correlation
with both MMSE and ADAS13 scores. The correlation coefficients were also comparable in the three
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(a) ε2: Stage vs MMSE (b) ε2: Stage vs ADAS13
(c) Homozygous ε3: Stage vs MMSE (d) Homozygous ε3: Stage vs ADAS13
(e) ε4: Stage vs MMSE (f) ε4: Stage vs ADAS13
Figure 8.7: Experiment 4: Correlation of estimated disease stages with MMSE and ADAS scores in the
APOE based groups of ε2 carriers, homozygous ε3 carriers, and ε4 carriers. The plot on top of each
subfigure shows the probability density function of the disease stages, and the plot on the right of each
subfigure shows the probability density function of the cognitive score in the subfigure. The 2D plot in
each subfigure shows the joint density function of the two axes. The line in each subfigure shows the
linear regression of MMSE / ADAS scores with the estimated disease stage and the shaded area around
the line shows its 95% confidence interval. Figures (a),(c) and (e) depict correlation between MMSE score
and obtained disease stages in the three APOE based groups. Figures (b), (d) and (f) depict correlation





DEBM models have been shown to be effective in determining the temporal cascade of biomarker
abnormality as AD progresses, from cross-sectional data. In this work, we introduced a novel concept
of splitting the different steps of DEBM into group-specific and group-aspecific parts for coupled training
in stratified population. We considered two novel variations to split the steps of DEBM in this manner
and through thorough experimentation in simulation datasets we observed that co-init DEBM helps
in obtaining more accurate orderings in a stratified population. Using this method, we estimated the
biomarker cascades in AD progression with ε2 alleles, homozygous ε3 alleles, and ε4 alleles of APOE,
based on cross-sectional ADNI data. While the findings in the homozygous ε3 carrier and ε4 carrier
groups fit the current understanding of progression of AD with high-confidence, the finding in the ε2
carrier group shows evidence for an alternative pathway (with relatively low confidence). In this section,
we discuss the insights provided by the simulation experiments (Section 8.5.1) used for method selection
as well as the insights into the AD progression pathways provided by our experiments on the ADNI
dataset (Section 8.5.2).
8.5.1 Choice of the method
Coupled DEBM and co-init DEBM both split DEBM into group-specific and group-aspecific steps for
coupled training of an EBM in stratified populations. Experiment 1 and 2 showed that coupled training of
the group-aspecific parts of DEBM and independently training the group-specific parts of DEBM results
in more accurate orderings in the groups better than the default approach of independently training a
DEBM model in each group.
While splitting DEBM into group-specific and group-aspecific parts, we started with the assumption that
the latent true normal and abnormal biomarker distributions in the groups are either same or similar. The
difference between co-init DEBM and coupled DEBM is that, co-init DEBM accounts for slight differences
in the underlying biomarker distributions between the groups whereas coupled DEBM does not.
The simulation dataset generated in Experiment 1 had the same true normal and abnormal biomarker
distributions in the different groups, from which the simulated subjects were randomly sampled, aligning
well with the assumption of coupled DEBM. However, this did not result in overall better accuracies for
coupled DEBM than that of co-init DEBM. Co-init DEBM was also more robust than coupled DEBM as its
accuracy was less dependent on εO , the distance between the ground-truth orderings in the two groups.
Another observation in Experiment 1, which was rather counter-intuitive, was that the errors made by the
co-init and coupled DEBM models decreased as the distance between the ground-truth orderings in the
two groups increased. When the orderings are further apart, the combined biomarker distributions in CN
and AD groups have a larger overlap. The non-overlapping initialization (before the GMM optimization)
thus results in the normal and abnormal distributions to be further apart. We hypothesize that this results
in a better estimation of the mixing parameters during GMM optimization and in-turn resulted in more
accurate orderings, as mixing-parameters are dependent on the biomarker’s position in the ordering.
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In Experiment 2, we checked the performance of our approaches when the assumption (true normal and
abnormal biomarker distributions being same across groups) is violated in the dataset. This experiment
showed that the orderings obtained using co-init DEBM are more robust to differences between the
abnormal Gaussians across groups than those obtained with coupled DEBM. With coupled DEBM, the
error increased in the group with weaker biomarkers i.e., Group 1 in the case of εG = +0.2d and Group 2
in the case of εG = −0.2d. This shows that coupled DEBM introduces a systematic bias in the estimation
of ordering that is detrimental to the group with weaker biomarkers. Co-init DEBM also showed a similar
bias, but to a much lesser extent.
We hence selected co-init DEBM as the preferred approach for splitting and performed our analysis on
ADNI dataset using this approach. We expect that this idea of splitting DEBM into group-specific and
group-aspecific parts can be easily extended to the EBM introduced by [53].
8.5.2 Cascade of biomarker changes in the APOE based groups
Dividing the total population into groups based on APOE carriership enabled us to create more
phenotypically homogeneous groups [288], each with potentially specific disease progression timeline.
In this section, we discuss our results in these APOE carriership based groups.
Our findings show that the three APOE-carriership based groups have significantly different temporal
cascades of disease progression. This suggests that the underlying pathways of progression are different
for the three genotypes. Among the CSF biomarkers in the homozygous ε3 carrier and the ε4
carrier groups, ABETA abnormality is the earliest biomarker event followed by PTAU. This fits current
understanding of AD progression [117]. It also confirms the need for preventing the accumulation of
ABETA in high-risk patients. NFL and NG are late biomarkers in the homozygous ε3 carrier and ε4
carrier groups, which suggests that axonal [298] and synaptic [292] degeneration do not occur until very
late in the disease process in these groups. NG being abnormal after PTAU and TAU in the homozygous
ε3 carrier and ε4 carrier groups is also consistent with the previous findings that Tau mediates synaptic
damage in AD [299].
In the ε2 carrier group, we found that the abnormal NG and PTAU are the earliest CSF events, even before
ABETA becomes abnormal. This could hint at the existence of an alternative pathway for the formation
of tau tangles in the brain before ABETA accumulation, as suggested in [280], but needs more extensive
validation.
Among the volumetric biomarkers, Entorhinal cortex is one of the early biomarkers in the ε4 carrier
group which is supported by the findings in [300], but is one of the last biomarkers to become abnormal
in the homozygous ε3 carrier group. Ventricular volume is a late biomarker in the ε4 carrier group
but it becomes abnormal quite early in the homozygous ε3 carrier group as also observed by [301].
Hippocampus volume is the earliest biomarker in the ε4 carrier group, but is a relatively late biomarker
in the homozygous ε3 carrier and ε2 carrier groups. This suggests that incidence of hippocampal sparing
AD [302] could correlate with APOE carriership.
The findings related to these orderings of biomarker events were validated by correlating the patient
stages derived from these orderings with MMSE and ADAS13 scores. Patient stages of subjects in all
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three groups, when used as test-subjects in a cross-validated manner, showed a significant correlation
(p < 0.001) with these scores. These correlations validate our findings and suggest that these genotype-
specific disease progression timelines could be used for patient monitoring.
8.6 Conclusion and Future work
We conclude that co-init DEBM provides the best accuracy and robustness when estimating orderings
in stratified populations. Future work on co-init DEBM can focus on extending the approach for high-
dimensional imaging biomarkers [303]. This work also provides groundwork for extending the method
towards hypothesis-free, data-driven stratification of phenotypes.
We gained new insights into the disease progression timeline of AD in the APOE based groups of
ε2 carriers, homozygous ε3 carriers, and ε4 carriers. While we observed that the estimated disease
progression timelines in the ε4 carrier and the homozygous ε3 carrier groups fit the current understanding
of AD progression with high confidence, the estimated timelines in the ε2 carrier group may suggest an
alternative pathway for the formation of tau tangles in the brain before amyloid β accumulation, albeit
with relatively low condence. We expect that these genotype-specific disease progression timelines will
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Data-driven disease progression models have provided important insight into the temporal cascade of
brain changes in AD phenotypes. However, their utility in predicting the progression of pre-symptomatic
AD in a population-based setting has not yet been investigated. In this study, we investigated if the
temporal cascades constructed in a case-controlled setting, with subjects stratified according to APOE
status, are generalizable to a population-based cohort, and if progression along these disease cascades
is predictive of AD. Seven volumetric biomarkers derived from structural MRI were considered. We
estimated APOE-specific temporal cascades of changes in these biomarkers using a recently proposed
method called co-initialized discriminative event-based modeling (co-init DEBM). This method can also
estimate a disease stage for new subjects by calculating their position along the temporal cascade. The
model was trained and cross-validated on the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
dataset, and tested on the population-based Rotterdam Study (RS) cohort. We compared the diagnostic
and prognostic value of the disease stage in the two cohorts. Furthermore, we investigated if the rate of
change of disease stage in RS participants with longitudinal MRI data was predictive of AD. In ADNI,
the estimated disease stage distinguished AD subjects from controls with an AUC of 0.83 in both APOE
ε4 non-carriers and carriers. In the RS cohort, we obtained an AUC of 0.83 and 0.85 in ε4 non-carriers
and carriers, respectively. Progression along the temporal cascades as estimated by the rate of change
of disease stage showed a significant difference (p < 0.005) for subjects with pre-symptomatic AD as
compared to the general aging population in RS. It distinguished pre-symptomatic AD subjects with
an AUC of 0.81 in APOE ε4 non-carriers and 0.88 in carriers, which was better than any individual
volumetric biomarker, or its rate of change, could achieve. Our results suggest that co-init DEBM trained
on case-controlled data is generalizable to a population-based cohort setting and that progression along
the temporal cascades is predictive of the development of AD in the general population. We expect that
this approach can help to identify at-risk individuals from the general population for targeted clinical
trials as well as to provide biomarker based objective assessment in such trials.
9.1 Introduction
Alzheimer’s disease (AD) is a chronic neurodegenerative disease that affects roughly 3% of the world’s
elderly population (above 60 years old) [279]. Genetic variations and in particular APOE genotypes
are not only the risk factors for the disease [27] but also affect its clinical [288, 304] and biological
phenotypes [38].
Neuroimaging biomarkers play an important role in disentangling these phenotypes [86, 305]. They could
also play an important role in finding disease modifying treatments [306]. There has been evidence that
selection of the study population at its pre-symptomatic stage is also crucial for the success of potential
modifying treatments for AD [44, 307]. Hence there is a crucial need for a way to objectively assess the
progression of pre-symptomatic AD (or lack thereof).
Biomarkers extracted from neuroimaging data in combination with machine learning approaches have
been shown to objectively assess the progression of AD in research cohorts [308] as well as in clinical
cohorts [309]. However, machine learning approaches are not explainable by default and the lack of
transparency in such approaches could hinder clinical decision making [310].
Disease progression models are data-driven approaches that are interpretable by design and can thus
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aid not only in predicting AD but also in explaining the decision and facilitating transparency and
trust [311]. In recent years, many disease progression models have emerged to provide insight into
neurodegenerative diseases such as AD [52, 53]. Such insights have also been shown to aid in objective
assessment of AD progression [58]. An example of such a model is the discriminative event-based model
(DEBM) [93], which estimates a cascade of AD related biomarker abnormality events in a data-driven way.
Such data-driven temporal cascades were also shown to be generalizable to multiple clinical cohorts [291].
However, the generalizability of such models to population-based cohorts and their utility in predicting
the progression of pre-symptomatic AD in a population-based setting have not yet been investigated.
In this work, we investigate if i) APOE-specific temporal cascades constructed in a case-controlled setting
are generalizable to a population-based cohort, and ii) if progression along these disease cascades is
predictive of AD. For constucting the APOE-specific temporal cascades, we use a recently developed
approach called co-initialized (co-init) DEBM [312] meant for obtaining temporal cascades in stratified
cross-sectional datasets. We demonstrate the potential of the method’s fine-grained disease stage
estimation in predicting the subjects with pre-symptomatic AD in the general population.
9.2 Methods
We first describe the inclusion criteria for participants and the method for obtaining the volumetric
biomarkers in the case-controlled Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset and the
population-based Rotterdam study (RS) dataset. This is followed by the description of co-init DEBM
used to construct APOE-specific temporal cascades of volumetric biomarkes from baseline scans of the
participants in the ADNI. We validated the temporal cascades constructed on ADNI by assessing their
generalizability to the population-based RS cohort, and by predicting the participants at-risk of becoming
symptomatic in the RS cohort.
9.2.1 Participants
ADNI
We considered the baseline measurements of 335 cognitively normal (CN), 565 non-AD, 167 incident-
AD and 223 AD participants (prevalent-AD) who had imaging data available in ADNI1, ADNIGO and
ADNI2 studies*. The non-AD cases were defined as ADNI participants who were either mild cognitively
impaired (MCI) or had subjective memory complaints at the time of the baseline MRI scan, and did not
develop AD within 3 years of follow-up. The incident-AD cases presented with MCI at baseline but
developed AD within 3 years. Characteristics of the subjects and their volumetric measures in the ADNI
dataset included in our study are shown in Table 9.1(a).
*ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W.
Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early




We considered participants from the population-based RS cohort, a prospective longitudinal study among
community-dwelling subjects aged 45 years and over [313]. Participants were screened for dementia at
baseline and at follow-up examinations with the Mini-Mental State Examination and the Geriatric Mental
Schedule organic level. Those with a Mini-Mental State Examination score < 26 or Geriatric Mental
Schedule score > 0 underwent further investigation and informant interview, including the Cambridge
Examination for Mental Disorders of the Elderly. In addition, the entire cohort was continuously under
surveillance for dementia through electronic linkage of the study database with medical records from
general practitioners and the regional institute for outpatient mental health care. Available information on
cognitive testing and clinical neuroimaging was used when required for diagnosis of dementia subtype.
A consensus panel led by a consultant neurologist established the final diagnosis of AD.
In this work, we included participants from the RS who had at least one MRI scan, who completed
cognitive testing, and were interviewed for the presence of subjective cognitive complaints at the time
of the MRI. The included participants were categorized into 4 groups: participants that were cognitively
normal at the time of the scan (CN), participants that had subjective memory complaints and/or objective
cognitive impairment [314], but who did not develop AD at follow-up (non-AD), participants with AD at
the time of the scan (prevalent-AD) and participants who developed AD after the MRI scan (incident-AD).
Unlike in ADNI, we did not set a threshold of conversion within 3 years to be included as an incident-AD
participant, since we wanted to assess the utility of our method in monitoring the progression of both
pre-clinical and prodromal AD subjects. Participants with clinical stroke were excluded.
In our experiments, we used two subsets of the RS cohort: the generalizibility set and the prediction set.
The generalizibility set consisted of the last MRI scan available for each partipant in the RS cohort. This
subset consisted of 998 CN, 2710 non-AD, 97 incident-AD, and 25 prevalent-AD cases and were used
for experiments validating the generalizability of the APOE-specific temporal cascades constructed using
co-init DEBM. The characteristics of the subjects in this subset are shown in Table 9.1(b). The prediction
set consisted of the last two MRI scans available for each participant, which were used to assess the
progression (or lack thereof) of pre-symptomatic AD in the participants. This subset consisted of 183
CN, 852 non-AD and 31 incident-AD cases. For the incident-AD cases, both the included scans were
performed before the AD diagnosis. Participants with prevalent-AD were excluded in this subset. The
characteristics of the subjects in this subset are shown in Table 9.1(c).
9.2.2 MRI acquisition and imaging biomarker extraction
The imaging biomarkers used in this study were estimated from T1-weighted (T1w) MRI scans. Details
of the MRI acquisition protocol can be found in [289, 290] (ADNI) and [315] (RS). The MRI scans
were analyzed with FreeSurfer software v6.0 cross-sectional stream (http://surfer.nmr.mgh.harvard.edu).
Outputs were visually checked for the ADNI dataset. In the RS dataset, an automated quality metric was
used to exclude scans with insufficient quality, which was visually verified in a randomly selected subset
of both selected and rejected scans [316].
The selected imaging markers were the same markers as that of [291], namely volumetric measures of:
total brain, ventricles, hippocampus, precuneus, middle temporal gyrus, fusiform gyrus and entorhinal
cortex. The volumes were defined as the summed volumes of the structure in the left and right
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hemisphere. The volumetric measures of CN subjects in ADNI were used to regress against age, sex and
intracranial volume to estimate their confounding effects. These estimates were used for confounding
factor correction in the remaining subjects in ADNI as well as in the RS cohort. The resultant volumetric
measures will be referred to as biomarkers in the remainder of the manuscript.
9.2.3 Construction of APOE-specific temporal cascades using co-init DEBM
The co-init DEBM model introduced in [312] constructs genotype-specific AD related temporal cascades
of biomarker changes, based on cross-sectional datasets. Such an estimation from cross-sectional data
is feasible because, in a cohort consisting of subjects encompassing a wide spectrum of severity, early
biomarkers have a higher prevalence of abnormal biomarker values as compared to biomarkers that
become abnormal later in the disease timeline. The co-init DEBM model estimates this timeline without
strictly considering the diagnostic labels of the subjects. The model uses a coupled mixture model
to jointly fit normal and abnormal distributions in the dataset stratified by (APOE) genotypes. The
model assumes that the normal and abnormal biomarker distributions in the different genotypes can
be approximately represented by Gaussians. It also assumes that the different genotypes’ abnormal (and
normal) biomarker distributions are close to each other.
After the estimation of the normal and abnormal biomarker distributions, the model computes the
probability of abnormality of each biomarker for each subject in the training dataset. Based on the
assumption that a biomarker that becomes abnormal earlier in the temporal cascade of events would
be more abnormal than the biomarker that becomes abnormal later, it estimates a subject-specific cascade
of biomarker changes in each subject of the dataset. A generalized Mallows model is used to average the
subject-specific biomarker cascades over the subjects within each genotypic group of the training set, to
construct average temporal cascades for APOE ε4 non-carriers and carriers. Along with the sequence of
the biomarker abnormality events, the model also estimates the relative positioning of such events with
respect to each other (event-centers). Absolute magnitudes for these event-centers are irrelevant as they
only convey relative (temporal) distances and in this study, they were normalized such that the first event
and the last event coincided at a value of 0.1 and 0.9 respectively.
To construct the temporal cascades, the co-init DEBM was trained on CN, incident-AD, and prevalent-
AD subjects from ADNI. The non-AD subjects in ADNI were excluded for training the model, to reduce
the chances of disorders unrelated to AD affecting the estimated cascades. The variance in the estimated
temporal cascades was computed using 100 independent bootstrap samples.
9.2.4 Estimating APOE-specific disease stages
After training the co-init DEBM model, the constructed APOE-specific temporal cascades were used to
estimate the disease stage at multiple timepoints for subjects of the RS cohort. For estimating the disease
stages of ADNI subjects, we used a 10-fold cross validation. The training set was used for constructing
the temporal cascades and the disease stages were estimated in the test set, including the non-AD subjects
excluded in the training phase. Disease stage quantifies the severity of the disease in a subject by
positioning them along the pre-constructed temporal cascade and is normalized between 0 and 1. The
estimated disease stages were used in two sets of experiments.
209
Chapter 9
ADNI dataset CN non-AD incident-AD prevalent-AD
Number of subjects 335 565 167 223
Number of women, % 174, 51.9 268, 47.4 68, 40.7 104, 46.6
Age (years) 74.3 ± 5.6 71.82 ± 7.2 73.1 ± 7.1 74.0 ± 7.9
Number of APOEε4 carriers, % 92, 27.5 238, 42.1 121, 72.5 151, 67.7
Intracranial volume (ml) 1504.0 ± 155.8 1520.9 ± 152.8 1546.2 ± 180.2 1524.2 ± 183.9
Total brain volume (ml) 1030.7 ± 98.7 1043.3 ± 100.0 1017.7 ± 111.7 991.8 ± 114.1
Ventricle volume (ml) 38.4 ± 18.1 41.0 ± 21.3 49.1 ± 23.9 51.4 ± 21.9
Hippocampus volume (ml) 7.3 ± 0.9 7.1 ± 1.0 6.3 ± 1.0 6.0 ± 1.0
Precuneus volume (ml) 16.7 ± 2.2 17.4 ± 2.4 16.2 ± 2.6 15.4 ± 2.5
Middle temporal gyrus volume (ml) 20.4 ± 2.7 20.4 ± 2.7 18.5 ± 2.9 17.6 ± 3.0
Fusiform gyrus volume (ml) 17.5 ± 2.1 17.6 ± 2.2 16.3 ± 2.4 15.5 ± 2.4
Entorhinal cortex volume (ml) 4.0 ± 0.7 3.9 ± 0.8 3.4 ± 0.8 3.2 ± 0.8
Time before AD diagnosis (years)* 1.4 ± 0.7
(a)
RS dataset - generalizability set CN non-AD incident-AD prevalent-AD
Number of subjects 998 2710 97 25
Number of women, % 500, 50.1 1200, 44.3 39, 40.2 10, 40.0
Age (years) 67.4 ± 8.3 70.9 ± 9.3 79.6 ± 5.7 80.2 ± 6.3
Number of APOEε4 carriers, % 255, 25.6 745, 27.5 45, 46.4 11, 44.0
Intracranial volume (ml) 1512.3 ± 157.6 1475.8 ± 155.3 1437.5 ± 156.6 1403.0 ± 163.9
Total brain volume (ml) 1050.3 ± 107.5 1012.6 ± 105.6 936.6 ± 94.9 884.5 ± 105.0
Ventricle volume (ml) 33.7 ± 17.3 36.5 ± 19.3 49.1 ± 21.1 59.9 ± 28.3
Hippocampus volume (ml) 7.9 ± 0.8 7.6 ± 0.8 6.7 ± 0.9 6.0 ± 1.0
Precuneus volume (ml) 18.2 ± 2.1 17.6 ± 2.0 16.8 ± 1.9 15.4 ± 2.2
Middle temporal gyrus volume (ml) 20.6 ± 2.7 19.9 ± 2.7 17.6 ± 2.5 16.2 ± 2.7
Fusiform gyrus volume (ml) 17.7 ± 2.2 17.2 ± 2.1 15.8 ± 2.0 14.5 ± 2.7
Entorhinal cortex volume (ml) 3.7 ± 0.6 3.6 ± 0.7 3.1 ± 0.8 2.6 ± 0.7
Time before AD diagnosis (years)* 2.8 ± 2.3
(b)
RS dataset - prediction set CN non-AD incident-AD
Number of subjects 183 852 31
Number of women, % 95, 51.9 412, 48.4 10, 32.3
Age (years)* 73.3 ± 5.5 75.5 ± 6.4 78.4 ± 6.8
Follow-up time (years) 3.5 ± 1.3 3.5 ± 1.4 2.9 ± 0.9
Number of APOEε4 carriers, % 39, 21.3 225, 26.4 13, 41.9
Intracranial volume (ml)* 1522.8 ± 156.6 1478.9 ± 156 1419.4 ± 126.9
Total brain volume (ml)* 1038.7 ± 100.7 998.4 ± 98.3 926.6 ± 91.4
Ventricle volume (ml)* 39.7 ± 20.2 41.1 ± 21.6 44.9 ± 17
Hippocampus volume (ml)* 7.8 ± 0.8 7.4 ± 0.8 6.7 ± 0.9
Precuneus volume (ml)* 18.0 ± 2.0 17.5 ± 1.9 16.5 ± 1.8
Middle temporal gyrus volume (ml)* 20.3 ± 2.6 19.5 ± 2.4 17.5 ± 2.4
Fusiform gyrus volume (ml)* 17.5 ± 2.1 17.0 ± 2.1 15.6 ± 2.1
Entorhinal cortex volume (ml)* 3.7 ± 0.7 3.6 ± 0.7 3.0 ±0.6
Time before AD diagnosis (years)* 2.4 ± 1.8
(c)
Table 9.1: Characteristics of the ADNI dataset (a), the generalizability set of the RS dataset (b), and the prediction set of
the RS dataset (c). * indicates values at last scan.
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group
Cases No. of Subjects in ADNI
(Reference group, Cases)







































Table 9.2: Generalizability assessment: The AUCs for distinguishing the different diagnostic classes using the estimated
disease stages and their corresponding 95% confidence intervals. The confidence intervals of the AUCs were determined
using bootstrap resampling while stratifying the diagnostic classes to maintain their relative proportions.
Experiment 1: Assessing the generalizability of co-init DEBM from ADNI to RS
In this experiment, we tested the generalizability of the co-init DEBM model trained on ADNI by
evaluating the diagnostic and prognostic value of its predicted disease stages in the RS cohort. First we
performed a visual assessment by constructing normalized histograms of the estimated APOE-specific
disease stages for the different diagnostic classes in ADNI and the generalizability set of the RS cohort.
Complementing this visual analysis, for assessing the diagnostic value we used the estimated
disease stages to distinguish prevalent-AD from two different reference groups in ADNI and in the
generalizability set of the RS cohort. First, only the CN subjects were included in the reference group. To
emulate a reference group of participants more representative of the general aging population than the CN
group, we used a combined set of CN and non-AD subjects as the second reference group. We computed
the area under the receiver operating curve (AUC) for distinguishing the diagnostic classes, and compared
the AUCs obtained in ADNI and RS. The confidence intervals of these AUCs were measured using
bootstrap resampling while stratifying the diagnostic classes to maintain their relative proportions.
For assessing the prognostic value, we used the estimated disease stages to distinguish incident-AD
from the aforementioned two reference groups in ADNI and in the generalizability set of RS cohort.
We computed the AUCs and their confidence intervals for distinguishing these diagnostic classes and
compared values obtained in ADNI and RS. Furthermore, we computed the correlation of the estimated
disease stages with time to dementia diagnosis for incident-AD subjects in ADNI as well as in RS.





Figure 9.1: Temporal cascades of APOE ε4 non-carriers (a) and carriers (b) estimated using co-init DEBM
in ADNI. The plot on top of each subfigure shows the event-centers of the different regions and their
respective standard deviation estimated from a batch of 100 independent bootstrap samples. The 3D
visualization [317] at the bottom of each subfigure highlights the region that becomes abnormal at the
corresponding disease stage. The vertical positioning of the biomarkers in the event-center part of each
subfigure shows the estimated temporal cascade in the APOE genotype, which is different for non-carriers
and carriers.
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Figure 9.2: Normalized histograms of the estimated APOE-specific disease stages for the different
diagnostic classes in ADNI and the generalizability set of RS. The normalized histograms of disease stages
are shown for (a) APOE ε4 non-carriers in ADNI, (b) APOE ε4 carriers in ADNI (c) APOE ε4 non-carriers
of the generalizability set in RS, and (d) APOE ε4 carriers of the generalizability set in RS. The x-axis
represents the disease stage based on the APOE-specific temporal cascades by the co-init DEBM model,
and the y-axis represents the relative percentage of subjects in each diagnostic class, meaning that the
relative percentages of all disease stages of one diagnostic category add up to one.
In this experiment, we assess if the evolution of the disease stages derived from longitudinal
neuroimaging data is predictive of AD in the prediction set of the RS cohort. This experiment is further
divided into three parts. In the first part, we build longitudinal trajectories of the disease stages and
observe the differences in CN, non-AD and incident-AD subjects. In the second part, we assess the
prognostic value of the rate of change of disease stages. Lastly, we assess the marginal utility of the
follow-up scans in AD prognostication.
Exp. 2.1: We used the disease stages obtained in the prediction set of the RS cohort for building the
trajectories of disease stages in the two APOE ε4 based groups. The trajectories were estimated using
linear mixed models with random intercepts and slopes. The time variable in these linear mixed models
was follow-up time in years since the first MRI of the subject. To allow different slopes for different
diagnostic classes, an interaction between follow-up time and the diagnosis was integrated in the model.
Covariates that were accounted for in the model were sex, age at the time of the first MRI, and the
interaction of age and follow-up time to allow slope differences for different ages.
Exp. 2.2: We used the rate of change of disease stages (delta disease stage) in the prediction set of the RS
cohort to distinguish incident-AD from two different reference groups. As in Experiment 1, the two
reference groups selected were CN, and a combined set of CN and non-AD subjects. We computed
the AUCs and their confidence intervals for distinguishing these diagnostic classes. For comparison,
the AUCs while using the rate of change of the volumetric measures (normalized to their respective





Figure 9.3: Average disease stage trajectories of participants within the prediction set of RS. The
trajectories are shown separately for CN, non-AD and incident-AD subjects within the APOE ε4 non-
carriers group (a) and the APOE ε4 carriers group (b). 95% confidence intervals are shown as shaded
regions around the trajectories.
Exp. 2.3: Lastly, to evaluate the marginal utility of the follow-up scans for identifying incident-AD
subjects, we used the estimated disease stage at the last MRI scan of the subjects in the prediction set
of the RS cohort to distinguish incident-AD from the aforementioned two different reference groups.
We computed the AUCs and their confidence intervals for distinguishing these diagnostic classes. As
a comparison, the AUCs based on participants’ age as well as of each individual volumetric imaging
biomarker were also computed.
9.3 Results
Figure 9.1 shows the APOE-specific temporal cascades constructed for the ε4 non-carriers and carriers
in the ADNI dataset. It shows the centers of the biomarker abnormality events along the cascade
representing their relative positioning with respect to each other. It can be seen that the temporal cascade
of APOE ε4 non-carriers and carriers were quite different. Most noticeably, ventricular volume and
total brain volume were estimated as early biomarkers for APOE ε4 non-carriers, whereas hippocampal
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Figure 9.4: Predicting incident-AD subjects in the RS cohort. Figures (a), (c), (e), and (g) show the AUCs
for distinguishing incident-AD while using data from two MRI scans based on longitudinal follow-up of
the participants. Figures (b), (d), (f), and (h) show the AUCs for distinguishing incident-AD using only
the last MRI scan available for each participant. Figures (a-d) are for APOE ε4 non-carriers, while (e-g) are
for carriers. Figures (a), (b), (e), and (f) use CN subjects as the reference group, while Figures (c), (d), (g),
and (h) uses CN + non-AD as the reference group.
volume and volume of the entorhinal cortex were estimated as early biomarkers for APOE ε4 carriers. It
can also be seen in Figure 9.1 that the uncertainty estimates in APOE ε4 non-carriers were greater than in
APOE ε4 carriers.
Experiment 1: Assessing the generalizability of co-init DEBM from ADNI to RS
The normalized histograms of the estimated APOE-specific disease stages for the different diagnostic
classes in ADNI and the generalizability set of RS are shown in Figure 9.2. It can be seen that the
distributions of the disease stages of the four diagnostic classes in ADNI were largely similar to those
in the generalizability set of RS. The CN and non-AD subjects were positioned towards the left side of
the spectrum, whereas the prevalent-AD were positioned predominantly towards the right. It can also
be seen that for a proportion of prevalent-AD subjects in the APOE ε4 non-carrier group, the model had
estimated a low disease stage in both ADNI and RS cohorts. A noticeable difference between ADNI and
RS was that a substantial proportion of incident-AD subjects in RS was positioned towards the left side of
the histograms in both APOE ε4 non-carriers and carriers.
The AUCs for distinguishing the different diagnostic classes using the estimated disease stages are shown
in Table 9.2, along with their confidence intervals. It can be observed that the performance of the disease
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stages in distinguishing prevalent-AD from the set of CN and non-AD subjects in ADNI (AUC = 0.83 for
both APOE ε4 non-carriers and carriers) was comparable to that in RS (AUC = 0.83 for APOE ε4 non-
carriers and AUC = 0.85 for ε4 carriers). It should however be noted that the confidence intervals were
larger in the RS cohort. It can also be observed that incident-AD subjects were harder to distinguish than
prevalent-AD in the RS cohort (AUC = 0.68 for ε4 non-carriers and AUC = 0.62 for ε4 carriers), but not in
ADNI (AUC = 0.81 for ε4 non-carriers and AUC = 0.79 for ε4 carriers).
Lastly, the estimated disease stages showed a significant Pearson correlation with time to diagnosis for
APOE ε4 carrier incident-AD subjects in both ADNI (R = 0.31, p = 0.0006) and RS cohorts (R = 0.29,
p = 0.04). However, the correlation was found to be insignificant for APOE ε4 non-carrier incident-AD
subjects in both ADNI (R = 0.04, p = 0.8) and RS cohorts (R = 0.1, p = 0.4).
Experiment 2: Predicting AD based on longitudinal data in the RS cohort
Exp. 2.1: In Figure 9.3, the trajectories of disease stage over time as estimated by linear mixed models are
shown for the CN, non-AD and incident-AD groups of the prediction set of RS. The interaction between
the incident-AD diagnosis and follow-up time was statistically significant in both APOE ε4 non-carriers
and carriers (CN vs. incident-AD p = 0.0032 and p = 0.0041 respectively; non-AD vs. incident-AD
p = 0.0039 and p = 0.0032 respectively), meaning that incident-AD subjects showed a significant increase
in disease stage compared to CN and non-AD subjects.
Exp. 2.2: In the left column of Figure 9.4, the AUCs and the corresponding 95% confidence intervals
for distinguishing incident-AD using two MRI scans based on longitudinal follow-up of participants are
shown for APOE ε4 non-carriers and carriers. It can be observed that for distinguishing incident-AD
from the reference group, delta disease stage consistently performed the best for both the genotypes. It
outperformed the rates of changes of volumetric measures, with respect to the obtained AUC. It can also
be observed that distinguishing incident-AD from CN and non-AD subjects in the reference group was
harder than distinguishing incident-AD from CN alone, as reflected by the lower AUCs for almost all the
measures used.
Exp. 2.3: The right column of Figure 9.4 shows that age was an important predictor for incident-AD. Age
distinguished incident-AD well from CN subjects (AUC of 0.73 for both ε4 non-carriers and carriers), but
the performance of age as a predictor dropped substantially when distinguishing incident-AD from CN
and non-AD subjects (AUC of 0.64 for ε4 non-carriers and 0.65 for ε4 carriers). When only the last MRI
scan was used for incident-AD prediction from a reference group of CN and non-AD subjects, volumes
of hippocampus and entorhinal cortex were good indicators in APOE ε4 carriers (AUC of 0.79 and 0.81
respectively) but not for APOE ε4 non-carriers (AUC of 0.64 and 0.63 respectively). Similarly, total brain
volume and ventricle volume were good indicators of incident-AD in APOE ε4 non-carriers (AUC of 0.73
and 0.68 respectively), but not for ε4 carriers (AUC of 0.64 and 0.59 respectively). Disease stage estimated
using the APOE-specific temporal cascades performed well consistently in both the APOE genotypes
(AUC of 0.74 for ε4 non-carriers and 0.76 carriers). The marginal utility of an additional MRI scan can be
observed by comparing the left column of Figure 9.4 with the right column of Figure 9.4. It can be seen
that delta disease stage was much better for incident-AD prediction from a reference group of CN and
non-AD subjects (AUC of 0.81 for ε4 non-carriers and 0.88 for carriers) than any measure obtained using
only the last MRI scan.
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9.4 Discussion
In this work, we constructed APOE-specific temporal cascades in a case-controlled setting and validated
their generalizability to a population-based setting. We assessed that progression along these cascades is
predictive of AD in the general population. In this section, we discuss the insights we obtained from our
results.
9.4.1 Generalizability of the APOE-specific temporal cascades
The temporal cascades showed the APOE genotype-specific differences in the loss of structural integrity
as AD progresses, with ventricular volume and total brain volume being early biomarkers for ε4 non-
carriers, and hippocampal volume and volume of the entorhinal cortex being early biomarkers for ε4
carriers. We observed in the normalized histograms that for a proportion of prevalent-AD subjects in the
ε4 non-carriers group, the model had estimated a low disease stage. This observation, in combination
with the greater uncertainty of the event-centers in that group suggests that there is intra-genotype
heterogeneity among the ε4 non-carriers.
We also observed that the normalized histograms of disease stages in the different diagnostic classes were
visually largely similar for ADNI and RS. An important difference between the two cohorts was that
the model estimated a low disease stage for a substantial proportion of incident-AD subjects in RS, but
not in ADNI. Complementing the qualitative analysis, we also observed that the disease stages could
distinguish prevalent-AD subjects from CN and non-AD subjects almost equally well in both ADNI and
RS cohorts. However, we noticed a lower performance in distinguishing incident-AD from CN and non-
AD subjects in RS as compared to ADNI. Three possible explanations for these differences between ADNI
and RS are given below.
First, the incident-AD group in ADNI only consisted of prodromal AD subjects with the mean time to AD
diagnosis of 1.4 years, whereas the incident-AD group in RS consisted of prodromal and preclinical AD
subjects with the mean time to AD diagnosis of 2.8 years. We observed in Experiment 1 that the obtained
disease stages of incident-AD subjects correlated with time to AD diagnosis for APOE ε4 carriers, making
AD harder to detect in the preclinical phase than in the prodromal phase. Hence the difference in the
mean time to diagnosis in the two datasets is expected to be a factor contributing to the observed lower
performance in the RS cohort.
Secondly, the prodromal AD subjects in ADNI were clinically defined amnestic MCI subjects who have
a much higher a priori chance of developing AD symptoms than in the general population, making the
prediction in the latter cohort a more difficult problem.
Thirdly, a factor contributing to the performance difference could be that ADNI excluded subjects with
severe cardiovascular risk factors whereas the RS did not. Hence the probability of co-morbidity of
vascular pathology was higher in the RS incident-AD subjects than in the corresponding ADNI set, which
could have led to the drop in performance.
Given the high AUCs for all other classification tasks, the comparable disease stage histograms in
ADNI and RS, and the possible explanations given above for the specific differences related to incident-
AD prediction, we conclude that the APOE-specific temporal cascades obtained by co-init DEBM are
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generalizable from a case-controlled to a population-based setting.
However, for precise classification of subjects into either diagnostic category, a cut-off point for disease
stage needs to be defined. We expect the cut-off point to be different in a case-controlled setting versus a
population-based setting. Estimating this cut-off point in a population should ideally be estimated using
an independent validation set taking several factors into consideration such as the a-priori prevalence of
AD in the cohort, and the risks associated with false positives and negatives of this classification.
9.4.2 Predicting pre-symptomatic AD in the RS cohort
We observed that a participant’s age distinguished incident-AD well from CN. This is in line with
earlier studies that identified age as an important predictor [318, 319]. However, we also observed that
the predictive performance of age deteriorated when the reference group was less healthy, i.e., when
distinguishing incident-AD from a combined reference group also consisting of subjects with subjective
or objective cognitive decline unrelated to AD. This is in line with the expectation that age is poor in
distinguishing cognitive decline due to AD and cognitive decline due to other causes.
The predictive performance of the volumetric biomarkers from a single MRI scan depended on the APOE
ε4 carriership. We observed that hippocampus and entorhinal cortex were good predictors in APOE
ε4 carriers. Interestingly, those biomarkers were estimated to be early in the corresponding temporal
cascade. Similarly, total brain volume and ventricle volume were good predictors in APOE ε4 non-carriers
which were also the early biomarkers in its temporal cascade. These results suggest that for predicting
pre-symptomatic AD, early biomarkers play an important role and that it is important to understand the
genotype-specific differences.
Lastly, we assessed the marginal utility of longitudinal MRI scans in identifying individuals at-risk of
developing AD symptoms. We observed that participants with incident-AD showed a significant increase
(p < 0.005) in disease stage over time as compared to CN and non-AD participants, in both APOE ε4
non-carriers and carriers. The rate of change of disease stage distinguished incident-AD subjects better
than the disease stage at only the last scan, clearly highlighting the added value of longitudinal MRI
scans, particularly in pre-symptomatic subjects. The rate of change of disease stage was also a better
predictor of incident-AD than any other volumetric biomarker used in this study. This showed that the
progression along the APOE-specific temporal cascade can be used to identify subjects in a population
at-risk of developing AD.
In this study, we only used imaging biomarkers because cerebrospinal fluid biomarkers in a pre-clinical
setting are usually not available. Recent breakthroughs in blood-based biomarkers [22] could help in
obtaining fluid biomarkers in the pre-clinical phase of the disease. Previous work on DEBM [93] and
co-init DEBM [312] had shown that the model is capable of incorporating biomarkers from multiple
modalities for constructing the temporal cascades. We expect that our current approach of predicting pre-
symptomatic AD in the general population would be applicable also in the presence of fluid biomarkers,
should they become available in the future.
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9.5 Conclusion and Future Work
We conclude that APOE-specific data-driven temporal cascades estimated by co-init DEBM are
generalizable to population-based cohorts and that progression of individuals along such cascades is
predictive of incident AD. Although the current study only considered volumetric biomarkers as inputs,
it can be extended to fluid-based biomarkers, if these would become available in a population based study.
Due to its robustness and explainability, we expect that our model can help identify at-risk individuals
from the general population for targeted clinical trials as well as provide biomarker based objective
assessment in such trials.
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The cacophony of neurodegeneration is orchestrated by the underlying symphony of
pathological processes of the disease. These pathological processes, be it in a fast progressing
one like Creutzfeldt-Jakob disease or in a slowly progressing one like Alzheimer’s disease,
are devastating to the patients and their caregivers in their own way. Understanding the
underlying order in the heterogeneous progression of these diseases is crucial for early
diagnosis, effective patient care, as well as in identifying novel disease modifying treatment
strategies. Disease progression modeling is a class of data-driven approaches that has
the potential to aid in these quests. It helps in understanding the pathophysiology of
neurodegenerative diseases, in objectively assessing the progression of these diseases, and
could potentially help in identifying novel therapeutic targets for such diseases.
In this thesis I focussed on developing novel disease progression models for estimating
disease progression timelines of neurodegenerative diseases. This research resulted in several
methodological innovations and provided novel insights into the disease processes of several
neurodegenerative diseases. In this chapter, in Section 11.1, I discuss the methodological
innovations presented in the thesis. This is followed, in Section 11.2, by a discussion on
the novel insights into neurodegenerative diseases provided in this thesis. Implications of
the findings in this thesis for clinical practice as well as drug trials and other interventions are
discussed in Sections 11.3 and 11.4 respectively. Lastly, the roadmap for future methodological
innovations in disease progression modeling is discussed in Section 11.5.
11.1 Methodological innovations
Event-based models (EBM) are disease progression models that estimate a temporal sequence
of abnormal biomarker events in neurodegeneration based on cross-sectional data. While
the concept of estimating a temporal sequence from cross-sectional data intrigued me when
I started this thesis in 2016, the existing EBM models available at the time were either too
restrictive in assuming that the subjects in the cohort followed a common temporal sequence
or did not scale well to more than a few biomarkers (as shown in Chapter 2). Another
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limitation in the existing EBMs was a result of strict quantization of position in the temporal
sequence of events, which could be non-intuitive in terms of inferring actual progression of
the disease (as also discussed in Chapter 2).
To address these limitations, I developed a novel framework of EBM called the discriminative
EBM (DEBM) (in Chapter 2). In this framework, first a noisy estimate of the subject-specific
temporal sequence of biomarker abnormalities is estimated independently for each subject in
the cohort, thereby accounting for heterogeneity in the cohort. This is followed by estimating
the mean disease progression timeline of the subjects in the cohort. Using this new framework
of EBM, one can not only estimate the temporal sequence of abnormality events but also the
event centers, referring to the relative temporal distance of these events from one-another.
Furthermore, using the estimated disease progression timeline, one can also estimate an
objective measure of disease severity in a patient based on the obtained biomarkers.
Apart from these novel steps which are specific to the DEBM framework, a novel mixture
modeling approach was developed in this work, which could be an integral part of all the
existing EBM frameworks. This mixture modeling approach improved the stability of the
obtained model parameters for EBM analysis. The validity and robustness of the different
aspects of the developed framework were tested extensively on synthetic datasets simulating
the progression of neurodegeneration as well as on a large AD cohort. Furthermore, the
generalizability of the disease progression timeline of AD constructed in the large AD cohort
to other clinical cohorts was verified in Chapter 3.
These extensive experimentations also led to some novel insights about the developed method
and shed light on its limitations. Limitations were related to: i) The stability of the mixture
modeling, ii) The importance of the choice of biomarkers in the accuracy of EBMs, iii)
The potential of DEBM for personalized prediction. These novel insights led to further
development of DEBM in the subsequent chapters, as detailed in the following paragraphs.
Stability of the mixture modeling: The different types of mixture modeling approaches
analyzed in Chapter 2 led to the conclusion that the stability of the mixture models is crucial
for building an accurate EBM. Hence, while studying the lateral asymmetry in brain in
Chapter 4, I developed a novel mixture modeling technique called siamese mixture modeling
to further improve the stability of the mixture model. While analyzing the effect of APOE on
the disease progression timeline of AD in Chapter 8, the mixture models in each of the APOE
based groups were initialized using data pooled from all the groups. This co-initializing
of the mixture models led to a substantial increase in the accuracy of the subsequently
estimated temporal sequence in the groups. This novel mixture-modeling approach was
further validated in Chapter 9, where it was used to train the DEBM model in a research-
based cohort, and validated in a population-based cohort, to investigate its generalizability.
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Choice of biomarkers: The simulation experiments in Chapter 2 showed that the accuracy
of estimating the disease progression timeline depends on the overlap between the normal
and abnormal biomarker distributions used in the model. It implied that when using
imaging biomarkers such as volume of a region, the high-dimensional information of the
brain regions available in the images are being reduced to scalar biomarkers potentially
increasing the overlap between the normal and abnormal distributionss. Hence, to address
this suboptimality, I developed a novel approach called n-dimensional DEBM (nDEBM) to
estimate the disease progression timeline using high-dimensional imaging biomarkers in
Chapter 7. In nDEBM semi-supervised support vector machines were used, replacing mixture
modeling in the DEBM framework. This was done to address a well-documented scalability
problem of mixture modeling [343], known as the curse of dimensionality.
Personalized prediction: Further methodological developments include using the output of
DEBM for: i) prediction of clinical status, ventricular volumes, and AD assessment scale
(ADAS) cognitive scores, in subjects of a large AD cohort in Chapters 6, ii) ante-mortem
prediction of molecular subtypes of sporadic Creutzfeldt-Jakob disease (sCJD) in Chapter 10,
both further detailed below.
In Chapter 6, DEBM was used in the TADPOLE challenge to assess the stage of the disease
in patients and use the rate of change of disease stages to predict the future biomarker values
of the subjects as well as to predict their symptom onset precisely. One of the commonly
used approaches for modeling and predicting longitudinal biomarker trajectories in AD is to
consider biomarker changes in AD as an accelerated form of biomarker changes in healthy
aging [51, 52, 58]. In the novel method developed for this challenge, I considered aging
and disease progression as independent factors affecting the progression of biomarker values
along with interaction between the two. This novelty helped me develop a highly accurate
model and the method was ranked first in predicting the future ventricular volumes in
subjects, among the various teams that participated in the challenge. In Chapter 9, the rate
of change of disease stage was also shown to identify subjects with preclinical or prodromal
AD in a population-based cohort.
In Chapter 10, I developed a novel classifier for ante-mortem identification of the molecular
subtypes of subjects with sCJD, using the distances of patient-specific spatio-temporal
sequence of abnormalities from several subtype-specific spatio-temporal sequences. Through
this method it was shown that the patient-specific sequence of abnormalities obtained from
DEBM could also be clinically useful for patient prognostication.
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11.2 Novel insights into neurodegenerative diseases
In collaboration with clinical researchers, I used DEBM to obtain novel insights into the
neurodegenerative disease processes in AD, frontotemporal dementia (FTD), CJD, and
multiple sclerosis (MS). I will discuss the major findings in the following paragraphs.
The first key insight addresses the effect of the APOE gene on the progression timeline of AD.
In Chapter 8, cerebrospinal fluid (CSF) biomarker Amyloidβ42 was identified as the earliest
biomarker to become abnormal among APOE ε4 carriers and homozygous ε3 carriers, which
is consistent with the current understanding of AD. However, it was not an early biomarker
among ε2 carriers. Furthermore, we also showed that APOE-ε2 carriers, homozygous APOE-
ε3 carriers, and APOE-ε4 carriers have significantly different disease progression timelines in
AD.
In Chapter 8, CSF neurofilament light chain (NfL) was consistently observed to be a late
biomarker of AD for all the APOE based genotypes. This was in contrast to our observation
in GRN related FTD (in Chapter 4) where serum NfL was one of the earliest biomarker
abnormality events. This insight could be useful for differential diagnosis of the two types
of dementias in the future. The analyses in Chapter 4 also showed that white matter tracts
were also early biomarkers, along with the cognitive biomarker of language and biomarkers
from the language networks of the brain. These results suggested that, for GRN related FTD
axonal degeneration and damage to the language network are two of the earliest disease
events. In this chapter, we also observed the presence of intra-phenotype heterogeneity in
the behavioural variant GRN related FTD whereas the non-fluent variant primary progressive
aphasia phenotype was quite homogeneous.
The timeline of biomarker abnormality events in multiple sclerosis (MS) was studied in
Chapter 5, using structural, functional, and cognitive biomarkers. Gray matter volumes of
thalamus, insula, hippocampus, and cerebellum were observed to be the earliest biomarkers
in MS, whereas white matter microstructure related biomarkers were predominantly late
biomarkers. These insights could help patient monitoring of MS in the future.
In Chapter 10, we studied the progression timelines of the different molecular subtypes of
sCJD where the two most predominant subtypes (MM1 and VV2) were observed to have
opposite lesion propagation timelines. In MM1, parietal and frontal cortices were observed to
have lesions early in the disease timeline, while thalamus was observed to have lesions only
towards the late stages of the disease. VV2, in contrast, had lesions in parietal and frontal
cortices very late in the disease. Caudate was the earliest region to have lesions in VV2, with
thalamus also being one of the early regions. These insights could be used for block allocation
in future clinical trials of sCJD.
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11.3 Implications for clinical practice
Clinical diagnosis of neurodegenerative disease requires interpretation of cognitive tests, fluid
biomarkers, and imaging biomarkers. Additionally, it could also require inputs from genetics
for the presence of any genetic risk factors. Diagnosing a patient based on such multi-
disciplinary inputs is quite complex and often subjective [344]. Data-driven approaches such
as DEBM and its variants presented in this thesis can elegantly combine multi-disciplinary
inputs in order to estimate a patient stage, and could act as an objective summary score for
evaluating a disease.
This thesis showed that patient stages quantified by positioning test subjects along the pre-
constructed progression timeline have diagnostic value in AD, GRN-related FTD, and MS. The
thesis also showed that the patient stages have prognostic value in AD. Their prognostic value
was not assessed for GRN-related FTD and MS in this thesis; this could be explored in the
future as more longitudinal datasets become available. In the experimentations on the sCJD
dataset, although the identification of molecular subtype in itself had prognostic value, time
of survival within a subtype did not correlate with the patient stage obtained for the subtype.
My interpretation of this negative result is that a key factor determining the prognostic value
of the patient stage obtained from DEBM is the variability in the rate of progression of the
disease across patients. When the variability in rate of progression is substantial compared to
the entire duration of the disease, the disease stage loses its prognostic value.
Apart from the diagnostic and prognostic value of the patient stages, there are a couple
of other important factors that influence the usefulness of data-driven methods in clinical
practice. These are: i) Generalizability of the data-driven methods trained in one cohort to
other cohorts [309]. ii) Explainability of the decisions obtained using data-driven approaches
in a way that can safeguard the accountability of the clinicians [335, 336].
Generalizability: The generalizability of the pre-constructed AD progression timeline to other
clinical cohorts was verified in Chapter 3. Their utility in predicting the progression of pre-
symptomatic AD in a population-based setting was verified in Chapter 9.
Explainability: The patient stages obtained using DEBM are explainable in terms of how the
observed biomarker values were used to assess disease severity of a patient, which is unlike
most of the widely used black-box approaches to machine learning. Furthermore, the results
of the DEBM based subtype classification method developed in Chapter 10 are also clinically
explainable since they are based on the observed differences between the patient-specific and
subtype-specific sequences of abnormalities.
The proven diagnostic and prognostic utility of the patient stages, the generalizability of the
method, together with the transparency it brings to the decision making process, make DEBM
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a strong candidate for aiding in clinical diagnosis of neurodegenerative diseases.
11.4 Implications for drug trials and other interventions
Patients with different subtypes of a neurodegenerative disease are likely to show different
characteristics, in terms of the cognitive domains that are affected. Identifying these subtypes
can hence be very helpful in patient management in terms of designing targeted supportive
therapies or prescribing symptomatic drugs. In Chapter 10, I showed that DEBM can be
used to identify subtypes. The developed method can be extended in the future for other
neurodegenerative diseases as well.
Subtypes of a neurodegenerative disease are a manifestation of the latent differences in
progression pathways of the disease. Identifying these subtypes based on the progression
timeline of the diseases could help in identifying candidates with similar disease progression
pathways. In the future, disease progression models, such as the ones presented in this
thesis, could become an integral part of targeted drug trials. I envision three important
roles of such models in targeted drug trials in the future: data-driven participant selection,
monitoring the efficacy of the drugs through biomarker-based objective disease severity
scores, and identifying novel therapeutic targets using a better understanding of the pathways
of progression.
11.5 Roadmap for future methodological innovations
There are several ways to extend the disease progression models presented in this thesis.
Although DEBM was designed to estimate disease progression timeline in the presence of
disease heterogeneity, staging patients on this timeline only accounts for progression along
this timeline and does not account for any heterogeneity. For addressing this limitation, a 2D
patient staging space could be explored where the x-axis and y-axis correspond to progression
of the patient along and away from the mean progression timeline.
A novel extension of the EBM framework to identify data-driven subtypes of the disease
has already been developed by Young et al. [86]. Further extensions of this to account for
disease progression due to multiple co-existing pathologies such as due to Amyloid-β and
TDP-43 [345] or due to Amyloid-β and vascular pathology [346], could be useful to provide
further insights into such amalgamation of symphonies.
One of the limitations identified in Chapter 2 was that the accuracy of EBMs decreases as
the number of events increases, even when the average quality of the biomarkers remained
the same. I suspect that this is an artefact of an old optimization technique [72] used in my
implementation of the generalized Mallows model, an integral part of DEBM. To improve
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the scalability of DEBM, future work can focus on using more recent optimization techniques
for generalized Mallows model, such as [347], which uses pairwise sequences of events to
estimate the overall event sequence.
My focus in this thesis was on disease progression modeling using cross-sectional data,
to estimate the mean progression timeline in a cohort or a subset of it. Patient-specific
variations of these progression sequences were estimated as a by-product that was not
validated extensively in this thesis. Future work could focus on in-depth analysis of these
patient-specific variations estimated using scalar as well as n-dimensional biomarkers. Use of
longitudinal extensions to EBM using hidden Markov model [348] to improve the accuracy of
these personalized disease progression patterns could also be an interesting area of research.
While the EBMs estimate the sequence of events as the disease progresses, the earlier events
cannot be interpreted to have a causal relationship with the later events. Developing novel
methods that integrates causal inference [349] with disease progression modeling could help
in achieving even greater understanding of the pathological pathways of neurodegenerative
diseases.
Lastly, the use of deep learning in event-based modeling has not yet been explored. A deep-
learning-based EBM could be developed by integrating the best of both worlds, combining
the scalability and robustness of deep learning methods with the explainability of an EBM.
Such a ‘deep event-based model’ may help for example in elucidating the role of the myriad
of proteins obtained from CSF proteomics [350] in the pathophysiology of the disease, or
in studying the spatio-temporal progression patterns at an unprecedented spatial resolution
based on voxel-wise imaging markers. The nDEBM approach presented in Chapter 7 is a first
step in this direction.
11.6 Conclusion
In this thesis, I developed a disease progression modeling framework called DEBM to provide
novel insights into the neurodegenerative disease progression using cross-sectional data, as
well as objectively assess the disease severity of patients with such diseases. This framework
was subsequently improved with variants such as nDEBM and co-init DEBM. These were
used to provide novel insights into the underlying order in the heterogeneous progression
of four neurodegenerative diseases, namely: AD, FTD, CJD, and MS. The spatio-temporal
disease progression timeline of structural abnormalities in the brain obtained using DEBM
from AD research cohorts was validated to be generalizable to clinical as well as population
based cohorts. Hence I conclude that there is great potential for the models developed in this
thesis to be useful for clinical diagnosis of neurodegenerative diseases, finding novel ways for




Neurodegenerative diseases such as Alzheimer’s disease (AD) are pathologically and
phenotypically heterogeneous. This heterogeneous cacophony of neurodegeneration is
orchestrated by the underlying symphony of pathological processes of the disease.
Understanding the underlying order in the heterogeneous progression of neurodegenerative
is crucial for early diagnosis and in identifying novel treatment strategies for drug trials.
In this thesis, I developed novel disease progression modeling methods to estimate the
progression timeline of neurodegenerative diseases in a data-driven way from in-vivo patient
data. In collaboration with clinical researchers, I used the developed approaches to obtain
novel insights into the neurodegenerative disease pathways of four such diseases: AD,
frontotemporal dementia (FTD), Creutzfeldt-Jakob disease (CJD) and multiple sclerosis
(MS). Lastly, to check the utility of the developed approaches for (pre-)clinical use, their
generalizability from research cohorts to clinical cohorts as well as their ability to identify
preclinical and prodromal stages in a population-based cohort was validated in this thesis.
Each of these aspects is summarized below:
Methodological innovations
In Chapter 2, I developed a novel method called discriminative event-based model (DEBM), to
estimate the mean progression timeline in a cross-sectional cohort with heterogeneous disease
progression patterns. To achieve this in a robust manner, I developed a novel optimization
strategy for Gaussian mixture modeling, which is an integral part of even-based models.
Furthermore, the novel concept of event-centers was introduced which estimates the relative
(temporal) distance between the biomarker abnormality events. Lastly, a novel patient-
staging approach was developed to estimate the disease severity in a patient using the disease
progression timeline. I validated the utility of each of these innovations in a synthetic dataset
simulating the progression of AD, as well in a large AD cohort.
To further improve the robustness of mixture modeling for DEBM analysis, two
methodological novelties were introduced in this thesis. First, while studying the brain’s
lateral asymmetry in progranulin (GRN) related familial FTD, in Chapter 4, a technique called
siamese mixture modeling was introduded. In this technique, Gaussian parameters were
shared between the corresponding regions from the left and right hemispheres of the brain,
while also retaining the flexibility of the model to estimate the relative temporal distance
between the two counterparts along the progression timeline. Secondly, while studying effect
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of APOE on the AD progression timeline, in Chapter 8, I proposed and evaluated novel
approaches for coupled training of DEBM in several subgroups. This was motivated from the
observation that mixture modeling after stratification into smaller disease subgroups, such as
based on genetics, would lead to more inaccurate models as compared to fitting the model on
the entire dataset. The approach of co-initializing and independently optimizing the DEBM
models (co-init DEBM) was found to be the best strategy for coupled training of DEBM.
For accurate estimation of spatio-temporal sequence of disease events, I further
extended DEBM to accommodate high-dimensional imaging data (nDEBM) in Chapter 7.
Methodological novelty in nDEBM was in using semi-supervised support vector machines
which scaled well to high-dimensional biomarkers, addressing a well-documented scalability
problem of the mixture modeling used in the DEBM framework. This method was also
validated in a synthetic dataset simulating the progression of AD, as well in a large AD
cohort. The synthetic dataset used for this validation was generated using a novel deep-
learning based simulation framework.
Further methodological developments include using the output of DEBM for patient
prognostication in AD and sporadic CJD (sCJD). I participated in a global challenge to predict
the future clinical diagnosis of subjects at risk of developing AD, volume of ventricles in
the brain of these subjects, as well as their cognitive summary scores. I developed a novel
prediction method for this challenge based on DEBM that considered aging and disease
progression as independent factors affecting the progression of biomarker values along with
interaction between the two. This ended up as the winning entry for the ventricular volume
prediction and came second in the overall challenge. The details of the challenge, comparative
analysis of all the submitted approaches, as well a brief algorithmic details of our developed
approach are provided in Chapter 6.
In Chapter 10, a novel approach was developed using DEBM for ante-mortem identification
of the molecular subtypes of sCJD. Since the survival times of sCJD patients with different
molecular subtypes are substantially different, this ante-mortem identification of the molecular
subtypes could be clinically used for patient prognostication. The methodological novelty was
in developing a nearest mean classifier using the distances of a single time-point approximate
estimate of the disease events in a test-subject from the mean spatio-temporal sequence of
disease events in different subtypes.
Novel insights into neurodegenerative diseases
In Chapter 4, we obtained novel insights into the progression of GRN related FTD, using
DEBM. In FTD-GRN, degeneration of axons and language deficits were observed to be two of
the earliest disease events.
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In Chapter 5, we obtained novel insights into the progression of relapse-onset MS using
structural, functional and cognitive biomarkers, using DEBM. Gray matter volumes of
thalamus, insula, hippocampus and cerebellum were observed to be among the earliest
biomarkers to become abnormal in relapse-onset MS.
In Chapter 8, we determined the effect of APOE alleles on the disease progression timeline of
AD using co-init DEBM and observed that APOE-ε2 carriers, homozygous APOE-ε3 carriers,
and APOE-ε4 carriers have significantly different disease progression timelines in AD.
In Chapter 10, we observed that the two most predominant molecular subtypes in sporadic
CJD (MM1 and VV2) have spatio-temporally contrasting lesion propagation timelines.
Multi-cohort validation
The methods developed in this thesis were validated for their generalizability to clinical
and population-based cohorts that were not used for training the model. In Chapter 3, we
validated the generalizability of the sequence of events provided by DEBM as well as the
original EBM methods in multiple clinical cohorts for AD.
In Chapter 9, we investigated if the disease progression timelines of AD constructed in a case-
controlled setting using co-init DEBM, with subjects stratified according to APOE status, are
generalizable to a population-based cohort. Our results validated the generalizability of co-
init DEBM and that progression along these disease timelines is predictive of AD.
Conclusion
In summary, my research demonstrates the utility of disease progression models in
understanding the complex progression pathways in neurodegenerative diseases. The
validated diagnostic and prognostic utilities of the models, their generalizability, together
with the transparency they bring to the clinical decision making process, make DEBM
and its variants, a strong candidate for aiding in clinical diagnosis and prognosis of
neurodegenerative diseases. The insights into disease progression pathways obtained using
these models, at a group level as well as for each patient, could be invaluable for targeted




Neurodegeneratieve ziekten, zoals de ziekte van Alzheimer (AD), zijn heterogeen
in pathologie en fenotype. Deze heterogene kakofonie van neurodegeneratie wordt
georkestreerd door de onderliggende symfonie van pathologische processen van de ziekte.
Het begrijpen van de onderliggende volgorde waarin de heterogene progressie van
neurodegeneratie plaatsvindt is cruciaal voor vroege diagnose en voor het identificeren van
nieuwe behandelingsstrategieën voor medicatietrials.
In deze thesis heb ik nieuwe datagestuurde methoden ontwikkeld om het ziekteproces te
modeleren. Deze methoden kunnen de tijdslijn van veranderingen in het ziekteproces van
neurodegeneratieve ziekten afschatten aan de hand van in-vivo gegevens van patiënten.
In samenwerking met klinische onderzoekers heb ik deze ontwikkelde methoden gebruikt
om nieuwe inzichten te verkrijgen in het ontstaan van neurodegeneratieve ziekten, in het
specifiek: AD, frontotemporale dementie (FTD), de ziekte van Creutzfeldt-Jakob (CJD) en
multiple sclerosis (MS). Tenslotte heb ik onderzocht in hoeverre de ontwikkelde methoden
geschikt zouden zijn voor toepassing in de klinische praktijk. Ik heb gevalideerd of de
methoden generaliseerbaar zijn van onderzoekscohorten naar klinische cohorten en of ze
gebruikt kunnen worden om individuen te identificeren die zich in een prodromale fase van
de ziekte bevinden. De verschillende aspecten van deze thesis zijn hieronder samengevat.
Methodologische innovaties
In Hoofdstuk 2 heb ik een nieuwe methode ontwikkeld, genaamd discriminative event-
based model (DEBM), om de gemiddelde ziekteprogressietijdlijn af te schatten in een
cross-sectioneel cohort met heterogene ziekteprogressiepatronen. Om dit op een robuuste
manier te kunnen doen, heb ik een nieuwe optimalisatiestrategie ontwikkeld voor Gaussian
mixture modeling, dat een integraal onderdeel is van een event-based model. Daarnaast
heb ik het nieuwe concept van eventcentra geı̈ntroduceerd. Dit is een schatting van
de relatieve (temporele) afstand tussen de momenten waarop verschillende biomarkers
abnormaal worden. Tenslotte heb ik een nieuwe patiëntstadiëringsmethode ontwikkeld om
op basis van de ziekteprogressietijdlijn de ernst van de ziekte van een patiënt te schatten.
Ik heb de bruikbaarheid van elk van deze innovaties gevalideerd in zowel een synthetische
dataset waarin de progressie van AD werd gesimuleerd, als in een groot AD-cohort.
*Translation of the summary by Eline J. Vinke.
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Samenvatting
Om de robuustheid van mixture modeling voor DEBM-analyses verder te optimaliseren
zijn twee nieuwe methodes geı̈ntroduceerd in deze thesis. In Hoofdstuk 4 wordt een
techniek genaamd siamese mixture modeling geı̈ntroduceerd voor de analyse van de laterale
asymmetrie van het brein in progranuline-gerelateerde (GRN) familiaire FTD. Met deze
techniek worden Gaussian parameters gedeeld tussen corresponderende regio’s van de linker
en rechter hersenhelft terwijl het model nog steeds de flexibiliteit heeft om de relatieve
temporale afstand tussen deze twee corresponderende regio’s in de ziekteprogressietijdlijn af
te schatten. In Hoofdstuk 8 introduceer en evalueer ik een nieuwe methode voor gekoppelde
training van DEBM in verschillende subgroepen. De reden hiervoor was dat we zagen dat
mixture modeling na stratificatie in kleinere subgroepen van ziekte, bijvoorbeeld gebaseerd
op genetica, leidde tot een lagere nauwkeurigheid dan wanneer de gehele dataset gebruikt
werd. De methode van co-initialiseren en onafhankelijke optimalisatie van DEBM-modellen
(co-init DEBM) was de beste strategie voor het gekoppeld trainen van DEBM-modellen.
Voor een nauwkeurige afschatting van de spatio-temporele opeenvolging van ziekte-events,
heb ik in Hoofdstuk 7 DEBM verder uitgebreid om het gebruik van hoog-dimensionale
beelddata mogelijk te maken (nDEBM). De belangrijkste methodologische ontwikkeling
in nDEBM was het gebruik van semi-gesuperviseerde support vector machines, die goed
schalen naar hoog-dimensionale biomarkers en zo het schaalbaarheidsprobleem van mixture
modeling aanpakken binnen het bestaande DEBM-framework. Deze methode is gevalideerd
in zowel een synthetische dataset waarin de ziekteprogressie van AD werd gesimuleerd, als
in een groot AD cohort. De synthetische dataset die is gebruikt voor deze validatie was
gegenereerd met behulp van nieuwe deep-learning gebaseerde simulatiesoftware.
Andere methodologische ontwikkelingen bestaan uit het gebruik van de DEBM-uitkomsten
voor het stellen van een prognose voor patiënten met AD en sporadische CJD (sCJD). Ik heb
deelgenomen aan een wereldwijde competitie waarin verschillende voorspellingsmethoden
werden vergeleken met gegevens van mensen die een risico lopen op het ontwikkelen van
AD. De methoden voorspelden de toekomstige klinische diagnoses, ventrikelvolumes van
het brein en samenvattende cognitieve scores. Voor deze competitie heb ik een nieuwe DEBM-
gebaseerde voorspellingsmethode ontwikkeld. Deze methode houdt rekening met leeftijd en
ziekteprogressie en de effecten hiervan op de verandering van biomarkerwaarden. Hierbij
nam ik leeftijd en ziekte mee als onafhankelijke factoren, alsook hun interactie. Deze methode
heeft de competitie gewonnen in de categorie van ventrikelvolumevoorspelling en heeft de
tweede plaats voor de competitie in zijn geheel behaald. Hoofdstuk 6 beschrijft de details
van de competitie, de analyses die gebruikt zijn voor de vergelijking van alle ingestuurde
methoden en de algoritmische details van onze ontwikkelde methode.
In Hoofdstuk 10 staat een nieuwe DEBM-gebaseerde methode beschreven die is ontwikkeld
voor het ante-mortem identificeren van moleculaire subtypes van sCJD. Aangezien de
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levensverwachting van sCJD patiënten sterk afhangt van de moleculaire subtypes, zou
deze ante-mortem-subtype-identificatiemethode ingezet kunnen worden in de kliniek, om een
prognose van de levensverwachting van een sCJD patiënt te maken. De methodologische
vernieuwing van dit model was de afschatting van de tijd tussen de ziekte-events per
individu.
Nieuwe inzichten in neurodegeneratieve ziekten
In Hoofdstuk 4 hebben we met behulp van DEBM nieuwe inzichten verkregen in de
progressie van GRN-gerelateerde FTD. In FTD-GRN, werden de degeneratie van axonen en
taalachterstanden geobserveerd als de eerste twee ziekte-events.
In Hoofdstuk 5 hebben we met behulp van DEBM nieuwe inzichten verkregen in de
progressie van relapse-onset MS door gebruik te maken van structurele, functionele en
cognitieve biomarkers. De grijze stof volumes van de thalamus, insula, hippocampus en het
cerebellum blijken de eerste biomarkers te zijn die abnormaal worden in relapse-onset MS.
In Hoofdstuk 8 hebben we met behulp van co-init DEBM het effect van APOE-allelen
bepaald op de ziekteprogressietijdlijn van AD. We hebben geobserveerd dat APOE-ε2
dragers, homozygote APOE-ε3 dragers and APOE-ε4 dragers een significant verschillende
ziekteprogressietijdslijn hebben.
In Hoofdstuk 10 hebben we geobserveerd dat de twee meest dominante moleculaire subtypes
in sCJD (MM1 en VV2) een contrasterende laesieverspreiding hebben.
Multi-cohort validatie
De nieuwe methoden zijn gevalideerd met betrekking tot hun generaliseerbaarheid naar
klinische cohorten en populatiecohorten die niet gebruikt zijn voor de training van de
modellen. In Hoofdstuk 3 hebben we de generaliseerbaarheid bepaald van zowel DEBM als
EBM voor het bepalen van de ziekteprogressietijdlijn in AD, in meerdere klinische cohorten.
In Hoofdstuk 9 hebben we onderzocht of de ziekteprogressietijdlijn van AD, geconstrueerd
aan de hand van data uit een case-control setting, generaliseerbaar is naar een
populatiecohort. Onze resultaten laten zien dat co-init DEBM, waarbij er gestratificeerd is op
basis van APOE, goed generaliseert. Daarnaast hebben we laten zien dat de ziekteprogressie




Samenvattend laat mijn onderzoek de voordelen zien van ziekteprogressiemodellen voor
het begrijpen van het ontstaan van complexe neurodegeneratieve ziekten. De validatie
voor diagnostiek en prognostiek, de generaliseerbaarheid, samen met de transparantie,
maken DEBM en de DEBM-gebaseerde modellen tot een krachtige potentiële tool voor het
ondersteunen van klinische diagnostiek en prognoses van neurodegeneratieve ziekten. De
verkregen inzichten in de onderliggende pathologie met behulp van deze modellen, zowel op
groepsniveau als op patiëntniveau, zouden van onschatbare waarde kunnen zijn voor gerichte
interventies en medicatietrials in de toekomst.
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Mar Tintoré, Anthony L Traboulsee, Maria Trojano, Bernard M J Uitdehaag, Sandra Vukusic,
Emmanuelle Waubant, Brian G Weinshenker, Stephen C Reingold, and Jeffrey A Cohen. Diagnosis
of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2):162 – 173,
2018.
[238] Madeleine H. Sombekke, Mike P. Wattjes, Lisanne J. Balk, Jessica M. Nielsen, Hugo Vrenken,
Bernard M.J. Uitdehaag, Chris H. Polman, and Frederik Barkhof. Spinal cord lesions in patients
with clinically isolated syndrome. Neurology, 80(1):69–75, 2013.
275
Bibliography
[239] Giulio Disanto, Christian Barro, Pascal Benkert, Yvonne Naegelin, Sabine Schädelin, Antonella
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Ekman, J. Muehlboeck, Andrew Simmons, José Barroso, Lars-olof Wahlund, and Eric Westman.
Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal
trajectories and clinical applications. Scientific Reports, 7:46263, 04 2017.
[303] Vikram Venkatraghavan, Florian Dubost, Esther E. Bron, Wiro J. Niessen, Marleen de Bruijne, and
Stefan Klein. Event-based modeling with high-dimensional imaging biomarkers for estimating
spatial progression of dementia. In Information Processing in Medical Imaging - 26th International
Conference, IPMI 2019, Proceedings, volume 11492 of Lecture Notes in Computer Science (including
subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics), pages 169–180.
Springer, 2019.
[304] Clive Holmes. Genotype and phenotype in Alzheimer’s disease. British Journal of Psychiatry,
180(2):131–134, 2002.
[305] Joanne Ryan, Peter Fransquet, Jo Wrigglesworth, and Paul Lacaze. Phenotypic heterogeneity in
dementia: A challenge for epidemiology and biomarker studies. Frontiers in Public Health, 6:181,
2018.
[306] Gayatri Devi and Philip Scheltens. Heterogeneity of Alzheimer’s disease: consequence for drug
trials? Alzheimer’s research & therapy, 10(1):122, December 2018.
[307] Reisa A Sperling, Jason Karlawish, and Keith A Johnson. Preclinical Alzheimer disease: The
challenges ahead. Nature Reviews. Neurology, 9(1):54—58, January 2013.
281
Bibliography
[308] Razvan V. Marinescu, Neil P. Oxtoby, Alexandra L. Young, Esther E. Bron, Arthur W. Toga,
Michael W. Weiner, Frederik Barkhof, Nick C. Fox, Arman Eshaghi, Tina Toni, Marcin Salaterski,
Veronika Lunina, Manon Ansart, Stanley Durrleman, Pascal Lu, Samuel Iddi, Dan Li, Wesley K.
Thompson, Michael C. Donohue, Aviv Nahon, Yarden Levy, Dan Halbersberg, Mariya Cohen,
Huiling Liao, Tengfei Li, Kaixian Yu, Hongtu Zhu, Jose G. Tamez-Pena, Aya Ismail, Timothy Wood,
Hector Corrada Bravo, Minh Nguyen, Nanbo Sun, Jiashi Feng, B. T. Thomas Yeo, Gang Chen,
Ke Qi, Shiyang Chen, Deqiang Qiu, Ionut Buciuman, Alex Kelner, Raluca Pop, Denisa Rimocea,
Mostafa M. Ghazi, Mads Nielsen, Sebastien Ourselin, Lauge Sorensen, Vikram Venkatraghavan,
Keli Liu, Christina Rabe, Paul Manser, Steven M. Hill, James Howlett, Zhiyue Huang, Steven
Kiddle, Sach Mukherjee, Anais Rouanet, Bernd Taschler, Brian D. M. Tom, Simon R. White, Noel
Faux, Suman Sedai, Javier de Velasco Oriol, Edgar E. V. Clemente, Karol Estrada, Leon Aksman,
Andre Altmann, Cynthia M. Stonnington, Yalin Wang, Jianfeng Wu, Vivek Devadas, Clementine
Fourrier, Lars Lau Raket, Aristeidis Sotiras, Guray Erus, Jimit Doshi, Christos Davatzikos, Jacob
Vogel, Andrew Doyle, Angela Tam, Alex Diaz-Papkovich, Emmanuel Jammeh, Igor Koval, Paul
Moore, Terry J. Lyons, John Gallacher, Jussi Tohka, Robert Ciszek, Bruno Jedynak, Kruti Pandya,
Murat Bilgel, William Engels, Joseph Cole, Polina Golland, Stefan Klein, and Daniel C. Alexander.
The Alzheimer’s disease prediction of longitudinal evolution (TADPOLE) challenge: Results after
1 year follow-up, 2020.
[309] S. Kloeppel, J. Peter, A. Ludl, A. Pilatus, S. Maier, I. Mader, B. Heimbach, L. Frings, K. Egger,
J. Dukart, M.l. Schroeter, R. Perneczky, P. Haussermann, W. Vach, H. Urbach, S. Teipel, M. Huell,
and A. Abdulkadir. Applying automated MR-based diagnostic methods to the memory clinic: A
prospective study. Journal of Alzheimers Disease, 47(4):939–954, Aug 2015.
[310] Sandra Wachter, Brent Mittelstadt, and Chris Russell. Counterfactual explanations without opening
the black box: Automated decisions and the GDPR, 2018.
[311] Andreas Holzinger, Chris Biemann, Constantinos S. Pattichis, and Douglas B. Kell. What do we
need to build explainable AI systems for the medical domain?, 2017.
[312] Vikram Venkatraghavan, Stefan Klein, Lana Fani, Leontine S. Ham, Henri Vrooman, M. Kamran
Ikram, Wiro J. Niessen, Esther E. Bron, and ADNI. Analyzing the effect of APOE on Alzheimer’s
disease progression using an event-based model for stratified populations. arXiv, 2020.
[313] M Arfan Ikram, Guy Brusselle, Mohsen Ghanbari, André Goedegebure, M Kamran Ikram, Maryam
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